U.S. patent application number 15/043729 was filed with the patent office on 2016-09-15 for gdf-8 inhibitors.
The applicant listed for this patent is Bristol-Myers Squibb Company, Rigel Pharmaceuticals, Inc.. Invention is credited to Somasekhar Bhamidipati, Robert M. Borzilleri, Pingyu Ding, Marina Gelman, Todd Kinsella, Hasibur Rahaman, Rajinder Singh, Upender Velaparthi, Jayakumar Sankara Warrier.
Application Number | 20160264553 15/043729 |
Document ID | / |
Family ID | 55587333 |
Filed Date | 2016-09-15 |
United States Patent
Application |
20160264553 |
Kind Code |
A1 |
Ding; Pingyu ; et
al. |
September 15, 2016 |
GDF-8 Inhibitors
Abstract
Disclosed are 2,2'-bipyridyl compounds, as well as
pharmaceutical compositions and methods of use thereof. One
embodiment is a compound having the structure ##STR00001## and
pharmaceutically acceptable salts, prodrugs and N-oxides thereof
(and solvates and hydrates thereof), wherein R.sup.1, Z and n are
as described herein. In certain embodiments, a compound disclosed
herein inhibits GDF8, and can be used to treat disease by blocking
GDF8 signaling.
Inventors: |
Ding; Pingyu; (Foster City,
CA) ; Gelman; Marina; (San Francisco, CA) ;
Kinsella; Todd; (Redwood City, CA) ; Singh;
Rajinder; (Belmont, CA) ; Bhamidipati;
Somasekhar; (Foster City, CA) ; Velaparthi;
Upender; (Cheshire, CT) ; Borzilleri; Robert M.;
(New Hope, PA) ; Rahaman; Hasibur; (Bangalore,
IN) ; Warrier; Jayakumar Sankara; (Bangalore,
IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Rigel Pharmaceuticals, Inc.
Bristol-Myers Squibb Company |
South San Francisco
Princeton |
CA
NJ |
US
US |
|
|
Family ID: |
55587333 |
Appl. No.: |
15/043729 |
Filed: |
February 15, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62119052 |
Feb 20, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 37/02 20180101;
A61P 21/02 20180101; C07D 401/14 20130101; C07D 471/04 20130101;
A61P 3/10 20180101; A61P 19/00 20180101; A61P 25/00 20180101; C07D
487/04 20130101; C07B 59/002 20130101; C07B 2200/05 20130101; A61P
3/04 20180101; A61P 11/00 20180101; C07C 53/18 20130101; A61P 5/24
20180101; C07C 53/06 20130101; A61P 5/14 20180101; A61P 3/08
20180101; A61P 43/00 20180101; A61P 21/00 20180101; A61P 19/10
20180101; A61P 3/06 20180101 |
International
Class: |
C07D 401/14 20060101
C07D401/14; C07B 59/00 20060101 C07B059/00; C07D 471/04 20060101
C07D471/04; C07D 487/04 20060101 C07D487/04; C07C 53/18 20060101
C07C053/18; C07C 53/06 20060101 C07C053/06 |
Claims
1. A compound having the structure of formula (I.degree.):
##STR00451## or a pharmaceutically acceptable salt, prodrug, or
N-oxide thereof, or a solvate or hydrate thereof, wherein n is 1,
2, 3 or 4; R.sup.1 is hydrogen, halogen, cyano, nitro,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, C.sub.3-8cycloalkyl, C.sub.3-8
cycloalkenyl, heterocyclyl, aryl, heteroaryl, --R.sup.a, or
--C.sub.1-6alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--O(CH.sub.2).sub.mC(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1 or
--N(R.sup.S1)S(O).sub.2R.sup.S1; wherein m is 0, 1, 2 or 3; and
wherein each R.sup.S1 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano; p is 1, 2, 3 or 4; R.sup.2 is
hydrogen, halogen, cyano, nitro, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, C.sub.3-8cycloalkyl, C.sub.3-8 cycloalkenyl,
heterocyclyl, aryl, heteroaryl, --R.sup.b, or
--C.sub.1-6alkyl-R.sup.b, wherein R.sup.b is --OR.sup.S4,
--SR.sup.S4, --NR.sup.S4R.sup.S4, --C(O)OR.sup.S4,
--C(O)NR.sup.S4R.sup.S4, --S(O).sub.2NR.sup.S4R.sup.S4,
--OC(O)R.sup.S4, --N(R.sup.S4)C(O)R.sup.S4, --OC(O)OR.sup.S4,
--O(CH.sub.2).sub.qC(O)NR.sup.S4R.sup.S4,
--N(R.sup.S4)C(O)OR.sup.S4, --N(R)C(O)NR.sup.S4R.sup.S4,
--N(R.sup.S4)S(O).sub.2NR.sup.S4R.sup.S4 or
--N(R.sup.S4)S(O).sub.2R.sup.S4; wherein q is 0, 1, 2 or 3; and
wherein each R.sup.S4 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano; Z is a fused bicyclic ring of
the formula, ##STR00452## wherein ring A is Ar or 6-membered Het,
ring B is 5- or 6-membered Het, wherein Z is optionally substituted
by one or two --R.sup.Z groups that are each independently halogen,
cyano, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy,
--OR.sup.S2, --SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2,
--C(O)OR.sup.S2, --C(O)NR.sup.S2.sub.2,
--S(O).sub.2NR.sup.S2.sub.2, --S(O).sub.2R.sup.S2, --OC(O)R.sup.S2,
--N(R.sup.S2)C(O)R.sup.S2, --OC(O)OR.sup.S2,
--OC(O)NR.sup.S2.sub.2, --N(R.sup.S2)C(O)OR.sup.S2,
--N(R.sup.S2)C(O)NR.sup.S2.sub.2, --N(R.sup.S2)S(O).sub.2R.sup.S2,
--OP(O)(OR.sup.S2).sub.2 or --CH.sub.2--OP(O)(OR.sup.S2), wherein
each alkyl, haloalkyl and alkoxy is optionally substituted by one
or two --R.sup.Z2 groups; wherein each R.sup.S2 is independently
hydrogen, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
C.sub.1-C.sub.6alkyl-O--C.sub.1-C.sub.6alkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano; and each --R.sup.Z2 is
independently halogen, cyano, C.sub.1-6alkyl, C.sub.1-6haloalkyl,
--C.sub.1-C.sub.6alkoxy, --OR.sup.S3, --SR.sup.S3,
--NR.sup.S3.sub.2, --C(O)R.sup.S3, --C(O)OR.sup.S3,
--C(O)NR.sup.S3.sub.2, --S(O).sub.2NR.sup.S3.sub.2,
--S(O).sub.2R.sup.S3, --OC(O)R.sup.S3, --N(R.sup.S3)C(O)R.sup.S3,
--OC(O)OR.sup.S3, --OC(O)NR.sup.S3.sub.2,
--N(R.sup.S3)C(O)OR.sup.S3, --N(R.sup.S3)C(O)NR.sup.S3.sub.2,
--N(R.sup.S3)S(O).sub.2R.sup.S3, --OP(O)(OR.sup.S3).sub.2 or
--CH.sub.2--OP(O)(OR.sup.S3); and wherein each R.sup.S' is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano.
2. (canceled)
3. (canceled)
4. The compound of claim 1, wherein Z is ##STR00453## wherein Z is
optionally substituted by one or two --R.sup.Z groups.
5. (canceled)
6. (canceled)
7. The compound of claim 1, wherein Z is ##STR00454##
8. (canceled)
9. The compound of claim 1, wherein n is 1 or 2 and each R.sup.1 is
independently halogen C.sub.1-6alkyl, C.sub.1-6haloalkyl or
C.sub.3-8cycloalkyl.
10. The compound of claim 1, wherein the compound has the structure
of one of Formulae (Ia)-(Ih): ##STR00455##
11. A compound according to claim 1 that is:
4-(6'-methyl-[2,2'-bipyridin]-3-yl)quinoline;
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine;
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-4-aminium
2,2,2-trifluoroacetate;
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-4-aminium formate;
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile;
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine;
7-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine;
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
6-([2,2'-Bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile;
6-([2,2'-Bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine;
6-([2,2'-Bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine;
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin-4-amine;
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin-4-aminium
2,2,2-trifluoroacetate;
6-([2,2'-bipyridin]-3-yl)quinazolin-4-amine;
6-([2,2'-bipyridin]-3-yl)quinazolin-4-aminium formate; or a
pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a
solvate or hydrate thereof.
12. A compound according to claim 1 having the structure of formula
(II): ##STR00456## or a pharmaceutically acceptable salt, prodrug
or N-oxide thereof, or solvate or hydrate thereof, wherein R.sup.1
is hydrogen, halogen, cyano, nitro, C.sub.1-6alkyl or
C.sub.1-6haloalkyl; Z is a fused bicyclic ring of the formula,
##STR00457## wherein ring A is Ar or 6-membered Het, ring B is 5-
or 6-membered Het, wherein Z is optionally substituted by one or
two --R.sup.Z groups that are each independently halogen, cyano,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy,
--OR.sup.S2, --SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2,
--C(O)OR.sup.S2, --C(O)NR.sup.S2.sub.2,
--S(O).sub.2NR.sup.S2.sub.2, --S(O).sub.2R.sup.S2, --OC(O)R.sup.S2,
--N(R.sup.S2)C(O)R.sup.S2, --OC(O)OR.sup.S2,
--OC(O)NR.sup.S2.sub.2, --N(R.sup.S2)C(O)OR.sup.S2,
--N(R.sup.S2)C(O)NR.sup.S2.sub.2, --N(R.sup.S2)S(O).sub.2R.sup.S2,
--OP(O)(OR.sup.S2).sub.2 or --CH.sub.2--OP(O)(OR.sup.S2); wherein
each R.sup.S2 is independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano; provided that the
compound is not
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole.
13. (canceled)
14. The compound of claim 12, wherein Z is ##STR00458## wherein Z
is optionally substituted by one or two --R.sup.Z groups.
15. (canceled)
16. The compound of claim 12, wherein Z is ##STR00459## wherein Z
is optionally substituted by one or two --R.sup.L groups.
17. (canceled)
18. The compound of claim 12, wherein R.sup.1 is hydrogen or
methyl.
19. The compound of claim 12, wherein the compound has the
structure of Formulae (IIa)-(IIh): ##STR00460## ##STR00461##
20. The compound according to claim 1 that is
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine;
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-4-aminium
2,2,2-trifluoroacetate;
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile;
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine;
7-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine;
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
6-([2,2'-Bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin-4-amine;
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin-4-aminium
2,2,2-trifluoroacetate;
6-([2,2'-bipyridin]-3-yl)quinazolin-4-amine;
6-([2,2'-bipyridin]-3-yl)quinazolin-4-aminium formate; or a
pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a
solvate or hydrate thereof.
21. A pharmaceutical composition comprising a compound or
pharmaceutically acceptable salt according to claim 1 and a
pharmaceutically acceptable carrier, excipient, or diluent.
22. A method for inhibiting GDF-8 in a cell comprising contacting
the cell with an effective amount of a compound according to claim
1.
23. A method for treating a patient suffering from a disease or
disorder, wherein the patient would therapeutically benefit from an
increase in mass or strength of muscle tissue, comprising
administering to a patient a therapeutically effective amount of a
compound according to claim 1.
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. A method for increasing muscle mass in a mammal comprising
administering a therapeutically effective amount of a compound
according to claim 1.
32. A method for increasing muscle strength in a mammal comprising
administering a therapeutically effective amount of a compound
according to claim 1.
33. A method for increasing trabecular bone density in a patient in
need thereof, comprising administering a therapeutically effective
amount of a compound according to claim 1.
34. (canceled)
35. (canceled)
36. The compound of claim 1, wherein the compound has the structure
of one of Formulae (Ii)-(Im), (IIi)-(IIk), and (III): ##STR00462##
##STR00463##
37. The compound according to claim 1 that is
6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-ca-
rbonitrile
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carbonitrile
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-ca-
rboxamide
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carbonitrile
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carboxamide methyl
3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carboxylate
methyl
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-car-
boxylate
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-ca-
rboxylic acid
6-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile
6-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-
e-3-carboxamide
6-(6'-ethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitri-
le
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxam-
ide
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxami-
de
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbon-
itrile
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-ca-
rboxamide
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xamide
6-(6'-(benzyloxy)[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
bonitrile
6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
6-(6'-acetyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
6-(6'-6-(6'-(2-hydroxypropan-2-yl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]py-
ridine-3-carbonitrile
6-(4',6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxam-
ide
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine--
3-carboxamide
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridin]-6-yl)methanesu-
lfonamide
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridin]-6-yl)-
acetamide
6-(6'-chloro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
oxamide 6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine
6-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine--
3-carbonitrile
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitri-
le
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxam-
ide
6-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-
-carboxamide
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamid-
e
6-(5'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitri-
le
6-(5'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxami-
de 6-(6'-methyl-[2, 2'-bipyridin]-3-yl)
imidazo[1,2-b]pyridazine-3-carbonitrile
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamid-
e
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3--
carbonitrile
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonit-
rile
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carb-
oxamide
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carb-
onitrile
2,2,2-trifluoro-N-(6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-
-a]pyridin-3-yl)acetamide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxylic
acid
N-(2,2-difluoroethyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-
-a]pyridine-3-carboxamide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(2,2,2-trifluoroethyl)imidazo[1,2-a-
]pyridine-3-carboxamide
N-(2-methoxyethyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
N--(.sup.2H.sub.3)methyl-6-[2-(6-methylpyridin-2-yl)pyridin-3-yl]imidazo[-
1,2-a]pyridine-3-carboxamide
methyl-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbox-
amide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbox-
ylic acid
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)imidazo[1,2-b-
]pyridazine-3-carboxamide
N-cyclopropyl-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-
-3-carboxamide
N-(6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamid-
e
N-(6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-2--
yl)acetamide
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxamide
6-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridi-
ne-2-carboxamide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-carboxamide
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-
e-3-carboxamide
6-(6'-(difluoromethyl)-5-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carbonitrile
6-(6'-(difluoromethyl)-5-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide 6-(5,
5'-difluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
oxamide
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-ca-
rbonitrile
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-
-carbonitrile
6-(6'-(difluoromethyl)-6-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
6-(6'-methyl-6-(trifluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carbonitrile
6-(6'-methyl-6-(trifluoromethyl)[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide methyl
3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridine]-4-carbo-
xylate
6-(4-(hydroxymethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]-
pyridine-3-carbonitrile
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carbonitrile
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
6-(6-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-c-
arboxamide
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyri-
din]-5-yl)acetamide
6-(5-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-c-
arboxamide
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridi-
ne-3-carboxamide
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xylic acid
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyri-
din]-4-yl)acetamide
6-(4-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xamide
6-(4-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridi-
ne-3-carboxamide
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-ami-
ne
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-ami-
ne
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
6-(6'-ethyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
6-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)quinazolin-4-amine
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxamide 6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)quinoxaline
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinoxaline
6-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)quinoxaline
5-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)-1H-indazole
5-(5'-fluoro-[2,2'-bipyridin]-3-yl)-1H-indazole
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole
3-(difluoromethyl)-5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1H-indaz-
ole
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboni-
trile
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbo-
xamide
5-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carbonitrile
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carbonitrile ethyl
5-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylate
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-
-carboxylic acid
N-methyl-5-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyri-
midine-3-carboxamide
N-cyclopropyl-5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
N-methyl-5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide
N-cyclopropyl-5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide ethyl
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylate
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylic acid
N-cyclopropyl-5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)pyrazolo[1,5-
-a]pyrimidine-3-carboxamide ethyl
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylate
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylic acid
5-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine or a
pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a
solvate or hydrate thereof.
38. (canceled)
39. (canceled)
Description
BACKGROUND OF THE DISCLOSURE
[0001] 1. Field of the Disclosure
[0002] This disclosure relates to pharmaceutically active compounds
and methods for their use. In particular the disclosure relates to
kinase inhibitors. In one aspect the compounds also inhibit the
signaling of cytokines such as TGF-.beta.1, Growth Differentiation
Factor-8 (GDF-8) and other members of the TGF-.beta.s, activins,
inhibins, bone morphogenetic proteins and Mullerian-inhibiting
substance, that signal through a family of transmembrane kinase
receptors. The inhibitors are useful for treating inflammatory
disorders, such as inflammatory or obstructive airway diseases,
such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis;
and cancer. The inhibitors are particularly useful for diagnosing,
preventing, or treating human or animal disorders in which an
increase in muscle tissue would be therapeutically beneficial.
Exemplary disorders include neuromuscular disorders (e.g., muscular
dystrophy and muscle atrophy), congestive obstructive pulmonary
disease, muscle wasting syndrome, sarcopenia, and cachexia; adipose
tissue disorders (such as obesity); type 2 diabetes; and bone
degenerative disease (such as osteoporosis).
[0003] 2. Summary of the Related Art
[0004] Growth and Differentiation Factor-8 (GDF-8), also known as
myostatin, and TGF-.beta. are a members of the Transforming Growth
Factor-beta (TGF-.beta.) superfamily of structurally related growth
factors, all of which possess physiologically important
growth-regulatory and morphogenetic properties (Kingsley et al.
(1994) Genes Dev., 8: 133-46; Hoodless et al. (1998) Curr. Topics
Microbiol. Immunol., 228: 235-72). For example, activation of
TGF-.beta.1 signaling and expansion of extracellular matrix are
early and persistent contributors to the development and
progression of fibrotic disorders, such as involved in chronic
renal disease and vascular disease. Border W. A., et al, N. Engl.
J. Med., 1994; 331(19), 1286-92. GDF-8 is a negative regulator of
skeletal muscle mass, and there is considerable interest in
identifying factors which regulate its biological activity. For
example, GDF-8 is highly expressed in the developing and adult
skeletal muscle. The GDF-8 null mutation in transgenic mice is
characterized by a marked hypertrophy and hyperplasia of the
skeletal muscle (McPherron et al. (1997) Nature, 387: 83-90).
Similar increases in skeletal muscle mass are evident in naturally
occurring mutations of GDF-8 in cattle (Ashmore et al. (1974)
Growth, 38: 501 507; Swatland and Kieffer (1994) J. Anim. Sci., 38:
752-757; McPherron and Lee (1997) Proc. Natl. Acad. Sci. USA, 94:
12457-12461; and Kambadur et al. (1997) Genome Res., 7: 910-915).
Since GDF-8 is expressed in both developing and adult muscles, it
is not clear whether it regulates muscle mass during development or
in adults. Thus, the question of whether or not GDF-8 regulates
muscle mass in adults is important from a scientific and
therapeutic perspective. Recent studies have also shown that muscle
wasting associated with HIV-infection in humans is accompanied by
increases in GDF-8 protein expression (Gonzalez-Cadavid et al.
(1998) PNAS, 95: 14938-43). In addition, GDF-8 can modulate the
production of muscle-specific enzymes (e.g., creatine kinase) and
modulate myoblast cell proliferation (WO 00/43781).
[0005] A number of human and animal disorders are associated with
loss or functional impairment of muscle tissue, including muscular
dystrophy, muscle atrophy, congestive obstructive pulmonary
disease, muscle wasting syndrome, sarcopenia, and cachexia. To
date, very few reliable or effective therapies exist for these
disorders. However, the terrible symptoms associated with these
disorders may be substantially reduced by employing therapies that
increase the amount of muscle tissue in patients suffering from the
disorders. While not curing the conditions, such therapies would
significantly improve the quality of life for these patients and
could ameliorate some of the effects of these diseases. Thus, there
is a need in the art to identify new therapies that may contribute
to an overall increase in muscle tissue in patients suffering from
these disorders.
[0006] In addition to its growth-regulatory and morphogenetic
properties in skeletal muscle, GDF-8 may also be involved in a
number of other physiological processes, including glucose
homeostasis in the development of type 2 diabetes and adipose
tissue disorders, such as obesity. For example, GDF-8 modulates
pre-adipocyte differentiation to adipocytes (Kim et al. (2001)
BBRC, 281: 902-906).
[0007] There are also a number of conditions associated with a loss
of bone, including osteoporosis, especially in the elderly and/or
postmenopausal women. Currently available therapies for these
conditions work by inhibiting bone resorption. A therapy that
promotes new bone formation would be a desirable alternative to or
addition to, these therapies.
[0008] Like TGF-.beta.-1, -2, and -3, the GDF-8 protein is
synthesized as a precursor protein consisting of an amino-terminal
propeptide and a carboxy-terminal mature domain (McPherron and Lee,
(1997) Proc. Natl. Acad. Sci. USA, 94: 12457-12461). Before
cleavage, the precursor GDF-8 protein forms a homodimer. The
amino-terminal propeptide is then cleaved from the mature domain.
The cleaved propeptide may remain noncovalently bound to the mature
domain dimer, inactivating its biological activity (Miyazono et al.
(1988) J. Biol. Chem., 263: 6407-6415; Wakefield et al. (1988) J.
Biol. Chem., 263; 7646-7654; and Brown et al. (1990) Growth
Factors, 3: 35-43). It is believed that two GDF-8 propeptides bind
to the GDF-8 mature dimer (Thies et al. (2001) Growth Factors, 18:
251-259). Due to this inactivating property, the propeptide is
known as the "latency-associated peptide" (LAP), and the complex of
mature domain and propeptide is commonly referred to as the "small
latent complex" (Gentry and Nash (1990) Biochemistry, 29:
6851-6857; Derynck et al. (1995) Nature, 316: 701-705; and Massague
(1990) Ann. Rev. Cell Biol., 12: 597-641). Other proteins are also
known to bind to GDF-8 or structurally related proteins and inhibit
their biological activity. Such inhibitory proteins include
follistatin, and potentially, follistatin-related proteins (Gamer
et al. (1999) Dev. Biol., 208: 222-232). The mature domain is
believed to be active as a homodimer when the propeptide is
removed.
[0009] GDF-8 is highly conserved in sequence and in function across
species. The amino acid sequence of murine and human GDF-8 is
identical, as is the pattern of mRNA expression (McPherron et al.
(1997) Nature 387: 83-90; Gonzalez-Cadavid et al. (1998) Proc.
Natl. Acad. Sci. USA 95: 14938-14943). This conservation of
sequence and function suggests that inhibition of GDF-8 in humans
is likely to have a similar effect to inhibition of GDF-8 in
mice.
[0010] GDF-8 is involved in the regulation of many critical
biological processes. Due to its key function in these processes,
GDF-8 may be a desirable target for therapeutic intervention.
[0011] For example, U.S. Pat. No. 7,320,789, shows that GDF-8
antibodies in mouse models can increase muscle strength (e.g., for
treating sarcopenia). increase muscle mass and strength in
dystrophic muscle (e.g., for treating Duchenne's muscular
dystrophy), increase bone mass and bone density (e.g., for
prevention and treatment of osteoporosis), augment bone healing
(e.g., for treating an established muscle or bone degenerative
disease (e.g., fracture repair and spine fusion, preventing the
decline in bone mass, microarchitecture and strength associated
with estrogen deficiency, increasing trabecular bone density), and
are useful for treatment of metabolic disorders such as type 2
diabetes, impaired glucose tolerance, metabolic syndrome (e.g.,
syndrome X), insulin resistance induced by trauma (e.g., burns),
and adipose tissue disorders (e.g., obesity).
[0012] In particular, therapeutic agents that inhibit the activity
of GDF-8 may be used to treat human or animal disorders in which an
increase in muscle tissue would be therapeutically beneficial,
particularly muscle and adipose tissue disorders, bone degenerative
diseases, neuromuscular disorders, and diabetes, as discussed
above.
SUMMARY OF THE DISCLOSURE
[0013] In one aspect, the present disclosure relates to compounds
of the formula (I),
##STR00002##
and pharmaceutically acceptable salts thereof, wherein n, R.sup.1
and Z are defined herein.
[0014] In another aspect, disclosed are pharmaceutical compositions
comprising a compound or pharmaceutically acceptable salt of a
compound according to formula (I) and a pharmaceutically acceptable
carrier, excipient, or diluent.
[0015] In another aspect, disclosed are methods for inhibiting
GDF-8 in a cell comprising contacting the cell with an effective
amount of a compound or pharmaceutically acceptable salt of a
compound according to formula (I) or a pharmaceutical composition
comprising a compound or pharmaceutically acceptable salt of a
compound according to formula (I) and a pharmaceutically acceptable
carrier, excipient, or diluent.
[0016] In another aspect, disclosed are methods for treating a
patient suffering from a disease or disorder, wherein the patient
would therapeutically benefit from an increase in mass or strength
of muscle tissue, comprising administering to a patient a
therapeutically effective amount of a compound or pharmaceutically
acceptable salt of a compound according to formula (I) or a
pharmaceutical composition comprising a compound or
pharmaceutically acceptable salt of a compound according to formula
(I) and a pharmaceutically acceptable carrier, excipient, or
diluent.
[0017] In another aspect, disclosed are methods for increasing
muscle mass in a mammal comprising administering a therapeutically
effective amount of a compound or pharmaceutically acceptable salt
of a compound according to formula (I) or a pharmaceutical
composition comprising a compound or pharmaceutically acceptable
salt of a compound according to formula (I) and a pharmaceutically
acceptable carrier, excipient, or diluent.
[0018] In another aspect, disclosed are methods for increasing
muscle strength in a mammal comprising administering a
therapeutically effective amount of a compound or pharmaceutically
acceptable salt according to formula (I) or a pharmaceutical
composition comprising a compound or pharmaceutically acceptable
salt according to formula (I) and a pharmaceutically acceptable
carrier, excipient, or diluent.
[0019] In another aspect, disclosed are methods for increasing
trabecular bone density in a patient in need thereof, comprising
administering a therapeutically effective amount of a compound or
pharmaceutically acceptable salt according to formula (I) or a
pharmaceutical composition comprising a compound or
pharmaceutically acceptable salt according to formula (I) and a
pharmaceutically acceptable carrier, excipient, or diluent.
[0020] In another aspect, the compounds and compositions disclosed
herein are useful for inhibiting a TGF-.beta. superfamily cytokine,
including without limitation, TGF-.beta., GDF-8, Activin-A, or
combinations thereof in vitro, ex vitro, and in vivo for the
purposes of studying the effects of GDF-8 inhibition on biological
processes influenced by GDF-8 activity. Embodiments according to
this aspect comprise contacting or administering (as appropriate) a
compound or composition described herein under circumstances that
facilitate contact between the compound or composition and GDF-8,
thereby facilitating inhibition of GDF-8 by the compound or
composition. Optionally, methods of inhibiting GDF-8 in vitro, ex
vitro, and in vivo are followed by an appropriate assay for
determining the effects of the inhibition. One embodiment of this
aspect comprises a method of inhibiting GDF-8 in vivo comprising
administering an effect GDF-8-inhibiting amount of a compound or
composition disclosed herein to a mammal, such as a human.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0021] In one aspect, the invention comprises compounds that
inhibit one or more kinases, such as a TGF-.beta. receptor
superfamily kinase. As such and without limitation to any
particular theory, the presently disclosed compounds inhibit
signaling of TGF-.beta. superfamily cytokines, such as TGF-.beta.,
Activin A, GDF-8 or combinations thereof.
[0022] In embodiment I.sub.0 of this first aspect, the compounds
have structural formula (P):
##STR00003##
or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof,
or a solvate or hydrate thereof, wherein
[0023] n is 1, 2, 3 or 4;
[0024] R.sup.1 is hydrogen, halogen, cyano, nitro, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, C.sub.3-8cycloalkyl, C.sub.3-8 cycloalkenyl,
heterocyclyl, aryl, heteroaryl, --R.sup.a, or --C.sub.1-6
alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1, --SR.sup.S1,
--NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--O(CH.sub.2).sub.mC(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1, or
--N(R.sup.S1)S(O).sub.2R.sup.S1; [0025] wherein m is 0, 1, 2 or 3;
and [0026] wherein each R.sup.si is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl, [0027]
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano;
[0028] p is 1, 2, 3 or 4;
[0029] R.sup.2 is hydrogen, halogen, cyano, nitro, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, C.sub.3-8cycloalkyl, C.sub.3-8cycloalkenyl,
heterocyclyl, aryl, heteroaryl, --R.sup.b, or
--C.sub.1-6alkyl-R.sup.b, wherein R.sup.b is --OR.sup.S4,
--SR.sup.S4; --NR.sup.S4R.sup.S4, --C(O)R.sup.S4, --C(O)OR.sup.S4,
--C(O)NR.sup.S4R.sup.S4, --S(O).sub.2NR.sup.S4R.sup.S4,
--OC(O)R.sup.S4, --N(R.sup.S4)C(O)R.sup.S4, --OC(O)OR.sup.S4,
--O(CH.sub.2).sub.qC(O)NR.sup.S4R.sup.S4,
--N(R.sup.S4)C(O)OR.sup.S4, --N(R)C(O)NR.sup.S4R.sup.S4,
--N(R.sup.S4)S(O).sub.2NR.sup.S4R.sup.S4 or
--N(R.sup.S4)S(O).sub.2R.sup.S4; [0030] wherein q is 0, 1, 2 or 3;
and [0031] wherein each R.sup.S4 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano;
[0032] Z is
[0033] a fused bicyclic ring of the formula,
##STR00004##
wherein [0034] ring A is Ar or 6-membered Het, [0035] ring B is 5-
or 6-membered Het,
[0036] wherein [0037] Z is optionally substituted by one or two
--R.sup.Z groups that are each independently halogen, cyano,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy,
--OR.sup.S2, --SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2,
--C(O)OR.sup.S2, --C(O)NR.sup.S2.sub.2,
--S(O).sub.2NR.sup.S2.sub.2, --S(O).sub.2R.sup.S2, --OC(O)R.sup.S2,
--N(R.sup.S2)C(O)R.sup.S2, --OC(O)OR.sup.S2,
--OC(O)NR.sup.S2.sub.2, --N(R.sup.S2)C(O)OR.sup.S2,
--N(R.sup.S2)C(O)NR.sup.S2.sub.2, --N(R.sup.S2)S(O).sub.2R.sup.S2,
--OP(O)(OR.sup.S2).sub.2 or --CH.sub.2--OP(O)(OR.sup.S2), wherein
each alkyl, haloalkyl and alkoxy is optionally substituted by one
or two --R.sup.Z2 groups; [0038] wherein each R.sup.S2 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl,
C.sub.1-C.sub.6alkyl-O--C.sub.1-C.sub.6alkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano; and [0039] each --R.sup.Z2 is
independently halogen, cyano, C.sub.1-6alkyl, C.sub.1-6haloalkyl,
--C.sub.1-C.sub.6alkoxy, --OR.sup.S3, --SR.sup.S3,
--NR.sup.S3.sub.2, --C(O)R.sup.S3, --C(O)OR.sup.S3,
--C(O)NR.sup.S3.sub.2, --S(O).sub.2NR.sup.S3.sub.2,
--S(O).sub.2R.sup.S3, --OC(O)R.sup.S3, --N(R.sup.S3)C(O)R.sup.S3,
--OC(O)OR.sup.S3, --OC(O)NR.sup.S3.sub.2,
--N(R.sup.S3)C(O)OR.sup.S3, --N(R.sup.S3)C(O)NR.sup.S3.sub.2,
--N(R.sup.S3)S(O).sub.2R.sup.S3, --OP(O)(OR.sup.S3).sub.2 or
--CH.sub.2--OP(O)(OR.sup.S3); and [0040] wherein each R.sup.S3 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano.
[0041] In embodiment I.sub.1 of this first aspect, the compounds
have structural formula (I):
##STR00005##
or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof,
or a solvate or hydrate thereof, wherein
[0042] n is 1, 2, 3 or 4;
[0043] R.sup.1 is hydrogen, halogen, cyano, nitro, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, C.sub.3-8cycloalkyl, C.sub.3-8cycloalkenyl,
heterocyclyl, aryl, heteroaryl, --R.sup.a, or --C.sub.1-6
alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1, --SR.sup.S1,
--NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--O(CH.sub.2).sub.mC(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2R.sup.S1; [0044] wherein m is 0, 1, 2 or 3;
and [0045] wherein each R.sup.S1 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano;
[0046] Z is
[0047] a fused bicyclic ring of the formula,
##STR00006##
wherein [0048] ring A is Ar or 6-membered Het, [0049] ring B is 5-
or 6-membered Het,
[0050] wherein [0051] Z is optionally substituted by one or two
--R.sup.Z groups that are each independently halogen, cyano,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy,
--OR.sup.S2, --SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2,
--C(O)OR.sup.S2, --C(O)NR.sup.S2.sub.2,
--S(O).sub.2NR.sup.S2.sub.2, --S(O).sub.2R.sup.S2, --OC(O)R.sup.S2,
--N(R.sup.S2)C(O)R.sup.S2, --OC(O)OR.sup.S2,
--OC(O)NR.sup.S2.sub.2, --N(R.sup.S2)C(O)OR.sup.S2,
--N(R.sup.S2)C(O)NR.sup.S2.sub.2, --N(R.sup.S2)S(O).sub.2R.sup.S2,
--OP(O)(OR.sup.S2).sub.2 or --CH.sub.2--OP(O)(OR.sup.S2), wherein
each alkyl, haloalkyl and alkoxy is optionally substituted by one
or two --R.sup.Z2 groups; [0052] wherein each R.sup.S2 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano; and [0053] each
--R.sup.Z2 is independently halogen, cyano, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy, --OR.sup.S3,
--SR.sup.S3, --NR.sup.S3.sub.2, --C(O)R.sup.S3, --C(O)OR.sup.S3,
--C(O)NR.sup.S3.sub.2, --S(O).sub.2NR.sup.S3.sub.2,
--S(O).sub.2R.sup.S3, --OC(O)R.sup.S3, --N(R.sup.S3)C(O)R.sup.S3,
--OC(O)OR.sup.S3, --OC(O)NR.sup.S3.sub.2,
--N(R.sup.S3)C(O)OR.sup.S3, --N(R.sup.S3)C(O)NR.sup.S3.sub.2,
--N(R.sup.S3)S(O).sub.2R.sup.S3, --OP(O)(OR.sup.S3).sub.2 or
--CH.sub.2--OP(O)(OR.sup.S3); and [0054] wherein each R.sup.S3 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano.
[0055] In embodiment I', the compounds are of embodiment I.sub.1,
provided that the compound is not any compound expressly recited in
International Publication No. WO 2014/055955 A1.
[0056] In embodiment I'', the compounds are of embodiment I.sub.0,
provided that the compound is not any compound expressly recited in
International Publication No. WO 2014/055955 A1.
[0057] In embodiment I.sub.2, the compounds are of embodiment
I.sub.1, provided that the compound is not
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole.
[0058] In embodiment I.sub.2', the compounds are of embodiment
I.sub.o, provided that the compound is not
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole.
[0059] In embodiment I.sub.3, the compounds are of embodiment
I.sub.1, wherein
Z is
[0060] a fused bicyclic ring of the formula,
##STR00007##
wherein
[0061] ring A is Ar or 6-membered Het,
[0062] ring B is 5- or 6-membered Het,
wherein
[0063] Z is optionally substituted by one or two --R.sup.Z groups
that are each independently halogen, cyano, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy, --OR.sup.S2,
--SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2, --C(O)OR.sup.S2,
--C(O)NR.sup.S2.sub.2, --S(O).sub.2NR.sup.S2.sub.2,
--S(O).sub.2R.sup.S2, --OC(O)R.sup.S2, --N(R.sup.S2)C(O)R.sup.S2,
--OC(O)OR.sup.S2, --OC(O)NR.sup.S2.sub.2,
--N(R.sup.S2)C(O)OR.sup.S2, --N(R.sup.S2)C(O)NR.sup.S2.sub.2,
--N(R.sup.S2)S(O).sub.2R.sup.S2, --OP(O)(OR.sup.S2).sub.2 or
--CH.sub.2--OP(O)(OR.sup.S2); [0064] wherein each R.sup.S2 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano.
[0065] In embodiment I.sub.4, the compounds are of embodiment
I.sub.1, wherein
Z is
[0066] a fused bicyclic ring of the formula,
##STR00008##
wherein [0067] (1) ring A is Ar or 6-membered Het, and [0068] ring
B is a 6-membered Het; or [0069] (2) ring A is 6-membered Het, and
[0070] ring B is a 5-membered Het; wherein Z is optionally
substituted by one or two --R.sup.Z groups.
[0071] In embodiment I.sub.4, the compounds are of embodiment
I.sub.1, wherein n is 1 or 2 and each R.sup.1 is independently
halogen C.sub.1-6alkyl, C.sub.1-6haloalkyl or
C.sub.3-8cycloalkyl.
[0072] The invention further comprises subgenera of formula (I) in
which structural formula (I), n, R.sup.1 and Z are any group or
combinations of groups as defined hereinbelow (e.g., wherein the
compound is of structural formula (I) as defined in any of the
above embodiments and Z is benzoimidizolyl optionally substituted
with one R.sup.Z group, wherein R.sup.Z is halogen; or the compound
is formula (Ib), Z is group (2g), R.sup.1 is group (1d) and n is
group (3e)):
[0073] Structural Formula (I) is One of Formulae (Ia)-(Im):
##STR00009## ##STR00010## ##STR00011##
[0074] R.sup.1 is Selected from One of the Following Groups
(1a)-(1tt): [0075] (1a) R.sup.1 is hydrogen, halogen, cyano, nitro,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkenyl, heterocyclyl, aryl, heteroaryl, --R.sup.a,
or --C.sub.1-6alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--O(CH.sub.2).sub.mC(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1 or
--N(R.sup.S1)S(O).sub.2R.sup.S1, [0076] wherein m is 0, 1, 2 or 3;
and [0077] wherein each R.sup.S1 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano. [0078] (1b) R.sup.1 is as
described in (1a), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0079] (1c) R.sup.1 is hydrogen, --R.sup.a,
or --C.sub.1-6alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--O(CH.sub.2).sub.mC(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2R.sup.S1, [0080] wherein m is 0, 1, 2 or 3;
and [0081] wherein each R.sup.S1 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano. [0082] (1d) R.sup.1 is as
described in (1c), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0083] (1e) R.sup.1 is hydrogen, halogen,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --R.sup.a, or
--C.sub.1-6alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--O(CH.sub.2).sub.mC(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1;
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1 or
--N(R.sup.S1)S(O).sub.2R.sup.S1, [0084] wherein m is 0, 1, 2 or 3;
and [0085] wherein each R.sup.S1 is independently hydrogen,
C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl,
--(C.sub.0-C.sub.6alkyl)-Ar, --(C.sub.0-C.sub.6alkyl)-Het,
--(C.sub.0-C.sub.6alkyl)-Cak, or --(C.sub.0-C.sub.6alkyl)-Hca,
wherein Ar, Het, Cak, Hca, alkyl, and haloalkyl are optionally
substituted with C.sub.1-C.sub.6alkyl, halogen,
C.sub.1-C.sub.6haloalkyl or cyano. [0086] (1f) R.sup.1 is as
described in (1e), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0087] (1g) R.sup.1 is hydrogen, halogen,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6haloalkyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkenyl, heterocyclyl, aryl,
heteroaryl, --R.sup.a, or --C.sub.1-6alkyl-R.sup.a, wherein R.sup.a
is --OR.sup.S1, --SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)R.sup.S1,
--C(O)OR.sup.S1, --C(O)NR.sup.S1R.sup.S1,
--S(O).sub.2NR.sup.S1R.sup.S1, --OC(O)R.sup.S1,
--N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, --N(R)C(O)NR.sup.S1R.sup.S1,
--N(R.sup.S1)S(O).sub.2NR.sup.S1R.sup.S1 or
--N(R.sup.S1)S(O).sub.2R.sup.S1, [0088] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0089] (1h) R.sup.1 is
as described in (1g), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0090] (1i) R.sup.1 is hydrogen, halogen,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --R.sup.a, or
--C.sub.1-6alkyl-R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1; [0091] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0092] (1j) R.sup.1 is
as described in (1i), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0093] (1k) R.sup.1 is hydrogen, halogen,
cyano, C.sub.1-6alkyl, --R.sup.a, or --C.sub.1-6alkyl-R.sup.a,
wherein R.sup.a is --OR.sup.S1, --SR.sup.S1, --NR.sup.S1R.sup.S1,
--C(O)R.sup.S1, --C(O)OR.sup.S1, --C(O)NR.sup.S1R.sup.S1,
--S(O).sub.2NR.sup.S1R.sup.S1, --OC(O)R.sup.S1,
--N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1, [0094] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0095] (1l) R.sup.1 is
as described in (1k), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0096] (1m) R.sup.1 is hydrogen, halogen,
cyano, C.sub.1-6alkyl or --R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1; [0097] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0098] (1n) R.sup.1 is
as described in (1m), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0099] (1o) R.sup.1 is hydrogen or --R.sup.a,
wherein R.sup.a is --OR.sup.S1, --SR.sup.S1, --NR.sup.S1R.sup.S1,
--C(O)R.sup.S1, --C(O)OR.sup.S1, --C(O)NR.sup.S1R.sup.S1,
--S(O).sub.2NR.sup.S1R.sup.S1, --OC(O)R.sup.S1,
--N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1; [0100] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0101] (1p) R.sup.1 is
as described in (1o), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0102] (1q) R.sup.1 is halogen, cyano,
C.sub.1-6alkyl or --R.sup.a, wherein R.sup.a is --OR.sup.S1,
--SR.sup.S1, --NR.sup.S1R.sup.S1, --C(O)R.sup.S1, --C(O)OR.sup.S1,
--C(O)NR.sup.S1R.sup.S1, --S(O).sub.2NR.sup.S1R.sup.S1,
--OC(O)R.sup.S1, --N(R.sup.S1)C(O)R.sup.S1, --OC(O)OR.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1; [0103] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0104] (1r) R.sup.1 is
as described in (1q), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0105] (1s) R.sup.1 is hydrogen or --R.sup.a,
wherein R.sup.a is --OR.sup.S1, --SR.sup.S1, --NR.sup.S1R.sup.S1,
--C(O)R.sup.S1, --C(O)OR.sup.S1, --C(O)NR.sup.S1R.sup.S1,
--S(O).sub.2NR.sup.S1R.sup.S1, --OC(O)R.sup.S1,
--N(R.sup.S1)C(O)R.sup.S1, --OC(O)R.sup.S1,
--N(R.sup.S1)C(O)OR.sup.S1; [0106] wherein each R.sup.S1 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano. [0107] (1t) R.sup.1 is
as described in (1s), wherein R.sup.S1 is independently hydrogen or
C.sub.1-C.sub.6alkyl. [0108] (1u) R.sup.1 is hydrogen, halogen,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6haloalkyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkenyl, heterocyclyl, aryl or
heteroaryl. [0109] (1v) R.sup.1 is hydrogen, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkenyl, heterocyclyl, aryl or heteroaryl. [0110]
(1w) R.sup.1 is hydrogen, halogen, cyano, nitro, C.sub.1-6alkyl or
C.sub.1-6haloalkyl. [0111] (1x) R.sup.1 is halogen, cyano, nitro,
C.sub.1-6alkyl or C.sub.1-6haloalkyl. [0112] (1y) R.sup.1 is
hydrogen, halogen, cyano or nitro. [0113] (1z) R.sup.1 is hydrogen,
halogen, nitro, C.sub.1-6alkyl or C.sub.1-6haloalkyl. [0114] (1aa)
R.sup.1 is hydrogen, halogen, cyano, C.sub.1-6alkyl or
C.sub.1-6haloalkyl. [0115] (1bb) R.sup.1 is hydrogen, halogen,
cyano, nitro or C.sub.1-6haloalkyl. [0116] (1cc) R.sup.1 is
hydrogen, cyano, nitro, C.sub.1-6alkyl or C.sub.1-6haloalkyl.
[0117] (1dd) R.sup.1 is hydrogen, cyano, C.sub.1-6alkyl or
C.sub.1-6haloalkyl. [0118] (1ee) R.sup.1 is hydrogen, halogen,
C.sub.1-6alkyl or C.sub.1-6haloalkyl. [0119] (1ff) R.sup.1 is
hydrogen, halogen, or C.sub.1-6alkyl. [0120] (1gg) R.sup.1 is
hydrogen or C.sub.1-6alkyl. [0121] (1hh) R.sup.1 is hydrogen or
halogen. [0122] (1ii) R.sup.1 is halogen or C.sub.1-6alkyl. [0123]
(1jj) R.sup.1 is halogen or C.sub.1-4alkyl. [0124] (1kk) R.sup.1 is
halogen or C.sub.1-4alkyl. [0125] (1ll) R.sup.1 is hydrogen,
halogen or methyl. [0126] (1 mm) R.sup.1 is halogen or methyl.
[0127] (1nn) R.sup.1 is hydrogen, fluoro or methyl. [0128] (1oo)
R.sup.1 is fluoro or methyl. [0129] (1pp) R.sup.1 is hydrogen,
fluoro. [0130] (1qq) R.sup.1 is fluoro. [0131] (1rr) R.sup.1 is
hydrogen, methyl. [0132] (1ss) R.sup.1 is methyl. [0133] (1tt)
R.sup.1 is hydrogen.
[0134] Z is Selected from One of the Following Groups
(2a)-(2dddd):
[0135] (2a) Z is [0136] a fused bicyclic ring of the formula,
##STR00012##
[0136] wherein [0137] ring A is Ar or 6-membered Het, [0138] ring B
is 5- or 6-membered Het,
[0139] wherein [0140] Z is optionally substituted by one or two
--R.sup.Z groups that are each independently halogen, cyano,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy,
--OR.sup.S2, --SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2,
--C(O)OR.sup.S2, --C(O)NR.sup.S2.sub.2,
--S(O).sub.2NR.sup.S2.sub.2, --S(O).sub.2R.sup.S2, --OC(O)R.sup.S2,
--N(R.sup.S2)C(O)R.sup.S2, --OC(O)OR.sup.S2,
--OC(O)NR.sup.S2.sub.2, --N(R.sup.S2)C(O)OR.sup.S2,
--N(R.sup.S2)C(O)NR.sup.S2.sub.2, --N(R.sup.S2)S(O).sub.2R.sup.S2,
--OP(O)(OR.sup.S2).sub.2 or --CH.sub.2--OP(O)(OR.sup.S2), [0141]
wherein each alkyl, haloalkyl and alkoxy is optionally substituted
by one or two --R.sup.Z2 groups; [0142] wherein each R.sup.S2 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano; and [0143] each
--R.sup.Z2 is independently halogen, cyano, C.sub.1-6alkyl,
C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy, --OR.sup.S3,
--SR.sup.S3, --NR.sup.S3.sub.2, --C(O)R.sup.S3, --C(O)OR.sup.S3,
--C(O)NR.sup.S3.sub.2, --S(O).sub.2NR.sup.S3.sub.2,
--S(O).sub.2R.sup.S3, --OC(O)R.sup.S3, --N(R.sup.S3)C(O)R.sup.S3,
--OC(O)OR.sup.S3, --OC(O)NR.sup.S3.sub.2,
--N(R.sup.S3)C(O)OR.sup.S3, --N(R.sup.S3)C(O)NR.sup.S3.sub.2,
--N(R.sup.S3)S(O).sub.2R.sup.S3, --OP(O)(OR.sup.S3).sub.2 or
--CH.sub.2--OP(O)(OR.sup.S3); and [0144] wherein each R.sup.S3 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano.
[0145] (2b) Z is as described in (2a), provided that Z is not
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole
[0146] (2c) Z is as described in (2a), provided that Z is not
##STR00013##
[0147] (2d) Z is [0148] a fused bicyclic ring of the formula,
##STR00014##
[0148] wherein [0149] ring A is Ar or 6-membered Het, [0150] ring B
is 5- or 6-membered Het,
[0151] wherein [0152] Z is optionally substituted by one or two
--R.sup.Z groups that are each independently halogen, cyano,
C.sub.1-6alkyl, C.sub.1-6haloalkyl, --C.sub.1-C.sub.6alkoxy,
--OR.sup.S2, --SR.sup.S2, --NR.sup.S2.sub.2, --C(O)R.sup.S2,
--C(O)OR.sup.S2, --C(O)NR.sup.S2.sub.2,
--S(O).sub.2NR.sup.S2.sub.2, --S(O).sub.2R.sup.S2, --OC(O)R.sup.S2,
--N(R.sup.S2)C(O)R.sup.S2, --OC(O)OR.sup.S2,
--OC(O)NR.sup.S2.sub.2, --N(R.sup.S2)C(O)OR.sup.S2,
--N(R.sup.S2)C(O)NR.sup.S2.sub.2, --N(R.sup.S2)S(O).sub.2R.sup.S2,
--OP(O)(OR.sup.S2).sub.2 or --CH.sub.2--OP(O)(OR.sup.S2).
[0153] (2e) Z is as described in (2d), provided that Z is not
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole
[0154] (2f) Z is as described in (2d), provided that Z is not
##STR00015##
[0155] (2g) Z is [0156] a fused bicyclic ring of the formula,
##STR00016##
[0156] wherein [0157] (1) ring A is Ar or 6-membered Het, and
[0158] ring B is a 6-membered Het; or [0159] (2) ring A is
6-membered Het, and [0160] ring B is a 5-membered Het; [0161]
optionally substituted as described in (2a) above.
[0162] (2h) Z is [0163] a fused bicyclic ring of the formula,
##STR00017##
[0163] wherein [0164] (1) ring A is Ar or 6-membered Het, and
[0165] ring B is a 6-membered Het; or [0166] (2) ring A is
6-membered Het, and [0167] ring B is a 5-membered Het; [0168]
optionally substituted as described in (2d) above.
[0169] (2i) Z is [0170] a fused bicyclic ring of the formula,
##STR00018##
[0170] wherein [0171] (1) ring A is Ar, and [0172] ring B is a
6-membered Het; or [0173] (2) ring A is 6-membered Het, and [0174]
ring B is a 5-membered Het; [0175] optionally substituted as
described in (2a) above.
[0176] (2j) Z is [0177] a fused bicyclic ring of the formula,
##STR00019##
[0177] wherein [0178] (1) ring A is Ar, and [0179] ring B is a
6-membered Het; or [0180] (2) ring A is 6-membered Het, and [0181]
ring B is a 5-membered Het; [0182] optionally substituted as
described in (2d) above.
[0183] (2k) Z is
[0184] a fused bicyclic ring of the formula,
##STR00020##
wherein [0185] (1) ring A is 6-membered Het, and [0186] ring B is a
6-membered Het; or [0187] (2) ring A is 6-membered Het, and [0188]
ring B is a 5-membered Het; [0189] optionally substituted as
described in (2a) above.
[0190] (2l) Z is [0191] a fused bicyclic ring of the formula,
##STR00021##
[0191] wherein [0192] (1) ring A is 6-membered Het, and [0193] ring
B is a 6-membered Het; or [0194] (2) ring A is 6-membered Het, and
[0195] ring B is a 5-membered Het; [0196] optionally substituted as
described in (2d) above.
[0197] (2m) Z is [0198] a fused bicyclic ring of the formula,
##STR00022##
[0198] wherein [0199] ring A is Ar or 6-membered Het, and [0200]
ring B is a 6-membered Het; or [0201] optionally substituted as
described in (2a) above.
[0202] (2n) Z is [0203] a fused bicyclic ring of the formula,
##STR00023##
[0203] wherein [0204] ring A is Ar or 6-membered Het, and [0205]
ring B is a 6-membered Het; or [0206] optionally substituted as
described in (2d) above.
[0207] (2o) Z is [0208] a fused bicyclic ring of the formula,
##STR00024##
[0208] wherein [0209] ring A is Ar, and [0210] ring B is a
6-membered Het; or [0211] optionally substituted as described in
(2a) above.
[0212] (2p) Z is [0213] a fused bicyclic ring of the formula,
##STR00025##
[0213] wherein [0214] ring A is Ar, and [0215] ring B is a
6-membered Het; or [0216] optionally substituted as described in
(2d) above.
[0217] (2q) Z is [0218] a fused bicyclic ring of the formula,
##STR00026##
[0218] wherein [0219] ring A is 6-membered Het, and [0220] ring B
is a 6-membered Het; or [0221] optionally substituted as described
in (2a) above.
[0222] (2r) Z is [0223] a fused bicyclic ring of the formula,
##STR00027##
[0223] wherein [0224] ring A is 6-membered Het, and [0225] ring B
is a 6-membered Het; or [0226] optionally substituted as described
in (2d) above.
[0227] (2s) Z is [0228] a fused bicyclic ring of the formula,
##STR00028##
[0228] wherein [0229] ring A is 6-membered Het, and [0230] ring B
is a 5-membered Het; [0231] optionally substituted as described in
(2a) above.
[0232] (2t) Z is [0233] a fused bicyclic ring of the formula,
##STR00029##
[0233] wherein [0234] ring A is 6-membered Het, and [0235] ring B
is a 5-membered Het; [0236] optionally substituted as described in
(2d) above.
[0237] (2u) Z is
##STR00030## [0238] optionally substituted as described in (2a)
above.
[0239] (2v) Z is
##STR00031## [0240] optionally substituted as described in (2d)
above.
[0241] (2w) Z is
##STR00032## [0242] optionally substituted as described in (2a)
above.
[0243] (2x) Z is
##STR00033## [0244] optionally substituted as described in (2d)
above.
[0245] (2y) Z is
##STR00034## [0246] optionally substituted as described in (2a)
above.
[0247] (2z) Z is
##STR00035## [0248] optionally substituted as described in (2d)
above.
[0249] (2aa) Z is
##STR00036## [0250] optionally substituted as described in (2a)
above.
[0251] (2bb) Z is
##STR00037## [0252] optionally substituted as described in (2d)
above.
[0253] (2cc) Z is
##STR00038## [0254] optionally substituted as described in (2a)
above.
[0255] (2dd) Z is
##STR00039## [0256] optionally substituted as described in (2d)
above.
[0257] (2ee) Z is,
##STR00040## [0258] optionally substituted as described in (2a)
above.
[0259] (2ff) Z is,
##STR00041## [0260] optionally substituted as described in (2d)
above.
[0261] (2gg) Z is
##STR00042## [0262] optionally substituted as described in (2a)
above.
[0263] (2hh) Z is
##STR00043## [0264] optionally substituted as described in (2d)
above.
[0265] (2ii) Z is
##STR00044## [0266] optionally substituted as described in (2a)
above.
[0267] (2jj) Z is
##STR00045## [0268] optionally substituted as described in (2d)
above.
[0269] (2kk) Z is
##STR00046## [0270] optionally substituted as described in (2d)
above.
[0271] (2ll) Z is
##STR00047## [0272] optionally substituted as described in (2d)
above.
[0273] (2 mm) Z is
##STR00048## [0274] optionally substituted as described in (2d)
above.
[0275] (2nn) Z is
##STR00049## [0276] optionally substituted as described in (2d)
above.
[0277] (2oo) Z is
##STR00050## [0278] optionally substituted as described in (2d)
above.
[0279] (2pp) Z is
##STR00051## [0280] optionally substituted as described in (2d)
above.
[0281] (2qq) Z is
##STR00052## [0282] optionally substituted as described in (2a)
above, and wherein R.sup.Z is as described in (2a) above.
[0283] (2rr) Z is
##STR00053## [0284] wherein R.sup.Z is as described in (2a)
above.
[0285] (2ss) Z is
##STR00054## [0286] wherein R.sup.Z is as described in (2a).
[0287] (2tt) Z is
##STR00055## [0288] wherein R.sup.Z is as described in (2d).
[0289] (2uu) Z is
##STR00056## [0290] wherein R.sup.Z is --NH.sub.2, -cyano or
--C(O)NH.sub.2.
[0291] (2vv) Z is
##STR00057## [0292] wherein R.sup.Z is as described in (2d).
[0293] (2ww) Z is
##STR00058## [0294] wherein R.sup.Z is as described in (2d).
[0295] (2xx) Z is
##STR00059## [0296] wherein R.sup.Z is as described in (2d).
[0297] (2yy) Z is
##STR00060## [0298] wherein R.sup.Z is as described in (2d).
[0299] (2zz) Z is
##STR00061## [0300] wherein R.sup.Z is as described in (2d).
[0301] (2aaa) Z is
##STR00062##
[0302] (2bbb) Z is
##STR00063##
[0303] (2ccc) Z is
##STR00064##
[0304] (2ddd) Z is
##STR00065##
[0305] (2eee) Z is
##STR00066##
[0306] (2fff) Z is
##STR00067##
[0307] (2ggg) Z is
##STR00068##
[0308] (2hhh) Z is
##STR00069##
[0309] (2iii) Z is
##STR00070##
[0310] (2jjj) Z is
##STR00071##
[0311] (2kkk) Z is
##STR00072##
[0312] (2lll) Z is
##STR00073##
[0313] (2mmm) Z is
##STR00074## [0314] optionally substituted as described in (2a)
above.
[0315] (2nnn) Z is
##STR00075## [0316] optionally substituted as described in (2d)
above.
[0317] (2ooo) Z is
##STR00076## [0318] optionally substituted as described in (2a)
above.
[0319] (2ppp) Z is
##STR00077## [0320] optionally substituted as described in (2d)
above.
[0321] (2qqq) Z is
##STR00078## [0322] optionally substituted as described in (2a)
above.
[0323] (2rrr) Z is
##STR00079## [0324] optionally substituted as described in (2d)
above.
[0325] (2sss) Z is
##STR00080## [0326] optionally substituted as described in (2a)
above.
[0327] (2ttt) Z is
##STR00081## [0328] optionally substituted as described in (2d)
above.
[0329] (2uuu) Z is
##STR00082## [0330] optionally substituted as described in (2a)
above.
[0331] (2vvv) Z is
##STR00083## [0332] optionally substituted as described in (2d)
above.
[0333] (2www) Z is
##STR00084## [0334] optionally substituted as described in (2a)
above.
[0335] (2xxx) Z is
##STR00085## [0336] optionally substituted as described in (2d)
above.
[0337] (2yyy) Z is
##STR00086## [0338] optionally substituted as described in (2d)
above.
[0339] (2zzz) Z is
##STR00087## [0340] optionally substituted as described in (2d)
above.
[0341] (2aaaa) Z is
##STR00088## [0342] wherein R.sup.Z is as described in (2a).
[0343] (2bbbb) Z is
##STR00089## [0344] wherein R.sup.Z is as described in (2d).
[0345] (2cccc) Z is
##STR00090## [0346] wherein R.sup.Z is as described in (2d).
[0347] (2dddd) Z is
##STR00091## [0348] wherein R.sup.Z is as described in (2d).
[0349] n is Selected from One of the Following Groups
(3a)-(3i):
[0350] (3a) n is 0, 1, 2, 3 or 4.
[0351] (3b) n is 0, 1, 2 or 3.
[0352] (3c) n is 0, 1 or 2.
[0353] (3d) n is 0 or 1.
[0354] (3e) n is O.
[0355] (3f) n is 1.
[0356] (3g) n is 2.
[0357] (3h) n is 3.
[0358] (3i) n is 4.
[0359] Particular embodiments of this aspect of the invention
comprise compounds of any one of the formulae (I), (I') and
(Ia)-(Im), each as defined in each of the following rows (or a
pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a
solvate or hydrate thereof), wherein each entry is a group number
as defined above (e.g., (3i) refers to n is 4 and a dash "-"
indicates that the variable is as defined in embodiment I.sub.1 or
defined according to any one of the applicable variable definitions
(1a)-(3i) [e.g., when R.sup.1 is a dash, it can be either as
defined in any of embodiments I.sub.1-I.sub.8 or any one of
definitions (1a)-(1tt)]:
TABLE-US-00001 (I) R.sup.1 Z n (1)-1 (Ia) X (2a) X (1)-2 (Ib) X
(2b) X (1)-3 (Ic) X (2d) (3d) (1)-4 (Id) (1aa) (2q) (3e) (1)-5 (Ie)
(1ff) X (3f) (1)-6 (If) (1m) X (3g) (1)-7 (Ig) (1s) X (3a) (1)-8
(Ih) (1rr) X (3c) (1)-9 (Ib) X (2p) (3d) (1)-10 (Ic) X (2r) (3e)
(1)-11 (Id) (1a) (2k) (3f) (1)-12 (Id) (1q) (2r) (3g) (1)-13 (Ia) X
(2w) X (1)-14 (Ib) X (2x) X (1)-15 (Ic) X (2bb) (3a) (1)-16 (Id)
(1aa) (2k) (3c) (1)-17 (Ie) (1ff) X (3d) (1)-18 (If) (1m) X (3e)
(1)-19 (Ig) (1s) X (3f) (1)-20 (Ih) (1rr) X (3g) (1)-21 (Ia) X
(2bbb) X (1)-22 (Ib) X (2d) X (1)-23 (Ic) X (2x) (3a) (1)-24 (Id)
(1q) (2r) (3c) (1)-25 (Ie) (1u) X (3d) (1)-26 (If) (1aa) X (3e)
(1)-27 (Ig) (1ff) X (3f) (1)-28 (Ih) (1m) X (3g) (1)-29 (Ib) X (2r)
-- (1)-30 (Ic) X (2t) (3d) (1)-31 (Id) (1ss) (2k) -- (1)-32 (Ia) X
(2w) X (1)-33 (Ib) X (2x) X (1)-34 (Ic) X (2bb) -- (1)-35 (Id)
(1rr) (2s) (3a) (1)-36 (Ie) (1rr) X (3c) (1)-37 (If) (2s) X (3d)
(1)-38 (Ig) (2j) X (3e) (1)-39 (Ih) (2o) X -- (1)-40 (Ie) (2p) X
(3a) (1)-41 (If) (1ff) X (3c) (1)-42 (Ig) (1m) X (3d) (1)-43 (Ih)
(1s) X (3e) (1)-44 (Ib) X (2p) X (1)-45 (Ic) X (2r) -- (1)-46 (Id)
(2j) (2q) (3d) (1)-47 (Ig) (2o) X -- (1)-48 (Ih) (2p) X (3d) (1)-49
(Ib) X (2x) X (1)-50 (Ic) X (2bb) (3a) (1)-51 (Id) (1aa) (2r) (3c)
(1)-52 (Ie) (1ff) X (3d) (1)-53 (If) (1m) X (3e) (1)-54 (Ig) (1s) X
(3f) (1)-55 (Ih) (1rr) X (3g) (1)-56 (Ib) X (2bbb) -- (1)-57 (Ic) X
(2x) (3d) (1)-58 (Id) (1a) (2k) -- (1)-59 (Ib) X (2ii) X (1)-60
(Ic) X (2jj) -- (1)-61 (Id) (1rr) (2s) (3a) (1)-62 (Ie) (2s) X (3c)
(1)-63 (If) (2j) X (3d) (1)-64 (Ig) (2o) X (3e) (1)-65 (Ih) (2p) X
(3f) (1)-66 (Ib) X (2i) X (1)-67 (Ic) X (2j) (3a) (1)-68 (Id) (2s)
(2q) (3c) (1)-69 (Ic) X (2p) (3d) (1)-70 (Id) (2o) (2k) (3e) (1)-71
(Ie) (2p) X (3f) (1)-72 (If) (1rr) X (3g) (1)-73 (Ig) (1ff) X --
(1)-74 (Ih) (1m) X -- (1)-75 (Ic) X (2bb) (3a) (1)-76 (Id) (1rr)
(2q) (3c) (1)-77 (Ie) (2s) X (3d) (1)-78 (If) (2j) X (3e) (1)-79
(Ig) (2o) X (3f) (1)-80 (Ih) (2p) X (3g) (1)-81 (Ib) X (2bbb) X
(1)-82 (Ic) X (2jj) -- (1)-83 (Id) (1ff) (2r) (3a) (1)-84 (Ic) X
(2ww) (3c) (1)-85 (Id) (1s) (2s) (3d) (1)-86 (Ie) (1rr) X (3e)
(1)-87 (If) (1rr) X (3f) (1)-88 (Ig) (1rr) X (3g) (1)-89 (Ih) (1rr)
X -- (1)-90 (Ib) X (2h) X (1)-91 (Ic) X (2i) -- (1)-92 (Id) (1rr)
(2k) -- (1)-93 (Ia) X (2o) X (1)-94 (Ib) X (2p) X (1)-95 (Ic) X
(2r) (3a) (1)-96 (Ig) (1m) X (3c) (1)-97 (Ih) (1s) X (3d) (1)-98
(Ic) X (2ww) (3e) (1)-99 (Id) (1rr) (2q) (3f) (1)-100 (Ia) X (2bbb)
X (1)-101 (Ib) X (2g) X (1)-102 (Ic) X (2h) (3a) (1)-103 (Id) (1ff)
(2k) (3c) (1)-104 (Ie) (1m) X (3d) (1)-105 (If) (1s) X (3e) (1)-106
(Ig) (1rr) X (3f) (1)-107 (Ih) (1rr) X (3g) (1)-108 (Ia) X (2t) X
(1)-109 (Ib) X (2u) X (1)-110 (Ic) X (2w) -- (1)-111 (Id) (1rr)
(2r) (3d) (1)-112 (Ib) X (2bb) X (1)-113 (Ic) X (2ii) -- (1)-114
(Id) (1aa) (2q) (3d) (1)-115 (Ie) (1ff) X (3a) (1)-116 (If) (1m) X
(3c) (1)-117 (Ig) (1s) X (3d) (1)-118 (Ih) (1rr) X (3e) (1)-119
(Ib) X (2qq) (3f) (1)-120 (Ic) X (2ww) (3g) (1)-121 (Id) (1a) (2q)
-- (1)-122 (Ia) X (2bbb) X (1)-123 (Ib) X (2b) -- (1)-124 (Ic) X
(2d) (3d) (1)-125 (Id) (1s) (2r) -- (1)-126 (Ia) X (2h) X (1)-127
(Ib) X (2i) X (1)-128 (Ic) X (2j) -- (1)-129 (Id) -- (2s) (3a)
(1)-130 (Ie) (2s) X (3c) (1)-131 (If) (2j) X (3d) (1)-132 (Ig) (2o)
X (3e) (1)-133 (Ih) (2p) X (3f) (1)-134 (Ia) X (2w) X (1)-135 (Ib)
X (2x) X (1)-136 (Ic) X (2bb) (3a) (1)-137 (Id) (2s) (2s) (3c)
(1)-138 (Ie) (2j) X (3d) (1)-139 (If) (2o) X (3e) (1)-140 (Ig) (2p)
X (3f) (1)-141 (Ih) (2p) X (3g) (1)-142 (Ia) (1rr) (2bbb) --
(1)-143 (Ib) X (2qq) X (1)-144 (Ic) X (2ww) (3d) (1)-145 (Id) (1m)
(2s) -- (1)-146 (Ie) (1s) X (3a) (1)-147 (If) (1rr) X (3c) (1)-148
(Ig) (1rr) X (3d) (1)-149 (Ih) (1rr) X (3e) (1)-150 (Ib) X (2i)
(3f) (1)-151 (Ic) X (2j) (3g) (1)-152 (Id) (1s) (2q) -- (1)-153
(Ia) X (2p) X (1)-154 (Ib) X (2r) X (1)-155 (Ic) -- (2t) -- (1)-156
(Ib) X (2u) X (1)-157 (Ic) X (2w) (3a) (1)-158 (Id) (1aa) (2k) (3c)
(1)-159 (Ie) (1ff) X (3d) (1)-160 (If) (1m) X (3e) (1)-161 (Ig)
(1s) X (3f) (1)-162 (Ih) (1rr) X (3g) (1)-163 (Ie) (1ss) X (3d)
(1)-164 (If) (1tt) X -- (1)-165 (Ig) (1a) X (3d) (1)-166 (Ih) (1q)
X -- (1)-167 (Ia) X (2qq) X (1)-168 (Ib) X (2qq) X (1)-169 (Ic) X
(2jj) (3a) (1)-170 (Id) (1ff) (2q) (3c) (1)-171 (Ie) (1m) X (3a)
(1)-172 (If) (1s) X (3c) (1)-173 (Ig) (1rr) X (3d) (1)-174 (Ih) --
X (3e) (1)-175 (Ic) -- (2h) (3a) (1)-176 (Id) (2s) (2k) (3c)
(1)-177 (Ie) (2j) X (3d) (1)-178 (If) (2o) X (3e) (1)-179 (Ig) (2p)
X (3f) (1)-180 (Ih) -- X (3g) (1)-181 (Ib) X (2t) X (1)-182 (Ic) X
(2u) -- (1)-183 (Id) (1rr) (2r) (3d) (1)-184 (Ia) X (2x) X (1)-185
(Ib) X (2bb) X (1)-186 (Ic) X (2ii) -- (1)-187 (Id) (1m) (2s) (3a)
(1)-188 (Ie) (1s) X (3c) (1)-189 (If) (1rr) X (3d) (1)-190 (Ig)
(2s) X (3e) (1)-191 (Ih) (2j) X (3f) (1)-192 (Ie) (2o) X (3g)
(1)-193 (If) (2p) X -- (1)-194 (Ig) (1rr) X (3d) (1)-195 (Ia) X
(2o) X (1)-196 (Ib) X (2p) X (1)-197 (Ic) X (2r) -- (1)-198 (Ia) X
(2t) X (1)-199 (Ib) X (2u) X (1)-200 (Ic) X (2w) -- (1)-201 (Ib) X
(2x) X (1)-202 (Ic) X (2bb) (3a) (1)-203 (Id) (1ff) (2r) (3c)
(1)-204 (Ie) (1m) X (3d) (1)-205 (If) (1s) X (3e) (1)-206 (Ig)
(1rr) X (3f) (1)-207 (Ih) -- X (3g) (1)-208 (Ib) X (2bbb) X (1)-209
(Ic) X (2jj) -- (1)-210 (Id) (1aa) (2s) (3d) (1)-211 (Ic) X (2ww)
-- (1)-212 (Id) (1m) (2r) (3a) (1)-213 (Ie) (1s) X (3c) (1)-214
(If) (1rr) X (3d) (1)-215 (Ig) (1ss) X (3e) (1)-216 (Ih) (1tt) X
(3f) (1)-217 (Ie) (1a) X (3g) (1)-218 (If) (1q) X -- (1)-219 (Ig)
(1rr) X -- (1)-220 (Ia) X (2i) X (1)-221 (Ib) X (2j) X (1)-222 (Ic)
X (2o) -- (1)-223 (Ih) -- (2s) -- (1)-224 (Ia) X (2r) X (1)-225
(Ib) X (2t) X (1)-226 (Ic) X (2u) (3a) (1)-227 (Id) (1m) (2k) (3c)
(1)-228 (Ie) (1s) X (3d) (1)-229 (If) (1rr) X (3e) (1)-230 (Ig)
(2j) X (3f) (1)-231 (Ih) (2o) X (3g) (1)-232 (Ie) (2p) X -- (1)-233
(If) (1rr) X (3d) (1)-234 (Ig) (1rr) X -- (1)-235 (Ib) X (2bbb) X
(1)-236 (Ic) X (2t) -- (1)-237 (Id) (2j) (2s) -- (1)-238 (Ie) (2o)
X (3a) (1)-239 (If) (2p) X (3c) (1)-240 (Ig) (1ff) X (3d) (1)-241
(Ih) (1m) X (3e) (1)-242 (Ie) (1s) X (3f) (1)-243 (If) (1rr) X (3g)
(1)-244 (Ig) -- X -- (1)-245 (Ia) X (2aaa) X (1)-246 (Ib) X (2bbb)
X
(1)-247 (Ic) X (2x) -- (1)-248 (Id) (2j) (2k) (3d) (1)-249 (Ie)
(2o) X -- (1)-250 (If) (2p) X -- (1)-251 (Ig) (1aa) X (3a) (1)-252
(Ih) (1ff) X (3c) (1)-253 (Id) (1m) (2r) (3d) (1)-254 (Ie) (1s) X
(3e) (1)-255 (If) (1rr) X (3f) (1)-256 (Ig) (1ss) X (3g) (1)-257
(Ih) (1u) X (3a) (1)-258 (Ie) (1aa) X (3c) (1)-259 (If) (1ff) X
(3d) (1)-260 (Ig) (1m) X (3a) (1)-261 (If) (1s) X (3c) (1)-262 (Ig)
(1rr) (2t) (3d) (1)-263 (Ih) (1ss) X (3e) (1)-264 (If) (1tt) X (3f)
(1)-265 (Ig) (1a) X (3g) (1)-266 (Ih) (1q) X -- (1)-267 (Ia) X (2j)
X (1)-268 (Ib) X (2o) X (1)-269 (Ic) X (2p) (3a) (1)-270 (Id) (2j)
(2r) (3c) (1)-271 (Ie) (2o) X (3d) (1)-272 (If) (2p) X (3e) (1)-273
(Ig) -- X (3f) (1)-274 (Ih) -- X (3g) (1)-275 (Ia) X (2bb) X
(1)-276 (Ib) X (2ii) X (1)-277 (Ic) X (2jj) -- (1)-278 (Id) (1aa)
(2q) (3a) (1)-279 (Ie) (1ff) X (3c) (1)-280 (If) (1m) X (3d)
(1)-281 (Ig) (1s) X (3e) (1)-282 (Ih) (1rr) X (3f) (1)-283 (Ie)
(1ss) X (3g) (1)-284 (If) (1tt) X (3e) (1)-285 (Ig) (1a) X (3f)
(1)-286 (Ih) (1q) X (3g) (1)-287 (If) (2s) X (3d) (1)-288 (Ig) (2j)
(2t) -- (1)-289 (Ih) (2o) (2t) -- (1)-290 (Ia) X (2bb) X (1)-291
(Ib) X (2ii) X (1)-292 (Ic) X (2jj) -- (1)-293 (Id) (1aa) (2q) (3d)
(1)-294 (Ie) (1ff) X (3a) (1)-295 (If) (1m) X (3c) (1)-296 (Ig)
(1s) X (3d) (1)-297 (Ih) (1rr) X (3e) (1)-298 (Ie) (1ss) X (3f)
(1)-299 (If) (1tt) X (3g) (1)-300 (Ig) (1a) X -- (1)-301 (Ih) (1u)
(2mmm) (3a) (1)-302 (Ii) (1aa) (2nnn) (3c) (1)-303 (Ij) (1ff)
(2ppp) (3d) (1)-304 (Ik) (1m) (2qqq) (3e) (1)-305 (Il) (1s) (2cccc)
(3f) (1)-306 (Im) (1rr) (2dddd) (3g) (1)-307 (Ih) (1ss) (2xxx) (3a)
(1)-308 (Ii) (1tt) (2yyy) (3c) (1)-309 (Ij) (1a) (2aaaa) (3d)
(1)-310 (Ik) (1q) (2bbbb) (3e) (1)-311 (Il) (1u) (2ppp) (3f)
(1)-312 (Im) (1aa) (2ppp) (3g) (1)-313 (Ih) (1ff) (2qqq) (3d)
(1)-314 (Ii) (1m) (2cccc) (3e) (1)-315 (Ij) (1s) (2ppp) (3d)
(1)-316 (Ik) (1rr) (2qqq) (3e) (1)-317 (Il) (1ss) (2cccc) (3f)
(1)-318 (Im) (1tt) (2nnn) (3g) (1)-319 (Ih) (1a) (2ppp) (3c)
(1)-320 (Ii) (1q) (2qqq) (3d) (1)-321 (Ij) (1m) (2cccc) (3e)
(1)-322 (Ik) (1s) (2dddd) (3f) (1)-323 (Il) (1rr) (2xxx) (3g)
(1)-324 (Im) (1ss) (2yyy) (3d) (1)-325 (Ih) (1tt) (2aaaa) (3e)
(1)-326 (Ii) (1a) (2bbbb) (3d) (1)-327 (Ij) (1q) (2mmm) (3e)
(1)-328 (Ik) (1aa) (2nnn) (3f) (1)-329 (Il) (1u) (2ppp) (3g)
(1)-330 (Im) (1aa) (2qqq) (3a) (1)-331 (Ih) (1ff) (2cccc) (3c)
(1)-332 (Ii) (1m) (2dddd) (3d) (1)-333 (Ij) (1s) (2xxx) (3d)
(1)-334 (Ik) (1rr) (2yyy) (3e) (1)-335 (Il) (1ss) (2aaaa) (3f)
(1)-336 (Im) (1tt) (2bbbb) (3g)
[0360] In some embodiments, the compound of formulae (I),
(Ia)-(Im), (II) or (IIa)-(IIl) is one of the following compounds
(or a pharmaceutically acceptable salt, prodrug, or N-oxide
thereof, or a solvate or hydrate thereof):
TABLE-US-00002 No. Structure Name 1 ##STR00092##
4-(6'-methyl-[2,2'-bipyridin]-3-yl)quinoline 2 ##STR00093##
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin- 4-amine 2A
##STR00094## 6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-
4-aminium 2,2,2-trifluoroacetate 2B ##STR00095##
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin- 4-aminium formate 3
##STR00096## 6-(6'-Methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine- 3-carbonitri1e 4 ##STR00097##
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)- [1,2,4]triazolo[1,5-a]pyridine
5 ##STR00098## 7-(6'-Methyl-[2,2'-bipyridin]-3-yl)-
[1,2,4]triazolo[1,5-a]pyridine 6 ##STR00099##
6-(6'-Methyl-[2,2'-bipyridin]-3- yl)imidazo[1,2-a]pyridine-
3-carboxamide 7 ##STR00100## 6-([2,2'-Bipyridin]-3-
yl)imidazo[1,2-a]pyridine- 3-carbonitrile 8 ##STR00101##
6-([2,2'-Bipyridin]-3-yl)- [1,2,4]triazolo[1,5-a]pyridine 9
##STR00102## 6-([2,2'-Bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 10 ##STR00103##
6-(6'-methyl-[2,2'-bipyridin]-3- yl)pyrido[3,2-d]pyrimidin-4-amine
11 ##STR00104## 6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin-
4-amine 11A ##STR00105##
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin- 4-aminium
2,2,2-trifluoroacetate 12 ##STR00106##
6-([2,2'-bipyridin]-3-yl)quinazolin-4-amine 12A ##STR00107##
6-([2,2'-bipyridin]-3-yl)quinazolin-4-aminium formate 13
##STR00108## 6-([2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 14 ##STR00109##
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 15 ##STR00110##
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 16 ##STR00111##
6-(4'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 17 ##STR00112##
6-(6'-methoxy-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 18 ##STR00113##
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 19 ##STR00114##
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 20 ##STR00115##
6-(5'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 21 ##STR00116##
6-(5'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 22 ##STR00117##
6-(4'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 23 ##STR00118##
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carbonitrile 24 ##STR00119##
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carboxamide 25 ##STR00120## methyl
3'-(3-cyanoimidazo[1,2-a]pyridin-
6-yl)-[2,2'-bipyridine]-5-carboxylate 26 ##STR00121## methyl
3'-(3-carbamoylimidazo[1,2-a]pyridin-
6-yl)-[2,2'-bipyridine]-5-carboxylate 27 ##STR00122##
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-
[2,2'-bipyridine]-5-carboxylic acid 28 ##STR00123##
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 29 ##STR00124##
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 30 ##STR00125##
6-(6'-ethyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 31 ##STR00126##
6-(6'-isopropyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 32 ##STR00127##
6-(6'-isopropyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 33 ##STR00128##
6-(6'-methoxy-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 34 ##STR00129##
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 35 ##STR00130##
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 36 ##STR00131##
6-(6'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 37 ##STR00132##
6-(6'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 38 ##STR00133##
6-(6'-(benzyloxy)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 39 ##STR00134##
6-([2,2'-bipyridin]-3- yl)imidazo[1,2-a]pyridine-3-carboxamide 40
##STR00135## 6-(6'-acetyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 41 ##STR00136##
6-(6'-6-(6'-(2-hydroxypropan-2-yl)-[2,2'-
bipyridin]-3-yl)imidazo[1,2-a]pyridine-3- carbonitrile 42
##STR00137## 6-(4',6'-dimethyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 43 ##STR00138##
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 44 ##STR00139##
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-
[2,2'-bipyridin]-6-yl)methanesulfonamide 45 ##STR00140##
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-
[2,2'-bipyridin]-6-yl)acetamide 46 ##STR00141##
6-(6'-chloro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 47 ##STR00142##
6-(6'-methyl-[2,2'-bipyridin]-3- yl)imidazo[1,2-a]pyridine 48
##STR00143## 6-(6'-(difluoromethyl)-5'-fluoro-
[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine 49 ##STR00144##
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 50 ##STR00145##
6-(6'-methoxy-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 51 ##STR00146##
6-(6'-methoxy-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 52 ##STR00147##
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 53 ##STR00148##
6-(5'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 54 ##STR00149##
6-(5'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 55 ##STR00150##
6-(5'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 56 ##STR00151##
6-(5'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 57 ##STR00152##
6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 58 ##STR00153##
6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 59 ##STR00154##
6-(4'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 60 ##STR00155##
6-(4'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 61 ##STR00156##
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 63 ##STR00157##
6-(6'-isopropyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 64 ##STR00158##
6-(6'-isopropyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 65 ##STR00159##
6-(6'-fluoro-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carbonitrile 66 ##STR00160##
2,2,2-trifluoro-N-(6-(6'-methyl-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridin-3-yl)acetamide 67 ##STR00161##
6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxylic acid 68 ##STR00162##
N-(2,2-difluoroethyl)-6-(6'-methyl-[2,2'-
bipyridin]-3-yl)imidazo[1,2-a]pyridine-3- carboxamide 69
##STR00163## 6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-
(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridine- 3-carboxamide 70
##STR00164## N-(2-methoxyethyl)-6-(6'-methyl-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carboxamide 71 ##STR00165##
N-(.sup.2H.sub.3)methyl-6-[2-(6-methylpyridin-2-
yl)pyridin-3-yl]imidazo[1,2-a]pyridine-3- carboxamide 72
##STR00166## methyl-6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 73 ##STR00167##
6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxylic acid 74 ##STR00168##
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-
3-yl)imidazo[1,2-b]pyridazine-3-carboxamide 75 ##STR00169##
N-cyclopropyl-6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-b]pyridazine-3-carboxamide 76 ##STR00170##
N-(6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridin-2-yl)acetamide 77 ##STR00171##
N-(6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridin-2-yl)acetamide 78 ##STR00172##
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-2-carboxamide 79 ##STR00173##
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-2-carboxamide 80 ##STR00174##
6-(6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-2-carboxamide 81 ##STR00175##
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 82 ##STR00176##
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 83 ##STR00177##
6-(6'-(difluoromethyl)-5-fluoro-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carbonitrile 84 ##STR00178##
6-(6'-(difluoromethyl)-5-fluoro-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carboxamide 85 ##STR00179##
6-(5,5'-difluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 86 ##STR00180##
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 87 ##STR00181##
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carbonitrile 88 ##STR00182##
6-(6'-(difluoromethyl)-6-methyl-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carboxamide 89 ##STR00183##
6-(6'-methyl-6-(trifluoromethyl)-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carbonitrile 90 ##STR00184##
6-(6'-methyl-6-(trifluoromethyl)-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carboxamide 91 ##STR00185## methyl
3-(3-cyanoimidazo[1,2-a]pyridin-6-
yl)-6'-methyl-[2,2'-bipyridine]-4-carboxylate 92 ##STR00186##
6-(4-(hydroxymethyl)-6'-methyl-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carbonitrile 93 ##STR00187##
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carbonitriIe 94 ##STR00188##
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-
3-yl)imidazo[1,2-a]pyridine-3-carboxamide 95 ##STR00189##
6-(6-acetamido-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 96 ##STR00190##
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-
6'-methyl-[2,2'-bipyridin]-5-yl)acetamide 97 ##STR00191##
6-(5-acetamido-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 98 ##STR00192##
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 99 ##STR00193##
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxylic acid 100 ##STR00194##
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-
6'-methyl-[2,2'-bipyridin]-4-yl)acetamide 101 ##STR00195##
6-(4-amino-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 102 ##STR00196##
6-(4-acetamido-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-3-carboxamide 103 ##STR00197##
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)pyrido[3,2-d]pyrimidin-4-amine 104 ##STR00198##
6-(5'-fluoro-[2,2'-bipyridin]-3- yl)pyrido[3,2-d]pyrimidin-4-amine
105 ##STR00199## 6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)pyrido[3,2-d]pyrimidin-4-amine 106 ##STR00200##
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-
yl)pyrido[3,2-d]pyrimidin-4-amine 107 ##STR00201##
6-(6'-ethyl-[2,2'-bipyridin]-3-yl)quinazolin- 4-amine 108
##STR00202## 6-(6'-isopropyl-[2,2'-bipyridin]-3-
yl)quinazolin-4-amine 109 ##STR00203##
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3- yl)quinazolin-4-amine
110 ##STR00204## 6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)imidazo[1,2-a]pyridine-2-carboxamide 111 ##STR00205##
6-(6'-isopropyl-[2,2'-bipyridin]-3- yl)quinazolin-4-amine 112
##STR00206## 6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)quinoxaline 113 ##STR00207##
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinoxaline 114 ##STR00208##
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3- yl)quinoxaline 115
##STR00209## 5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)-1H-indazole 116 ##STR00210##
5-(5'-fluoro-[2,2'-bipyridin]-3-yl)-1H-indazole 117 ##STR00211##
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3- yl)-1H-indazole 118
##STR00212## 3-(difluoromethyl)-5-(6'-(difluoromethyl)-
[2,2'-bipyridin]-3-yl)-1H-indazole 119 ##STR00213##
5-(6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 120 ##STR00214##
5-(6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 121 ##STR00215##
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 122 ##STR00216##
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 123 ##STR00217## ethyl
5-(6'-(trifluoromethyl)-[2,2'-
bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxylate 124
##STR00218## 5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 125 ##STR00219##
N-methyl-5-(6'-(trifluoromethyl)-[2,2'-
bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 126
##STR00220## N-cyclopropyl-5-(6'-(trifluoromethyl)-[2,2'-
bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 127
##STR00221## N-methyl-5-(6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 128 ##STR00222##
N-cyclopropyl-5-(6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 129 ##STR00223##
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-
3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 130 ##STR00224## ethyl
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 131 ##STR00225##
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 132 ##STR00226##
N-cyclopropyl-5-(5'-fluoro-6'-methyl-[2,2'-
bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 133
##STR00227## 5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-
N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 134
##STR00228## ethyl 5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 135 ##STR00229##
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 136 ##STR00230##
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine 137 ##STR00231##
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-
yl)pyrazolo[1,5-a]pyrimidine 138 ##STR00232##
5-(6'-methyl-[2,2'-bipyridin]-3- yl)pyrazolo[1,5-a]pyrimidine
[0361] In embodiment II.sub.1 of this aspect, the invention
comprises compounds having the structure of formula (II):
##STR00233##
or a pharmaceutically acceptable salt, prodrug or N-oxide thereof,
or solvate or hydrate thereof, wherein [0362] R.sup.1 is hydrogen,
halogen, cyano, nitro, C.sub.1-6alkyl or C.sub.1-6haloalkyl; [0363]
Z is [0364] a fused bicyclic ring of the formula,
##STR00234##
[0364] wherein [0365] ring A is Ar or 6-membered Het, [0366] ring B
is 5- or 6-membered Het, [0367] wherein [0368] Z is optionally
substituted by one or two --R.sup.Z groups that are each
independently halogen, cyano, C.sub.1-6alkyl, C.sub.1-6haloalkyl,
--C.sub.1-C.sub.6alkoxy, --OR.sup.S2, --SR.sup.S2,
--NR.sup.S2.sub.2, --C(O)R.sup.S2, --C(O)OR.sup.S2,
--C(O)NR.sup.S2.sub.2, --S(O).sub.2NR.sup.S2.sub.2,
--S(O).sub.2R.sup.S2, --OC(O)R.sup.S2, --N(R.sup.S2)C(O)R.sup.S2,
--OC(O)OR.sup.S2, --OC(O)NR.sup.S2.sub.2,
--N(R.sup.S2)C(O)OR.sup.S2, --N(R.sup.S2)C(O)NR.sup.S2.sub.2,
--NR.sup.S2)S(O).sub.2R.sup.S2, --OP(O)(OR.sup.S2).sub.2 or
--CH.sub.2--OP(O)(OR.sup.S2); [0369] wherein each R.sup.S2 is
independently hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.1-C.sub.6haloalkyl, --(C.sub.0-C.sub.6alkyl)-Ar,
--(C.sub.0-C.sub.6alkyl)-Het, --(C.sub.0-C.sub.6alkyl)-Cak, or
--(C.sub.0-C.sub.6alkyl)-Hca, wherein Ar, Het, Cak, Hca, alkyl, and
haloalkyl are optionally substituted with C.sub.1-C.sub.6alkyl,
halogen, C.sub.1-C.sub.6haloalkyl or cyano.
[0370] In embodiment II.sub.2, the compounds are of embodiment
II.sub.1, provided that the compound is not
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole.
[0371] In embodiment II.sub.3, the compounds are of embodiment
II.sub.1, wherein
Z is
[0372] a fused bicyclic ring of the formula,
##STR00235##
wherein [0373] (1) ring A is Ar or 6-membered Het, and [0374] ring
B is a 6-membered Het; or [0375] (2) ring A is 6-membered Het, and
[0376] ring B is a 5-membered Het; wherein Z is optionally
substituted by one or two --R.sup.Z groups.
[0377] In embodiment II.sub.4, the compounds are of embodiment
II.sub.1, wherein
Z is
##STR00236##
[0378] wherein Z is optionally substituted by one or two --R.sup.Z
groups.
[0379] In embodiment II.sub.5, the compounds are of embodiment
II.sub.1, wherein
Z is
##STR00237##
[0381] wherein Z is optionally substituted by one or two --R.sup.Z
groups.
[0382] In embodiment II.sub.6, the compounds are of embodiment
II.sub.1, wherein
Z is
##STR00238##
[0383] wherein Z is optionally substituted by one or two --R.sup.Z
groups.
[0384] In embodiment II.sub.7, the compounds are of any of
embodiments II.sub.1-II.sub.6, wherein Z is unsubstituted.
[0385] In embodiment II.sub.8, the compounds are of any of
embodiments II.sub.1-II.sub.7, wherein R.sup.1 is hydrogen or
methyl.
[0386] In embodiment II.sub.9, the compounds of the invention are
one of formulae (IIa)-(IIl), wherein R.sup.1 and Z are as defined
in embodiments II.sub.1-II.sub.8 above:
[0387] Structural Formula (II) is One of Formulae (IIa)-(IIl):
##STR00239## ##STR00240##
[0388] Particular embodiments of this aspect of the invention
comprise compounds of any one of the formulae (II), and
(IIa)-(IIg), each as defined in each of the following rows (or a
pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a
solvate or hydrate thereof), wherein each entry is a group number
as defined above (e.g., (1ss) refers to R.sup.1 is methyl, and a
dash "-" indicates that the variable is as defined in embodiment
I.sub.1 or defined according to any one of the applicable variable
definitions (1a)-(1tt) and (2a)-(2dddd) [e.g., when R.sup.1 is a
dash, it can be either as defined in any of embodiments
II.sub.1-II.sub.8 or any one of the applicable definitions
(1a)-(1tt)]:
TABLE-US-00003 (II) R.sup.1 Z (2)-1 (IIa) X (2a) (2)-2 (IIb) X (2b)
(2)-3 (IIc) X (2d) (2)-4 (IId) (1aa) (2q) (2)-5 (IIe) (1ff) (2s)
(2)-6 (IIf) (1m) (2m) (2)-7 (IIg) (1s) (2s) (2)-8 (IIh) (1rr) (2t)
(2)-9 (IIh) (1ss) (2p) (2)-10 (IIf) (1tt) (2r) (2)-11 (IIb) (1a)
(2k) (2)-12 (IIc) (1q) (2r) (2)-13 (IId) X (2w) (2)-14 (IIf) X (2x)
(2)-15 (IIb) (1u) (2bb) (2)-16 (IIc) (1aa) (2k) (2)-17 (IId) (1ff)
(2q) (2)-18 (IIc) (1m) (2q) (2)-19 (IId) (1s) (2t) (2)-20 (IIe)
(1rr) (2t) (2)-21 (IIf) X (2bbb) (2)-22 (IIg) X (2d) (2)-23 (IIh)
(1a) (2x) (2)-24 (IIh) (1q) (2r) (2)-25 (IIf) (1u) (2q) (2)-26
(IIb) (1aa) (2n) (2)-27 (IIc) (1ff) (2s) (2)-28 (IId) (1m) (2s)
(2)-29 (IIc) (1s) (2r) (2)-30 (IId) (1rr) (2t) (2)-31 (IIb) (1ss)
(2k) (2)-32 (IIc) X (2w) (2)-33 (IId) X (2x) (2)-34 (IIe) (1q)
(2bb) (2)-35 (IIf) (1rr) (2s) (2)-36 (IIg) (1rr) (2l) (2)-37 (IIh)
(2s) (2p) (2)-38 (IIh) (2j) (2t) (2)-39 (IIc) (2o) (2s) (2)-40
(IId) (2p) (2l) (2)-41 (IIb) (1ff) (2m) (2)-42 (IIc) (1m) (2s)
(2)-43 (IId) (1s) (2t) (2)-44 (IIc) X (2p) (2)-45 (IId) (2s) (2r)
(2)-46 (IIb) (2j) (2q) (2)-47 (IIc) (2o) (2t) (2)-48 (IId) (2p)
(2s) (2)-49 (IIe) X (2x) (2)-50 (IIf) (1u) (2bb) (2)-51 (IIg) (1aa)
(2r) (2)-52 (IIh) (1ff) (2l) (2)-53 (IIe) (1m) (2o) (2)-54 (IIf)
(1s) (2t) (2)-55 (IIb) (1rr) (2t) (2)-56 (IIc) (1ss) (2bbb) (2)-57
(IId) (1tt) (2x) (2)-58 (IIc) (1a) (2k) (2)-59 (IId) X (2ii) (2)-60
(IIb) (1rr) (2jj) (2)-61 (IIc) (1rr) (2s) (2)-62 (IId) (2s) (2r)
(2)-63 (IIe) (2j) (2p) (2)-64 (IIf) (2o) (2s) (2)-65 (IIg) (2p)
(2s) (2)-66 (IIh) X (2i) (2)-67 (IId) (1rr) (2j) (2)-68 (IIf) (2s)
(2q) (2)-69 (IIb) (2j) (2p) (2)-70 (IIc) (2o) (2k) (2)-71 (IId)
(2p) (2l) (2)-72 (IIg) (1rr) (2q) (2)-73 (IIh) (1ff) (2t) (2)-74
(IIc) (1m) (2s) (2)-75 (IIc) (1s) (2bb) (2)-76 (IId) (1rr) (2q)
(2)-77 (IIe) (2s) (2q) (2)-78 (IIf) (2j) (2q) (2)-79 (IIg) (2o)
(2s) (2)-80 (IIh) (2p) (2t) (2)-81 (IIf) X (2bbb) (2)-82 (IIf)
(1rr) (2jj) (2)-83 (IIb) (1ff) (2r) (2)-84 (IIc) (1m) (2ww) (2)-85
(IId) (1s) (2s) (2)-86 (IIf) (1rr) (2r) (2)-87 (IIb) (1rr) (2m)
(2)-88 (IIc) (1rr) (2t) (2)-89 (IId) (1rr) (2t) (2)-90 (IId) X (2h)
(2)-91 (IIe) (1rr) (2i) (2)-92 (IIf) (1rr) (2k) (2)-93 (IIg) X (2o)
(2)-94 (IIh) X (2p) (2)-95 (IIa) X (2r) (2)-96 (IIf) (1m) (2t)
(2)-97 (IIb) (1s) (2t) (2)-98 (IIc) (1rr) (2ww) (2)-99 (IId) (1rr)
(2q) (2)-100 (IIf) X (2bbb) (2)-101 (IIb) X (2g) (2)-102 (IIc)
(1rr) (2h) (2)-103 (IId) (1ff) (2k) (2)-104 (IId) (1m) (2q) (2)-105
(IIe) (1s) (2r) (2)-106 (IIf) (1rr) (2t) (2)-107 (IIg) (1rr) (2s)
(2)-108 (IIh) X (2t) (2)-109 (IIg) X (2u) (2)-110 (IId) (1rr) (2w)
(2)-111 (IIf) (1rr) (2r) (2)-112 (IIb) X (2bb) (2)-113 (IIc) (1u)
(2ii) (2)-114 (IId) (1aa) (2q) (2)-115 (IId) (1ff) (2k) (2)-116
(IIe) (1m) (2n) (2)-117 (IIf) (1s) (2t) (2)-118 (IIg) (1rr) (2t)
(2)-119 (IIh) (1ss) (2qq) (2)-120 (IId) (1tt) (2ww) (2)-121 (IIf)
(1a) (2q) (2)-122 (IIb) X (2bbb) (2)-123 (IIc) (1ff) (2b) (2)-124
(IId) (1m) (2d) (2)-125 (IIb) (1s) (2r) (2)-126 (IIc) X (2h)
(2)-127 (IId) X (2i) (2)-128 (IIe) -- (2j) (2)-129 (IIf) -- (2s)
(2)-130 (IIg) (2s) (2k) (2)-131 (IIh) (2j) (2p) (2)-132 (IIb) (2o)
(2t) (2)-133 (IIf) (2p) (2t) (2)-134 (IIb) X (2w) (2)-135 (IIc) X
(2x) (2)-136 (IId) -- (2bb) (2)-137 (IIf) (2s) (2s) (2)-138 (IIb)
(2j) (2l) (2)-139 (IIc) (2o) (2q) (2)-140 (IId) (2p) (2s) (2)-141
(IId) (2t) (2)-142 (IIe) (1rr) (2bbb) (2)-143 (IIf) X (2qq) (2)-144
(IIg) (1ff) (2ww) (2)-145 (IIh) (1m) (2s) (2)-146 (IIa) X (2k)
(2)-147 (IIf) (1rr) (2o) (2)-148 (IIb) (1rr) (2s) (2)-149 (IIc)
(1rr) (2s) (2)-150 (IId) (1ff) (2i) (2)-151 (IIb) (1m) (2j) (2)-152
(IIc) (1s) (2q) (2)-153 (IId) X (2p) (2)-154 (IIe) X (2r) (2)-155
(IIf) -- (2t) (2)-156 (IIg) X (2u) (2)-157 (IIh) (1u) (2w) (2)-158
(IIf) (1aa) (2k) (2)-159 (IId) (1ff) (2q) (2)-160 (IIe) (1m) (2n)
(2)-161 (IIf) (1s) (2s) (2)-162 (IIg) (1rr) (2t) (2)-163 (IIh)
(1ss) (2r) (2)-164 (IIb) (1tt) (2r) (2)-165 (IIf) (1a) (2t) (2)-166
(IIb) (1q) (2s) (2)-167 (IIc) X (2qq) (2)-168 (IId) X (2qq) (2)-169
(IIb) -- (2jj) (2)-170 (IIc) (1ff) (2q) (2)-171 (IId) (1m) (2r)
(2)-172 (IIe) (1s) (2o) (2)-173 (IIf) (1rr) (2s) (2)-174 (IIg) --
(2s) (2)-175 (IIh) -- (2h) (2)-176 (IIa) X (2k) (2)-177 (IId) (2j)
(2k) (2)-178 (IIe) (2o) (2o) (2)-179 (IIf) (2p) (2t) (2)-180 (IIb)
-- (2t) (2)-181 (IIc) X (2t) (2)-182 (IId) (1rr) (2u) (2)-183 (IIe)
(1rr) (2r) (2)-184 (IIf) X (2x) (2)-185 (IIg) X (2bb) (2)-186 (IIh)
(1ff) (2ii) (2)-187 (IIa) (1m) (2s) (2)-188 (IIf) (1s) (2l) (2)-189
(IIb) (1rr) (2n) (2)-190 (IIc) (2s) (2t) (2)-191 (IId) (2j) (2t)
(2)-192 (IIg) (2o) (2q) (2)-193 (IIh) (2p) (2o) (2)-194 (IId) (1rr)
(2s) (2)-195 (IIb) X (2o) (2)-196 (IIc) X (2p) (2)-197 (IId) --
(2r) (2)-198 (IIe) X (2t) (2)-199 (IIf) X (2u) (2)-200 (IIg) --
(2w) (2)-201 (IIh) X (2x) (2)-202 (IIb) -- (2bb) (2)-203 (IId)
(1ff) (2r) (2)-204 (IIe) (1m) (2q) (2)-205 (IIf) (1s) (2q) (2)-206
(IIb) (1rr) (2t) (2)-207 (IIc) -- (2s) (2)-208 (IId) X (2bbb)
(2)-209 (IIe) (1u) (2jj) (2)-210 (IIf) (1aa) (2s) (2)-211 (IIg)
(1ff) (2ww) (2)-212 (IIh) (1m) (2r) (2)-213 (IIf) (1s) (2q) (2)-214
(IId) (1rr) (2m) (2)-215 (IIe) (1ss) (2s) (2)-216 (IIf) (1tt) (2s)
(2)-217 (IIa) X (2r) (2)-218 (IIb) (1q) (2p) (2)-219 (IIc) (1rr)
(2t) (2)-220 (IId) X (2i) (2)-221 (IIa) X (2j) (2)-222 (IIb) --
(2o) (2)-223 (IIc) -- (2s) (2)-224 (IId) X (2r) (2)-225 (IIe) X
(2t) (2)-226 (IIf) (1ff) (2u) (2)-227 (IIg) (1m) (2k) (2)-228 (IIh)
(1s) (2q) (2)-229 (IIa) X (2q) (2)-230 (IIg) (2j) (2s) (2)-231
(IIh) (2o) (2t) (2)-232 (IIg) (2p) (2r) (2)-233 (IIf) (1rr) (2o)
(2)-234 (IIa) X (2t) (2)-235 (IIb) X (2bbb) (2)-236 (IIc) (2s) (2t)
(2)-237 (IId) (2j) (2s) (2)-238 (IIe) (2o) (2r) (2)-239 (IIf) (2p)
(2n) (2)-240 (IIg) (1ff) (2t) (2)-241 (IIg) (1m) (2s) (2)-242 (IIh)
(1s) (2l) (2)-243 (IIb) (1rr) (2r) (2)-244 (IId) -- (2s) (2)-245
(IIe) X (2aaa) (2)-246 (IIf) X (2bbb)
(2)-247 (IIg) (2s) (2x) (2)-248 (IIh) (2j) (2k) (2)-249 (IIe) (2o)
(2q) (2)-250 (IIg) (2p) (2jj) (2)-251 (IIh) (1aa) (2t) (2)-252
(IIe) (1ff) (2t) (2)-253 (IId) (1m) (2r) (2)-254 (IIe) (1s) (2k)
(2)-255 (IIf) (1rr) (2r) (2)-256 (IId) (1ss) (2t) (2)-257 (IIe)
(1u) (2s) (2)-258 (IIf) (1aa) (2q) (2)-259 X (1ff) (2p) (2)-260
(IIb) (1m) (2s) (2)-261 (IIc) (1s) (2q) (2)-262 (IId) (1rr) (2t)
(2)-263 (IIe) (1ss) (2t) (2)-264 (IIf) (1tt) (2m) (2)-265 (IIg)
(1a) (2s) (2)-266 (IIh) (1q) (2s) (2)-267 (IIc) X (2j) (2)-268
(IId) X (2o) (2)-269 (IIe) (2s) (2p) (2)-270 (IIf) (2j) (2r)
(2)-271 (IIe) (2o) (2k) (2)-272 (IIf) (2p) (2o) (2)-273 (IIg) --
(2t) (2)-274 (IIh) -- (2t) (2)-275 (IId) X (2bb) (2)-276 (IIe) X
(2ii) (2)-277 (IIf) (1u) (2jj) (2)-278 (IIg) (1aa) (2q) (2)-279
(IIh) (1ff) (2q) (2)-280 (IIb) (1m) (2q) (2)-281 (IIe) (1s) (2t)
(2)-282 (IIf) (1rr) (2t) (2)-283 (IIb) (1ss) (2r) (2)-284 (IIc)
(1tt) (2p) (2)-285 (IId) (1a) (2t) (2)-286 (IIe) (1q) (2t) (2)-287
(IIf) (2s) (2p) (2)-288 (IIg) (2j) (2t) (2)-289 (IIh) (2o) (2t)
(2)-290 (IIe) X (2bb) (2)-291 (IIc) X (2ii) (2)-292 (IId) (1u)
(2jj) (2)-293 (IIe) (1aa) (2q) (2)-294 (IIf) (1ff) (2k) (2)-295
(IIg) (1m) (2n) (2)-296 (IIh) (1s) (2s) (2)-297 (IIa) X (2s)
(2)-298 (IId) (1ss) (2r) (2)-299 (IIe) (1tt) (2n) (2)-300 (IIf)
(1a) (2s) (2)-301 (IIh) (1u) (2mmm) (2)-302 (IIi) (1aa) (2nnn)
(2)-303 (IIj) (1ff) (2ppp) (2)-304 (IIk) (1m) (2qqq) (2)-305 (IIl)
(1s) (2cccc) (2)-306 (IIh) (1rr) (2dddd) (2)-307 (IIi) (1ss) (2xxx)
(2)-308 (IIj) (1tt) (2yyy) (2)-309 (IIk) (1a) (2aaaa) (2)-310 (IIl)
(1q) (2bbbb) (2)-311 (IIh) (1u) (2ppp) (2)-312 (IIi) (1aa) (2ppp)
(2)-313 (IIj) (1ff) (2qqq) (2)-314 (IIk) (1m) (2cccc) (2)-315 (IIl)
(1s) (2ppp) (2)-316 (IIh) (1rr) (2qqq) (2)-317 (IIi) (1ss) (2cccc)
(2)-318 (IIj) (1tt) (2nnn) (2)-319 (IIk) (1a) (2ppp) (2)-320 (IIh)
(1q) (2qqq) (2)-321 (IIi) (1m) (2cccc) (2)-322 (IIj) (1s) (2dddd)
(2)-323 (IIk) (1rr) (2xxx) (2)-324 (IIh) (1ss) (2yyy) (2)-325 (IIi)
(1tt) (2aaaa) (2)-326 (IIj) (1a) (2bbbb) (2)-327 (IIk) (1q) (2mmm)
(2)-328 (IIh) (1aa) (2nnn) (2)-329 (IIi) (1u) (2ppp) (2)-330 (IIj)
(1aa) (2qqq) (2)-331 (IIk) (1ff) (2cccc) (2)-332 (IIh) (1m) (2dddd)
(2)-333 (IIi) (1s) (2xxx) (2)-334 (IIj) (1rr) (2yyy) (2)-335 (IIk)
(1ss) (2aaaa) (2)-336 (IIh) (1tt) (2bbbb)
[0389] In some embodiments, the compound of formulae (II) or
(IIa)-(IIg) is one of the following compounds (or a
pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a
solvate or hydrate thereof): 2, 2A, 3, 4, 5, 6, 9, 11, 11A, 12 and
12A.
[0390] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 2 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0391] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 2A (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0392] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 3 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0393] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 4 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0394] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 5 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0395] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 6 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0396] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 9 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0397] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 11 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0398] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 11A (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0399] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 12 (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0400] In other embodiments, the compound of formulae (II) or
(IIa)-(IIg) is compound 12A (or a pharmaceutically acceptable salt,
prodrug, or N-oxide thereof, or a solvate or hydrate thereof).
[0401] In another aspect, the present invention comprises
pharmaceutical compositions comprising a compound according to any
one of the preceding aspects of the invention or any embodiment
thereof, together with a pharmaceutically acceptable excipient,
diluent, or carrier.
[0402] In another aspect, the invention comprises the use of a
compound described by any one of the preceding aspects of the
invention or any embodiment thereof, for the preparation of a
medicament for the treatment of medical diseases or conditions that
benefit from the inhibition of cytokine signaling. Medical
conditions contemplated in this aspect include all diseases and
conditions described herein.
[0403] The compounds of formulae (I.degree.), (I), (I'), (Ia)-(Im),
(II) and (IIa)-(IIl) described above are useful as kinase
inhibitors and/or inhibitors of cytokine signaling. Exemplary
kinases inhibited by the presently disclosed compounds include,
without limitation, ACVR1; ACVR1B (ALK-4); ACVR1C; ACVR2A; ACVR2B;
ACVRL1; BMPR1A; BMPR1B; BMPR2; TGFBR1 (ALK-5), PI3K and MAP4K4
(HGK). Exemplary cytokines, the signaling of which is inhibited by
the present compounds include, without limitation, TGF-.beta.
superfamily, including Activin, Nodal, TGF-.beta.1, and GDF-8. In
one aspect the present compounds are selective for one or more
kinase and/or cytokine signaling pathway. For example, exemplary
compounds inhibit TGF-.beta.1 signaling, GDF-8 signaling, or both.
In one aspect the present compounds inhibit GDF-8 signaling
preferentially to TGF-.beta.1 signaling, such that GDF8 signaling
is inhibited at least about 1.5-fold more potently or from about
1.1-fold to about 25-fold more potently. In one embodiment certain
compounds inhibit GDF8 signaling at least about 5-fold more
potently, such as from about 8-fold to about 50-fold, or at least
about 10-fold more potently, such as from about 15-fold to about
300-fold more potently.
[0404] In particular, the present compounds can be use to treat
disorders, such as pulmonary hypertension, chronic renal disease,
acute renal disease, wound healing, arthritis, osteoporosis, kidney
disease, congestive heart failure, ulcers, ocular disorders,
corneal wounds, diabetic nephropathy, impaired neurological
function, Alzheimer's disease, atherosclerosis, peritoneal and
sub-dermal adhesion, kidney fibrosis, lung fibrosis, including
idiopathic pulmonary fibrosis, and liver fibrosis, hepatitis B,
hepatitis C, alcohol-induced hepatitis, cancer, haemochromatosis,
primary biliary cirrhosis, restenosis, retroperitoneal fibrosis,
mesenteric fibrosis, endometriosis, keloids, cancer, abnormal bone
function, inflammatory disorders, scarring and photoaging of the
skin.
[0405] Particular proliferative diseases that can be treated with
the present compounds include those selected from a benign or
malignant tumor, carcinoma of the brain, kidney, liver, adrenal
gland, bladder, breast, stomach, gastric tumors, ovaries, colon,
rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma,
glioblastomas, multiple myeloma or gastrointestinal cancer,
especially colon carcinoma or colorectal adenoma or a tumor of the
neck and head, an epidermal hyperproliferation, melanoma,
psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of
epithelial character, leukemias and lymphomas, a mammary carcinoma
or a leukemia.
[0406] The compounds described herein also include isotopically
labeled compounds where one or more atoms have an atomic mass
different from the atomic mass conventionally found in nature.
Examples of isotopes that may be incorporated into the compounds
disclosed herein include, but are not limited to, .sup.2H, .sup.3H,
.sup.11C, .sup.13C, .sup.14C, .sup.15N, .sup.18O, .sup.17O, 18F
etc. Thus, the disclosed compounds may be enriched in one or more
of these isotopes relative to the natural abundance of such
isotope. As is known to those of skill in the art, such
isotopically enriched compounds are useful for a variety of
purposes. For example, substitution with heavier isotopes such as
deuterium (.sup.2H) may afford certain therapeutic advantages that
result from greater metabolic stability. Substitution with positron
emitting isotopes, such as 18F can be useful in Positron Emission
Tomography (PET) studies. By way of example, deuterium (.sup.2H)
has a natural abundance of about 0.015%. Accordingly, for
approximately every 6,500 hydrogen atoms occurring in nature, there
is one deuterium atom. Specifically contemplated herein are
compounds enriched in deuterium at one or more positions. Thus,
deuterium containing compounds of the disclosure have deuterium at
one or more positions (as the case may be) in an abundance of
greater than 0.015%.
[0407] In another aspect, the invention comprises combination
therapies for the treatment of cancer, including both pre-malignant
and malignant neoplasms. In this aspect, the invention comprises a
method of treating cancer comprising administering to a subject a
compound disclosed herein in conjunction with a therapeutic
treatment of cancer. In some embodiments of the invention, the
compounds disclosed herein are used in combination of standard of
care anti-proliferative treatments of cancer. The amount of a
compound disclosed herein for use in the combination therapy is an
amount sufficient to inhibit signaling by members of the TGF-.beta.
superfamily, such as Nodal and Activin, which promote the survival
and/or differentiation of cancer stem cells and thereby enhance the
efficacy of the therapeutic treatment. Treatment with the present
compounds thus blocks the ability of cancer stem cells to
recapitulate a tumor destroyed by treatment with standard of care.
Efficacy of treatment can be determined by any art recognized
method generally employed for the particular cancer being treated
and includes, for example, retardation, inhibition, or regression
of tumor growth.
[0408] Reference to "combination therapy" and treatment with a
compound disclosed herein "in conjunction with" another therapeutic
treatment means that the compound and other therapeutic treatment
can be administered simultaneously or sequentially such that the
resultant treatment is more efficacious than either treatment
alone.
[0409] One embodiment of treating cancer in a subject comprises
administering to a subject in need thereof an amount described
above of a compound disclosed herein in combination with the
administration of a therapeutically effective amount of one or more
chemotherapeutic agents, wherein the one or more chemotherapeutic
agents is selected from the group consisting of antimetabolites,
alkylating agents, coordination compounds, platinum complexes, DNA
cross-linking compounds, inhibitors of transcription enzymes,
tyrosine kinase inhibitors, protein kinase inhibitors,
topoisomerase inhibitors, DNA minor-groove binding compounds, vinca
alkyloids, taxanes, antitumor antibiotics, hormones, aromatase
inhibitors, enzymes, growth factor receptors antibodies, cytokines,
cell surface markers antibodies, HDAC inhibitors, HSP 90
inhibitors, BCL-2 inhibitors, B-raf inhibitors, MEK inhibitors,
mTOR inhibitors, proteasome inhibitors and monoclonal
antibodies.
[0410] Among the BCL-2 inhibitors useful in the invention is
ABT-199.
[0411] Another embodiment of methods for treating a subject
comprises administering to the subject an amount (as described
above) of a compound disclosed herein in combination with the
administration of a therapeutically effective amount of one or more
chemotherapeutic agents, the one or more chemotherapeutic agents
being independently selected from the group consisting of
mechlorothamine, cyclophosphamide, ifosfamide, melphalan,
chlorambucil, ethyleneimines, methylmelamines, procarbazine,
dacarbazine, temozolomide, busulfan, carmustine, lomustine,
methotrexate, fluorouracil, capecitabine, cytarabine, gemcitabine,
cytosine arabinoside, mecaptopurine, fludarabine, cladribine,
thioguanine, azathioprine, vinblastine, vincristine, paclitaxel,
docetaxel, colchicine, actinomycin D, daunorubicin, bleomycin,
L-asparaginase, cisplatin, carboplatin, oxaliplatin, prednisone,
dexamethasone, amino glutethimide, formestane, anastrozole,
hydroxyprogesterone caproate, medroxyprogesterone, tamoxifen,
amsacrine, mitoxantrone, topotecan, irinotecan, camptothecin,
afatinib, axitinib, bosutinib, bortezomib, carfilzomib,
cabozantinib, cediranib, crizotinib, dasatinib, dabrafenib,
evorolimus, ibrutinib, LDK378, LGX818, MEK162, regorafenib,
ruxolitinib, selumetinib, sorafenib, trametinib, vemurafenib,
erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib,
palbociclib, pazopanib, pomatinib, semaxanib, sirolimus, sunitinib,
temsirolimus, vatalanib, vandetanib, anti Her2 antibodies,
interferon-.alpha., interferon-.gamma., interleukin 2, GM CSF, anti
CTLA 4 antibodies, rituximab, anti CD33 antibodies, MGCD0103,
vorinostat, 17-AAG, thalidomide, lenalidomide, rapamycin, CCI-779,
doxorubicine, gemcitabine, melphalan, NPI052, gemtuzumab,
alemtuzumab, cetuximab, ibritumomab tiuxaetan, tositumomab,
iodine-131 tositumomab, trastuzumab, ado-trastuzumab emtansine,
obinutuzumab, bevacizumab, rituximab, and anti-TRAIL death receptor
antibodies.
[0412] Among the CTLA 4 antibodies that can be used in the present
invention is ipilimumab, marketed as YERVOY.RTM. by Bristol-Myers
Squibb.
[0413] Other chemotherapeutic agents include checkpoint pathway
inhibitors, e.g., PD-1 inhibitors, such as nivolumab and
lambrolizumab, and PD-Ll inhibitors, such as pembrolizumab,
MEDI-4736 and MPDL3280A/RG7446. Additional checkpoint inhibitors
for combination with the compounds disclosed herein include,
Anti-LAG-3 agents, such as BMS-986016 (MDX-1408).
[0414] Further chemotherapeutic agents for combination with the
presently disclosed TGF-.beta. signalling inhibitors include
Anti-SLAMF7 agents, such as the humanized monoclonal antibody
elotuzumab (BMS-901608), anti-KIR agents, such as the anti-KIR
monoclonal antibody lirilumab (BMS-986015), and anti-CD137 agents,
such as the fully human monoclonal antibody urelumab
(BMS-663513).
[0415] The following table displays exemplary cancers treatable in
the combination therapies of the invention and the therapeutic drug
and/or other treatment for use with the compounds disclosed
herein:
TABLE-US-00004 Cancer Drug or Treatment Glioma lomustine,
temozolide and/or radiation hepatocellular carcinoma sorafenib,
regorafenib myelodysplastic syndromes decitabine or azacytidine
pancreatic cancer Gemcitabine ovarian cancer, such as carboplatin,
cisplatin, doxorubicin, epithelial ovarian carcinoma gemcitabine,
paclitaxel breast cancer Trastuzumab basal and squamous
5-fluorouracil, imiquimod, photodynamic skin carcinomas therapy
(e.g. with 5-aminolevulinic acid), head and neck carcinoma
bleomycin, cisplatin, cetuximab, docetaxel, fluorouracil,
methotrexate triple negative breast cancer Paclitaxel Prostate
abiraterone, enzalutamide
[0416] In another aspect, the invention comprises a method of
determining and measuring the ability of the compounds disclosed
herein to inhibit signaling by members of the TGF-.beta.
superfamily, such as Nodal and Activin, in order to identify
cancers and, more specifically, tumors. In one embodiment,
neoplasms susceptible to such combination therapy can be identified
by testing for Nodal and Activin signaling activity using
techniques known to those skilled in the art, including, for
example, assays described in Lonardo, E. et al. (2011) Cell Stem
Cell 9, 433-446 (which is hereby incorporated by reference in its
entirety). Optionally in this embodiment, where the tested compound
is found to inhibit signalling of a member of the TGF-.beta.
superfamily, such as Nodal and Activin, in the tested neoplasm, the
compound is subsequently used in a combination therapy for
treatment of the neoplasm, as described herein.
DEFINITIONS
[0417] Terms used herein may be preceded and/or followed by a
single dash, "-", or a double dash, "=", to indicate the bond order
of the bond between the named substituent and its parent moiety; a
single dash indicates a single bond and a double dash indicates a
double bond or a pair of single bonds in the case of a
spiro-substituent. In the absence of a single or double dash it is
understood that a single bond is formed between the substituent and
its parent moiety; further, substituents are intended to be read
"left to right" unless a dash indicates otherwise. For example,
arylalkyl, arylalkyl-, and alkylaryl indicate the same
functionality.
[0418] For simplicity, chemical moieties are defined and referred
to throughout primarily as univalent chemical moieties (e.g.,
alkyl, aryl, etc.). Nevertheless, such terms are also used to
convey corresponding multivalent moieties under the appropriate
structural circumstances clear to those skilled in the art. For
example, while an "alkyl" moiety can refer to a monovalent radical
(e.g. CH.sub.3--CH.sub.2--), in some circumstances a bivalent
linking moiety can be "alkyl," in which case those skilled in the
art will understand the alkyl to be a divalent radical (e.g.,
--CH.sub.2--CH.sub.2--), which is equivalent to the term
"alkylene." (Similarly, in circumstances in which a divalent moiety
is required and is stated as being "aryl," those skilled in the art
will understand that the term "aryl" refers to the corresponding
divalent moiety, arylene). All atoms are understood to have their
normal number of valences for bond formation (i.e., 4 for carbon, 3
for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation
state of the S). Nitrogens in the presently disclosed compounds can
be hypervalent, e.g., an N-oxide or tetrasubstituted ammonium salt.
On occasion a moiety may be defined, for example, as (A).sub.a-B--,
wherein a is 0 or 1. In such instances, when a is 0 the moiety is
B-- and when a is 1 the moiety is A-B--.
[0419] As used herein, the term "alkyl" includes alkyl, alkenyl and
alkynyl groups of a designed number of carbon atoms, such as 1 to 6
carbons (i.e., inclusive of 1 and 6), 1 to 6 carbons, 1 to 3
carbons, or 1, 2, 3, 4, 5 or 6. The term "C.sub.m-C.sub.nalkyl"
means an alkyl group having from m to n carbon atoms (i.e.,
inclusive of m and n). The term "C.sub.m-C.sub.nalkyl" means an
alkyl group having from m to n carbon atoms. For example,
"C.sub.1-C.sub.6alkyl" is an alkyl group having from one to six
carbon atoms. Alkyl and alkyl groups may be straight or branched
and depending on context, may be a monovalent radical or a divalent
radical (i.e., an alkylene group). In the case of an alkyl or alkyl
group having zero carbon atoms (i.e., "C.sub.0alkyl"), the group is
simply a single covalent bond if it is a divalent radical or is a
hydrogen atom if it is a monovalent radical. For example, the
moiety "--(C.sub.0-C.sub.6alkyl)-Ar" signifies connection of an
optionally substituted aryl through a single bond or an alkylene
bridge having from 1 to 6 carbons. Examples of "alkyl" include, for
example, methyl, ethyl, propyl, isopropyl, butyl, iso-, sec- and
tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, 3-hexenyl and
propargyl. If the number of carbon atoms is not specified, the
subject "alkyl" or "alkyl" moiety has from 1 to 6 carbons.
[0420] The term "haloalkyl" is an alkyl group substituted with one
or more halogen atoms, e.g. F, Cl, Br and I. A more specific term,
e.g., "fluoroalkyl" is an alkyl group substituted with one or more
fluorine atoms. Examples of "fluoroalkyl" include fluoromethyl,
difluoromethyl, trifluoromethyl, pentafluoroethyl,
hexafluoroisopropyl and the like. In certain embodiments of the
compounds disclosed herein, each haloalkyl is a fluoroalkyl.
[0421] The term "aryl" or "Ar" represents an aromatic ring system
having a single ring (e.g., phenyl) which is optionally fused to
other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings.
"Aryl" includes ring systems having multiple condensed rings and in
which at least one is carbocyclic and aromatic, (e.g.,
1,2,3,4-tetrahydronaphthyl, naphthyl). Examples of aryl groups
include phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl,
dihydronaphthyl, fluorenyl, tetralinyl, and
6,7,8,9-tetrahydro-5H-benzo[a]cycloheptenyl. In certain examples,
aryl groups include those having a first carbocyclic, aromatic ring
fused to an aromatic or aliphatic heterocycle, for example,
2,3-dihydrobenzofuranyl. The aryl groups herein are unsubstituted
or, when specified as "optionally substituted", can unless stated
otherwise be substituted in one or more substitutable positions
with various groups, as described below.
[0422] The term "heteroaryl" or "Het" refers to an aromatic ring
system containing at least one heteroatom selected from nitrogen,
oxygen and sulfur in an aromatic ring. Most commonly, the
heteroaryl groups will have 1, 2, 3, or 4 heteroatoms. The
heteroaryl may be fused to one or more non-aromatic ring, for
example, cycloalkyl or heterocycloalkyl rings, wherein the
cycloalkyl (Cak) and heterocycloalkyl (Hca) rings are described
herein. In one embodiment of the present compounds the heteroaryl
group is bonded to the remainder of the structure through an atom
in a heteroaryl group aromatic ring. In another embodiment, the
heteroaryl group is bonded to the remainder of the structure
through a non-aromatic ring atom. Examples of heteroaryl groups
include, for example, pyridyl, pyrimidinyl, quinolinyl,
benzothienyl, indolyl, indolinyl, pyridazinyl, pyrazinyl,
isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl,
imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl,
indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl,
benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl,
thiadiazolyl, benzo[1,4]oxazinyl, triazolyl, tetrazolyl,
isothiazolyl, naphthyridinyl, isochromanyl, chromanyl,
tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl,
isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl,
pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl,
purinyl, benzodioxolyl, triazinyl, pteridinyl, benzothiazolyl,
imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl,
benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl,
benzopyranyl, benzothiopyranyl, chromonyl, chromanonyl,
pyridinyl-N-oxide, tetrahydroquinolinyl, dihydroquinolinyl,
dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl,
dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl,
benzoxazolinonyl, pyrrolyl N-oxide, pyrimidinyl N-oxide,
pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl
N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl
N-oxide, quinoxalinyl N-oxide, phthalazinyl N-oxide, imidazolyl
N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide,
indolizinyl N-oxide, indazolyl N-oxide, benzothiazolyl N-oxide,
benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide,
thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide,
benzothiopyranyl S-oxide, benzothiopyranyl S,S-dioxide. Preferred
heteroaryl groups include pyridyl, pyrimidyl, quinolinyl, indolyl,
pyrrolyl, furanyl, thienyl and imidazolyl, pyrazolyl, indazolyl,
thiazolyl and benzothiazolyl. In certain embodiments, each
heteroaryl is selected from pyridyl, pyrimidinyl, pyridazinyl,
pyrazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl,
furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl,
tetrazolyl, isothiazolyl, pyridinyl-N-oxide, pyrrolyl N-oxide,
pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide,
imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl
N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl
N-oxide, triazolyl N-oxide, and tetrazolyl N-oxide. Preferred
heteroaryl groups include pyridyl, pyrimidyl, quinolinyl, indolyl,
pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, indazolyl,
thiazolyl and benzothiazolyl. The heteroaryl groups herein are
unsubstituted or, when specified as "optionally substituted", can
unless stated otherwise be substituted in one or more substitutable
positions with various groups, as described below.
[0423] The term "heterocycloalkyl" or "Hca" refers to a
non-aromatic ring or ring system containing at least one heteroatom
that is preferably selected from nitrogen, oxygen and sulfur,
wherein said heteroatom is in a non-aromatic ring. The
heterocycloalkyl may have 1, 2, 3 or 4 heteroatoms. The
heterocycloalkyl may be saturated (i.e., a heterocycloalkyl) or
partially unsaturated (i.e., a heterocycloalkenyl).
Heterocycloalkyl includes monocyclic groups of three to eight
annular atoms as well as bicyclic and polycyclic ring systems,
including bridged and fused systems, wherein each ring includes
three to eight annular atoms. The heterocycloalkyl ring is
optionally fused to other heterocycloalkyl rings and/or
non-aromatic hydrocarbon rings and/or phenyl rings. In certain
embodiments, the heterocycloalkyl groups have from 3 to 7 members
in a single ring. In other embodiments, heterocycloalkyl groups
have 5 or 6 members in a single ring. In some embodiments, the
heterocycloalkyl groups have 3, 4, 5, 6 or 7 members in a single
ring. Examples of heterocycloalkyl groups include, for example,
azabicyclo[2.2.2]octyl (in each case also "quinuclidinyl" or a
quinuclidine derivative), azabicyclo[3.2.1]octyl,
2,5-diazabicyclo[2.2.1]heptyl, morpholinyl, thiomorpholinyl,
thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide,
2-oxazolidonyl, piperazinyl, homopiperazinyl, piperazinonyl,
pyrrolidinyl, azepanyl, azetidinyl, pyrrolinyl, tetrahydropyranyl,
piperidinyl, tetrahydrofuranyl, tetrahydrothienyl,
3,4-dihydroisoquinolin-2(1H)-yl, isoindolindionyl, homopiperidinyl,
homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl
S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl,
dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrofuryl, dihydropyranyl, imidazolidonyl, tetrahydrothienyl
S-oxide, tetrahydrothienyl S,S-dioxide and homothiomorpholinyl
S-oxide. Especially desirable heterocycloalkyl groups include
morpholinyl, 3,4-dihydroisoquinolin-2(1H)-yl, tetrahydropyranyl,
piperidinyl, aza-bicyclo[2.2.2]octyl, .gamma.-butyrolactonyl (i.e.,
an oxo-substituted tetrahydrofuranyl), .gamma.-butryolactamyl
(i.e., an oxo-substituted pyrrolidine), pyrrolidinyl, piperazinyl,
azepanyl, azetidinyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide,
2-oxazolidonyl, imidazolidonyl, isoindolindionyl, piperazinonyl.
The heterocycloalkyl groups herein are unsubstituted or, when
specified as "optionally substituted", can unless stated otherwise
be substituted in one or more substitutable positions with various
groups, as described below.
[0424] The term "cycloalkyl" or "Cak" refers to a non-aromatic
carbocyclic ring or ring system, which may be saturated (i.e., a
cycloalkyl) or partially unsaturated (i.e., a cycloalkenyl). The
cycloalkyl ring optionally fused to or otherwise attached (e.g.,
bridged systems) to other cycloalkyl rings. Certain examples of
cycloalkyl groups present in the disclosed compounds have from 3 to
7 members in a single ring, such as having 5 or 6 members in a
single ring. In some embodiments, the cycloalkyl groups have 3, 4,
5, 6 or 7 members in a single ring. Examples of cycloalkyl groups
include, for example, cyclohexyl, cyclopentyl, cyclobutyl,
cyclopropyl, tetrahydronaphthyl and bicyclo[2.2.1]heptane. The
cycloalkyl groups herein are unsubstituted or, when specified as
"optionally substituted", may be substituted in one or more
substitutable positions with various groups.
[0425] The term "ring system" encompasses monocycles, as well as
fused and/or bridged polycycles.
[0426] The term "oxa" means a divalent oxygen radical in a chain,
sometimes designated as --O--.
[0427] The term "oxo" means a doubly bonded oxygen, sometimes
designated as .dbd.O or for example in describing a carbonyl "C(O)"
may be used to show an oxo substituted carbon.
[0428] The term "electron withdrawing group" means a group that
withdraws electron density from the structure to which it is
attached than would a similarly-attached hydrogen atom. For
example, electron withdrawing groups can be selected from the group
consisting of halo (e.g., fluoro, chloro, bromo, and iodo), cyano,
--(C.sub.1-C.sub.4 fluoroalkyl), --O--(C.sub.1-C.sub.4
fluoroalkyl), --C(O)--(C.sub.0-C.sub.4alkyl),
--C(O)O--(C.sub.0-C.sub.4alkyl),
--C(O)N(C.sub.0-C.sub.4alkyl)(C.sub.0-C.sub.4alkyl),
--S(O).sub.2O--(C.sub.0-C.sub.4alkyl), NO.sub.2 and --C(O)--Hca in
which the Hca includes a nitrogen atom to which the --C(O)-- is
bound, in which no alkyl, fluoroalkyl or heterocycloalkyl is
substituted with an aryl, heteroaryl, cycloalkyl or
heterocycloalkyl-containing group.
[0429] The term "substituted," when used to modify a specified
group or radical, means that one or more hydrogen atoms of the
specified group or radical are each, independently of one another,
replaced with the same or different substituent groups as defined
below, unless specified otherwise.
[0430] Substituent groups for substituting for hydrogens on
saturated carbon atoms in the specified group or radical are,
unless otherwise specified, --R.sup.60, halo, --O.sup.-M.sup.+,
.dbd.O, --OR.sup.70, --SR.sup.70, --S.sup.-M.sup.+, .dbd.S,
--NR.sup.80, .dbd.NR.sup.70, .dbd.N--OR.sup.70, trihalomethyl,
--CF.sub.3, --CN, --OCN, --SCN, --NO, --NO.sub.2, .dbd.N.sub.2,
--N.sub.3, --SO.sub.2R.sup.70, --SO.sub.2O.sup.-M.sup.+,
--SO.sub.2OR.sup.70, --OSO.sub.2R.sup.70,
--OSO.sub.2O.sup.-M.sup.+, --OSO.sub.2OR.sup.70,
--P(O)(O.sup.-).sub.2(M.sup.+).sub.2,
--P(O)(OR.sup.70)O.sup.-M.sup.+, --P(O)(OR.sup.70).sub.2,
--C(O)R.sup.70, --C(S)R.sup.70, --C(NR.sup.70)R.sup.70,
--C(O)O.sup.- M.sup.+, --C(O)OR.sup.70, --C(S)OR.sup.70,
--C(O)NR.sup.80R.sup.80, --C(NR.sup.70)NR.sup.80R.sup.80,
--OC(O)R.sup.70, --OC(S)R.sup.70, --OC(O)O.sup.- M.sup.+,
--OC(O)OR.sup.70, --OC(S)OR.sup.70, --NR.sup.70C(O)R.sup.70,
--NR.sup.70C(S)R.sup.70, --NR.sup.70CO.sub.2.sup.-M.sup.+,
--NR.sup.70CO.sub.2R.sup.70, --NR.sup.70C(S)OR.sup.70,
--NR.sup.70C(O)NR.sup.80R.sup.80, --NR.sup.70C(NR.sup.70)R.sup.70
and --NR.sup.70C(NR.sup.70)NR.sup.80R.sup.80. Each R.sup.60 is
independently selected from the group consisting of alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl,
each of which is optionally substituted with 1, 2, 3, 4 or 5 groups
selected from the group consisting of halo, --O.sup.- M.sup.+,
.dbd.O, --OR.sup.71, --SR.sup.71, --S.sup.-M.sup.+, .dbd.S,
--NR.sup.81R.sup.81, .dbd.NR.sup.71, .dbd.N--OR.sup.71,
trihalomethyl, --CF.sub.3, --CN, --OCN, --SCN, --NO, --NO.sub.2,
.dbd.N.sub.2, --N.sub.3, --SO.sub.2R.sup.71,
--SO.sub.2O.sup.-M.sup.+, --SO.sub.2OR.sup.71, --OSO.sub.2R.sup.71,
--OSO.sub.2O.sup.-M.sup.+, --OSO.sub.2OR.sup.71,
--P(O)(O.sup.-).sub.2(M.sup.+).sub.2,
--P(O)(OR.sup.71)O.sup.-M.sup.+, --P(O)(OR.sup.71).sub.2,
--C(O)R.sup.71, --C(S)R.sup.71, --C(NR.sup.71)R.sup.71,
--C(O)O.sup.-M.sup.+, --C(O)OR.sup.71, --C(S)OR.sup.71,
--C(O)NR.sup.81R.sup.81, --C(NR.sup.71)NR.sup.81R.sup.81,
--OC(O)R.sup.71, --OC(S)R.sup.71, --OC(O)O.sup.-M.sup.+,
--OC(O)OR.sup.71, --OC(S)OR.sup.71, --NR.sup.71C(O)R.sup.71,
--NR.sup.71C(S)R.sup.71, --NR.sup.71CO.sub.2.sup.-M.sup.+,
--NR.sup.71CO.sub.2R.sup.71, --NR.sup.71C(S)OR.sup.71,
--NR.sup.71C(O)NR.sup.81R.sup.81, --NR.sup.71C(NR.sup.71)R.sup.71
and --NR.sup.71C(NR.sup.71)NR.sup.81R.sup.81. Each R.sup.70 is
independently hydrogen or R.sup.60; each R.sup.80 is independently
R.sup.70 or alternatively, two R.sup.80's, taken together with the
nitrogen atom to which they are bonded, form a 5-, 6- or 7-membered
heterocycloalkyl which may optionally include from 1 to 4 of the
same or different additional heteroatoms selected from the group
consisting of O, N and S, of which N may have --H or
C.sub.1-C.sub.3alkyl substitution; and each M.sup.+ is a counter
ion with a net single positive charge. Each R.sup.71 is
independently hydrogen or R.sup.61, in which R.sup.61 is alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl,
each of which is optionally substituted with 1, 2, 3, 4 or 5 groups
selected from the group consisting of halo, --O.sup.-M.sup.+,
.dbd.O, --OR.sup.72, --SR.sup.72, --S.sup.- M.sup.+, .dbd.S,
--NR.sup.82R.sup.82, .dbd.NR.sup.72, .dbd.N--OR.sup.72,
trihalomethyl, --CF.sub.3, --CN, --OCN, --SCN, --NO, --NO.sub.2,
.dbd.N.sub.2, --N.sub.3, --SO.sub.2R.sup.71,
--SO.sub.2O.sup.-M.sup.+, --SO.sub.2OR.sup.72, --OSO.sub.2R.sup.72,
--OSO.sub.2O.sup.-M.sup.+, --OSO.sub.2OR.sup.72,
--P(O)(O.sup.-).sub.2(M.sup.+).sub.2,
--P(O)(OR.sup.72)O.sup.-M.sup.+, --P(O)(OR.sup.72).sub.2,
--C(O)R.sup.72, --C(S)R.sup.72, --C(NR.sup.72)R.sup.72,
--C(O)O.sup.-M.sup.+, --C(O)OR.sup.72, --C(S)OR.sup.72,
--C(O)NR.sup.82R.sup.82, --C(NR.sup.72)NR.sup.82R.sup.82,
--OC(O)R.sup.72, --OC(S)R.sup.72, --OC(O)O.sup.-M.sup.+,
--OC(O)OR.sup.72, --OC(S)OR.sup.72, --NR.sup.72C(O)R.sup.72,
--NR.sup.72C(S)R.sup.72, --NR.sup.72CO.sub.2.sup.-M.sup.+,
--NR.sup.72CO.sub.2R.sup.72, --NR.sup.72C(S)OR.sup.72,
--NR.sup.72C(O)NR.sup.82R.sup.82, --NR.sup.72C(NR.sup.72)R.sup.72
and --NR.sup.72C(NR.sup.72)NR.sup.82R.sup.82; and each R.sup.81 is
independently R.sup.71 or alternatively, two R.sup.81s, taken
together with the nitrogen atom to which they are bonded, form a
5-, 6- or 7-membered heterocycloalkyl which may optionally include
from 1 to 4 of the same or different additional heteroatoms
selected from the group consisting of O, N and S, of which N may
have --H or C.sub.1-C.sub.3 alkyl substitution. Each R.sup.72 is
independently hydrogen, (C.sub.1-C.sub.6alkyl) or
(C.sub.1-C.sub.6fluoroalkyl); each R.sup.82 is independently
R.sup.72 or alternatively, two R.sup.82s, taken together with the
nitrogen atom to which they are bonded, form a 5-, 6- or 7-membered
heterocycloalkyl which may optionally include 1, 2, 3 or 4 of the
same or different additional heteroatoms selected from the group
consisting of O, N and S, of which N may have --H or
C.sub.1-C.sub.3alkyl substitution. Each M.sup.+ may independently
be, for example, an alkali ion, such as K.sup.+, Na.sup.+,
Li.sup.+; an ammonium ion, such as .sup.+N(R.sup.60).sub.4; or an
alkaline earth ion, such as [Ca.sup.2+].sub.0.5,
[Mg.sup.2+].sub.0.5, or [Ba.sup.2+].sub.0.5 ("subscript 0.5 means
e.g. that one of the counter ions for such divalent alkali earth
ions can be an ionized form of a presently disclosed compound and
the other a typical counter ion such as chloride, or two ionized
presently disclosed molecules can serve as counter ions for such
divalent alkali earth ions, or a doubly ionized compound can serve
as the counter ion for such divalent alkali earth ions). As
specific examples, --NR.sup.80R.sup.80 is meant to include
--NH.sub.2, --NH-alkyl, N-pyrrolidinyl, N-piperazinyl,
4-methyl-piperazin-1-yl and N-morpholinyl.
[0431] Substituent groups for hydrogens on unsaturated carbon atoms
in "substituted" alkene, alkyne, aryl and heteroaryl groups are,
unless otherwise specified, --R.sup.60, halo, --O.sup.-M.sup.+,
--OR.sup.70, --SR.sup.70, --S.sup.-M.sup.+, --NR.sup.80R.sup.80,
trihalomethyl, --CF.sub.3, --CN, --OCN, --SCN, --NO, --NO.sub.2,
--N.sub.3, --SO.sub.2R.sup.70, --SO.sub.3.sup.-M.sup.+,
--SO.sub.3R.sup.70, --OSO.sub.2R.sup.70, --OSO.sub.3.sup.-M.sup.+,
--OSO.sub.3R.sup.70, --PO.sub.3.sup.-2(M.sup.+).sub.2,
--P(O)(OR.sup.70)O.sup.-M.sup.+, --P(O)(OR.sup.70).sub.2,
--C(O)R.sup.70, --C(S)R.sup.70, --C(NR.sup.70)R.sup.70,
--CO.sub.2.sup.-M.sup.+, --CO.sub.2R.sup.70, --C(S)OR.sup.70,
--C(O)NR.sup.80R.sup.80, --C(NR.sup.70)NR.sup.80R.sup.80,
--OC(O)R.sup.70, --OC(S)R.sup.70, --OCO.sub.2.sup.-M.sup.+,
--OCO.sub.2R.sup.70, --OC(S)OR.sup.70, --NR.sup.70C(O)R.sup.70,
--NR.sup.70C(S)R.sup.70, --NR.sup.70CO.sub.2.sup.-M.sup.+,
--NR.sup.70CO.sub.2R.sup.70, --NR.sup.70C(S)OR.sup.70,
--NR.sup.70C(O)NR.sup.80R.sup.80, --NR.sup.70C(NR.sup.70)R.sup.70
and --NR.sup.70C(NR.sup.70)NR.sup.80R.sup.80, where R.sup.60,
R.sup.70, R.sup.80 and M.sup.+ are as previously defined.
[0432] Substituent groups for hydrogens on nitrogen atoms in
"substituted" heteroalkyl and heterocycloalkyl groups are, unless
otherwise specified, --R.sup.60, --O.sup.-M.sup.+, --OR.sup.70,
--SR.sup.70, --S.sup.-M.sup.+, --NR.sup.80R.sup.80, trihalomethyl,
--CF.sub.3, --CN, --NO, --NO.sub.2, --S(O).sub.2R.sup.70,
--S(O).sub.2O.sup.-M.sup.+, --S(O).sub.2OR.sup.70,
--OS(O).sub.2R.sup.70, --OS(O).sub.2O.sup.-M.sup.+,
--OS(O).sub.2OR.sup.70, --P(O)(O.sup.-).sub.2(M.sup.+).sub.2,
--P(O)(OR.sup.70)O.sup.-M.sup.+, --P(O)(OR.sup.70)(OR.sup.70),
--C(O)R.sup.70, --C(S)R.sup.70, --C(NR.sup.70)R.sup.70,
--C(O)OR.sup.70, --C(S)OR.sup.70, --C(O)NR.sup.80R.sup.80,
--C(NR.sup.70)NR.sup.80R.sup.80, --OC(O)--R.sup.70,
--OC(S)R.sup.70, --OC(O)OR.sup.70, --OC(S)OR.sup.70,
--NR.sup.70C(O)R.sup.70, --NR.sup.70C(S)R.sup.70,
--NR.sup.70C(O)OR.sup.70, --NR.sup.70C(S)OR.sup.70,
--NR.sup.70C(O)NR.sup.80R.sup.80, --NR.sup.70C(NR.sup.70)R.sup.70
and --NR.sup.70C(NR.sup.70)NR.sup.80R.sup.80, where R.sup.60,
R.sup.70, R.sup.80 and M.sup.+ are as previously defined.
[0433] In certain embodiments of the compounds disclosed herein, a
group that is substituted has 1, 2, 3, or 4 substituents, 1, 2, or
3 substituents, 1 or 2 substituents, or 1 substituent.
[0434] In certain embodiments, substituent groups on "substituted"
alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are
-halo, --OH, --O--(C.sub.1-C.sub.4alkyl),
--O--(C.sub.1-C.sub.4haloalkyl),
--N(C.sub.0-C.sub.4alkyl)(C.sub.0-C.sub.4alkyl), --SH,
--S(O).sub.0-2--(C.sub.1-C.sub.4alkyl), --(C.sub.1-C.sub.4alkyl),
--(C.sub.1-C.sub.4haloalkyl), --C(O)--(C.sub.0-C.sub.4alkyl),
--C(O)N(C.sub.0-C.sub.4alkyl)(C.sub.0-C.sub.4alkyl),
--N(C.sub.0-C.sub.4alkyl)C(O)(C.sub.0-C.sub.4alkyl)(C.sub.0-C.sub.4alkyl)-
, --C(O)O--(C.sub.0-C.sub.4alkyl), --OC(O)--(C.sub.0-C.sub.4alkyl),
S(O).sub.2--O(C.sub.0-C.sub.4alkyl), and --NO.sub.2, in which no
alkyl is further substituted.
[0435] The compounds disclosed herein can also be provided as
pharmaceutically acceptable salts. The term "pharmaceutically
acceptable salts" or "a pharmaceutically acceptable salt thereof"
refer to salts prepared from pharmaceutically acceptable non-toxic
acids or bases including inorganic acids and bases and organic
acids and bases. If the compound is basic, salts may be prepared
from pharmaceutically acceptable non-toxic acids. Such salts may
be, for example, acid addition salts of at least one of the
following acids: benzenesulfonic acid, citric acid,
.alpha.-glucoheptonic acid, D-gluconic acid, glycolic acid, lactic
acid, malic acid, malonic acid, mandelic acid, phosphoric acid,
propanoic acid, succinic acid, sulfuric acid, tartaric acid (d, l,
or dl), tosic acid (toluenesulfonic acid), valeric acid, palmitic
acid, pamoic acid, sebacic acid, stearic acid, lauric acid, acetic
acid, adipic acid, carbonic acid, 4-chlorobenzenesulfonic acid,
ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, galactaric
acid (mucic acid), D-glucuronic acid, 2-oxo-glutaric acid,
glycerophosphoric acid, hippuric acid, isethionic acid
(ethanolsulfonic acid), lactobionic acid, maleic acid,
1,5-naphthalene-disulfonic acid, 2-naphthalene-sulfonic acid,
pivalic acid, terephthalic acid, thiocyanic acid, cholic acid,
n-dodecyl sulfate, 3-hydroxy-2-naphthoic acid,
1-hydroxy-2-naphthoic acid, oleic acid, undecylenic acid, ascorbic
acid, (+)-camphoric acid, d-camphorsulfonic acid, dichloroacetic
acid, ethanesulfonic acid, formic acid, hydriodic acid, hydrobromic
acid, hydrochloric acid, methanesulfonic acid, nicotinic acid,
nitric acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic
acid, saccharine, salicylic acid, gentisic acid, and/or
4-acetamidobenzoic acid.
[0436] The compounds described herein can also be provided in
prodrug form. "Prodrug" refers to a derivative of an active
compound (drug) that undergoes a transformation under the
conditions of use, such as within the body, to release the active
drug. Prodrugs are frequently, but not necessarily,
pharmacologically inactive until converted into the active drug.
Prodrugs are typically obtained by masking a functional group in
the drug believed to be in part required for activity with a
progroup (defined below) to form a promoiety which undergoes a
transformation, such as cleavage, under the specified conditions of
use to release the functional group, and hence the active drug. The
cleavage of the promoiety can proceed spontaneously, such as by way
of a hydrolysis reaction, or it can be catalyzed or induced by
another agent, such as by an enzyme, by light, by acid, or by a
change of or exposure to a physical or environmental parameter,
such as a change of temperature. The agent can be endogenous to the
conditions of use, such as an enzyme present in the cells to which
the prodrug is administered or the acidic conditions of the
stomach, or it can be supplied exogenously. A wide variety of
progroups, as well as the resultant promoieties, suitable for
masking functional groups in the active drugs to yield prodrugs are
well-known in the art. For example, a hydroxyl functional group can
be masked as a sulfonate, ester or carbonate promoiety, which can
be hydrolyzed in vivo to provide the hydroxyl group. An amino
functional group can be masked as an amide, carbamate, imine, urea,
phosphenyl, phosphoryl or sulfenyl promoiety, which can be
hydrolyzed in vivo to provide the amino group. A carboxyl group can
be masked as an ester (including silyl esters and thioesters),
amide or hydrazide promoiety, which can be hydrolyzed in vivo to
provide the carboxyl group. Specific examples of suitable progroups
and their respective promoieties will be apparent to those of skill
in the art.
[0437] The compounds disclosed herein can also be provided as
N-oxides.
[0438] The presently disclosed compounds, salts, prodrugs and
N-oxides can be provided, for example, in solvate or hydrate
form.
[0439] One of ordinary skill in the art of medicinal chemistry also
will appreciate that the disclosed structures are intended to
include isotopically enriched forms of the present compounds. As
used herein "isotopes" includes those atoms having the same atomic
number but different mass numbers. As is known to those of skill in
the art, certain atoms, such as hydrogen occur in different
isotopic forms. For example, hydrogen includes three isotopic
forms, protium, deuterium and tritium. As will be apparent to those
of skill in the art upon consideration of the present compounds,
certain compounds can be enriched at a given position with a
particular isotope of the atom at that position. For example,
compounds having a fluorine atom, may be synthesized in a form
enriched in the radioactive fluorine isotope .sup.18F. Similarly,
compounds may be enriched in the heavy isotopes of hydrogen:
deuterium and tritium; and similarly can be enriched in a
radioactive isotope of carbon, such as .sup.13C. Such isotopic
variant compounds undergo different metabolic pathways and can be
useful, for example, in studying one or more kinase and/or cytokine
signaling pathway and its role in disease.
[0440] As used herein, the term "cell" is meant to refer to a cell
that is in vitro, ex vivo or in vivo. In some embodiments, an ex
vivo cell can be part of a tissue sample excised from an organism
such as a mammal. In some embodiments, an in vitro cell can be a
cell in a cell culture. In some embodiments, an in vivo cell is a
cell living in an organism such as a mammal.
[0441] As used herein, the term "contacting" refers to the bringing
together of indicated moieties in an in vitro system or an in vivo
system. For example, "contacting" an enzyme with a compound
includes the administration of a compound described herein to an
individual or patient, such as a human, as well as, for example,
introducing a compound into a sample containing a cellular or
purified preparation containing the enzyme.
[0442] As used herein, the terms "individual," "patient," or
"subject" are used interchangeably, refers to any animal, including
mammals, preferably mice, rats, other rodents, rabbits, dogs, cats,
swine, cattle, sheep, horses, or primates, and most preferably
humans.
[0443] As used herein, the phrase "therapeutically effective
amount" refers to the amount of active compound or pharmaceutical
agent that elicits the biological or medicinal response that is
being sought in a tissue, system, animal, individual or human by a
researcher, veterinarian, medical doctor or other clinician.
[0444] In certain embodiments, a therapeutically effective amount
can be an amount suitable for
[0445] (1) preventing the disease; for example, preventing a
disease, condition or disorder in an individual who may be
predisposed or otherwise susceptible to the disease, condition or
disorder but does not yet experience or display the pathology or
symptomotology of the disease;
[0446] (2) inhibiting the disease; for example, inhibiting a
disease, condition or disorder in an individual who is experiencing
or displaying the pathology or symptomotology of the disease,
condition or disorder; or
[0447] (3) ameliorating the disease (including a symptom thereof);
for example, ameliorating a disease, condition or disorder in an
individual who is experiencing or displaying the pathology or
symptomotology of the disease, condition or disorder (i.e.,
reversing the pathology and/or symptomotology) such as decreasing
the severity of disease.
[0448] As used here, the terms "treatment" and "treating" means (i)
ameliorating the referenced disease state, condition, or disorder
(or a symptom thereof), such as, for example, ameliorating a
disease, condition or disorder in an individual who is experiencing
or displaying the pathology or symptomotology of the disease,
condition or disorder (i.e., reversing or improving the pathology
and/or symptomotology) such as decreasing the severity of disease
or symptom thereof; or (ii) eliciting the referenced biological
effect (e.g., modulation or inhibition of GDF-8 or
TGF-.beta.1).
[0449] Manifestation of amelioration of a disease condition by
inhibiting GDF-8 or TGF-.beta.1 may require the concomitant or
sequential administration of additional therapeutic agents, such as
antineoplastic agents in the case of cancer, or antiretroviral
agents in the case of viral diseases. For example, administration
of GDF-8 and TGF-.beta.1 inhibitors for the treatment of cancer
does not always produce a direct antitumor effect when used as a
single agent. However, when combined with chemotherapeutic drugs
(antineoplastic) the antitumor effect observed is higher than the
sum of effects of each agent alone.
[0450] As used herein, the terms "catalytic pocket", "catalytic
site", "active site" collectively and indistinctly refer to a
region of the enzyme that contains amino acid residues responsible
for the substrate binding (charge, hydrophobicity, steric
hindrance) and catalytic amino acid residues which act as proton
donors or acceptors or are responsible for binding a cofactor and
participate in the catalysis of a chemical reaction.
[0451] As used herein, the phrase "pharmaceutically acceptable
salt" refers to both pharmaceutically acceptable acid and base
addition salts and solvates. Such pharmaceutically acceptable salts
include salts of acids such as hydrochloric, phosphoric,
hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic,
methanesulfonic, nitric, benzoic, citric, tartaric, maleic,
hydroiodic, alkanoic such as acetic, HOOC--(CH.sub.2).sub.n--COOH
where n is 0-4, and the like. Non-toxic pharmaceutical base
addition salts include salts of bases such as sodium, potassium,
calcium, ammonium, and the like. Those skilled in the art will
recognize a wide variety of non-toxic pharmaceutically acceptable
addition salts.
Pharmaceutical Formulations and Dosage Forms
[0452] The compounds of structural formulae (I)-(II) can be
administered, for example, orally, topically, parenterally, by
inhalation or spray or rectally in dosage unit formulations
containing one or more pharmaceutically acceptable carriers,
diluents or excipients. The term parenteral as used herein includes
percutaneous, subcutaneous, intravascular (e.g., intravenous),
intramuscular, or intrathecal injection or infusion techniques and
the like.
[0453] Pharmaceutical compositions can be made using the presently
disclosed compounds. For example, in one embodiment, a
pharmaceutical composition includes a pharmaceutically acceptable
carrier, diluent or excipient, and compound as described above with
reference to structural formulae (I)-(II).
[0454] In the pharmaceutical compositions disclosed herein, one or
more compounds of structural formulae (I)-(II) may be present in
association with one or more pharmaceutically acceptable carriers,
diluents or excipients, and, if desired, other active ingredients.
The pharmaceutical compositions containing compounds of structural
formulae (I)-(II) may be in a form suitable for oral use, for
example, as tablets, troches, lozenges, aqueous or oily
suspensions, dispersible powders or granules, emulsion, hard or
soft capsules, or syrups or elixirs.
[0455] Compositions intended for oral use can be prepared according
to any suitable method for the manufacture of pharmaceutical
compositions and such compositions may contain one or more agents
selected from the group consisting of sweetening agents, flavoring
agents, coloring agents and preservative agents in order to provide
pharmaceutically elegant and palatable preparations. Tablets
contain the active ingredient in admixture with non-toxic
pharmaceutically acceptable excipients that are suitable for the
manufacture of tablets. These excipients can be for example, inert
diluents, such as calcium carbonate, sodium carbonate, lactose,
calcium phosphate or sodium phosphate; granulating and
disintegrating agents, for example, corn starch, or alginic acid;
binding agents, for example starch, gelatin or acacia, and
lubricating agents, for example magnesium stearate, stearic acid or
talc. The tablets can be uncoated or they can be coated by known
techniques. In some cases such coatings can be prepared by suitable
techniques to delay disintegration and absorption in the
gastrointestinal tract and thereby provide a sustained action over
a longer period. For example, a time delay material such as
glyceryl monostearate or glyceryl distearate can be employed.
[0456] Formulations for oral use can also be presented as hard
gelatin capsules, wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin or olive oil.
[0457] Formulations for oral use can also be presented as
lozenges.
[0458] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients can be suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone,
gum tragacanth and gum acacia; dispersing or wetting agents such as
a naturally-occurring phosphatide, for example, lecithin, or
condensation products of an alkylene oxide with fatty acids, for
example polyoxyethylene stearate, or condensation products of
ethylene oxide with long chain aliphatic alcohols, for example
heptadecaethyleneoxycetanol, or condensation products of ethylene
oxide with partial esters derived from fatty acids and a hexitol
such as polyoxyethylene sorbitol monooleate, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and hexitol anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions may also contain one or more
preservatives, for example ethyl, or n-propyl p-hydroxybenzoate,
one or more coloring agents, one or more flavoring agents, and one
or more sweetening agents, such as sucrose or saccharin.
[0459] Oily suspensions can be formulated by suspending the active
ingredients in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
and flavoring agents may be added to provide palatable oral
preparations. These compositions may be preserved by the addition
of an anti-oxidant such as ascorbic acid.
[0460] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents or suspending agents are exemplified by those
already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, can also be present.
[0461] Pharmaceutical compositions can also be in the form of
oil-in-water emulsions. The oily phase can be a vegetable oil or a
mineral oil or mixtures of these. Suitable emulsifying agents can
be naturally-occurring gums, for example gum acacia or gum
tragacanth, naturally-occurring phosphatides, for example soy bean,
lecithin, and esters or partial esters derived from fatty acids and
hexitol, anhydrides, for example sorbitan monooleate, and
condensation products of the said partial esters with ethylene
oxide, for example polyoxyethylene sorbitan monooleate. The
emulsions can also contain sweetening and flavoring agents.
[0462] In some embodiments, the pharmaceutically acceptable
carrier, diluent, or excipient is not water. In other embodiments,
the water comprises less than 50% of the composition. In some
embodiments, compositions comprising less than 50% water have at
least 1%, 2%, 3%, 4% or 5% water. In other embodiments, the water
content is present in the composition in a trace amount.
[0463] In some embodiments, the pharmaceutically acceptable
carrier, diluent, or excipient is not alcohol. In other
embodiments, the alcohol comprises less than 50% of the
composition. In some embodiments, compositions comprising less than
50% alcohol have at least 1%, 2%, 3%, 4% or 5% alcohol. In other
embodiments, the alcohol content is present in the composition in a
trace amount.
[0464] Syrups and elixirs can be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol, glucose or
sucrose. Such formulations can also contain a demulcent, a
preservative, flavoring, and coloring agents. The pharmaceutical
compositions can be in the form of a sterile injectable aqueous or
oleaginous suspension. This suspension can be formulated according
to the known art using those suitable dispersing or wetting agents
and suspending agents that have been mentioned above. The sterile
injectable preparation can also be a sterile injectable solution or
suspension in a non-toxic parentally acceptable diluent or solvent,
for example as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that can be employed are water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils can be employed as a solvent or suspending
medium. For this purpose any bland fixed oil can be employed
including synthetic mono- or diglycerides. In addition, fatty acids
such as oleic acid find use in the preparation of injectables.
[0465] Compounds of structural formulae (I)-(II) can also be
administered in the form of suppositories, e.g., for rectal
administration of the drug. These compositions can be prepared by
mixing the compound with a suitable non-irritating excipient that
is solid at ordinary temperatures but liquid at the rectal
temperature and will therefore melt in the rectum to release the
drug. Such materials include cocoa butter and polyethylene
glycols.
[0466] Compounds of structural formula (I)-(II) can also be
administered parenterally in a sterile medium. The drug, depending
on the vehicle and concentration used, can either be suspended or
dissolved in the vehicle. Advantageously, adjuvants such as local
anesthetics, preservatives and buffering agents can be dissolved in
the vehicle.
[0467] The compositions can be formulated in a unit dosage form,
each dosage containing from about 5 to about 100 mg, more usually
about 10 to about 30 mg, of the active ingredient. The term "unit
dosage forms" refers to physically discrete units suitable as
unitary dosages for human subjects and other mammals, each unit
containing a predetermined quantity of active material calculated
to produce the desired therapeutic effect, in association with a
suitable pharmaceutical excipient.
[0468] The active compound can be effective over a wide dosage
range and is generally administered in a pharmaceutically effective
amount. It will be understood, however, that the amount of the
compound actually administered will usually be determined by a
physician, according to the relevant circumstances, including the
condition to be treated, the chosen route of administration, the
actual compound administered, the age, weight, and response of the
individual patient, the severity of the patient's symptoms, and the
like.
[0469] For preparing solid compositions such as tablets, the
principal active ingredient is mixed with a pharmaceutical
excipient to form a solid preformulation composition containing a
homogeneous mixture of a compound described herein. When referring
to these preformulation compositions as homogeneous, the active
ingredient is typically dispersed evenly throughout the composition
so that the composition can be readily subdivided into equally
effective unit dosage forms such as tablets, pills and capsules.
This solid preformulation is then subdivided into unit dosage forms
of the type described above containing from, for example, 0.1 to
about 500 mg of the active ingredient of a compound described
herein.
[0470] The tablets or pills can be coated or otherwise compounded
to provide a dosage form affording the advantage of prolonged
action. For example, the tablet or pill can comprise an inner
dosage and an outer dosage component, the latter being in the form
of an envelope over the former. The two components can be separated
by an enteric layer which serves to resist disintegration in the
stomach and permit the inner component to pass intact into the
duodenum or to be delayed in release. A variety of materials can be
used for such enteric layers or coatings, such materials including
a number of polymeric acids and mixtures of polymeric acids with
such materials as shellac, cetyl alcohol, and cellulose
acetate.
[0471] The amount of compound or composition administered to a
patient will vary depending upon what is being administered, the
purpose of the administration, such as prophylaxis or therapy, the
state of the patient, the manner of administration, and the like.
In therapeutic applications, compositions can be administered to a
patient already suffering from a disease in an amount sufficient to
cure or at least partially arrest the symptoms of the disease and
its complications. Effective doses will depend on the disease
condition being treated as well as by the judgment of the attending
clinician depending upon factors such as the severity of the
disease, the age, weight and general condition of the patient, and
the like.
[0472] The compositions administered to a patient can be in the
form of pharmaceutical compositions described above. These
compositions can be sterilized by conventional sterilization
techniques, or may be sterile filtered. Aqueous solutions can be
packaged for use as is, or lyophilized, the lyophilized preparation
being combined with a sterile aqueous carrier prior to
administration. The pH of the compound preparations typically will
be between 3 and 11, more preferably from 5 to 9 and most
preferably from 7 to 8. It will be understood that use of certain
of the foregoing excipients, carriers, or stabilizers will result
in the formation of pharmaceutical salts.
[0473] The therapeutic dosage of the compounds can vary according
to, for example, the particular use for which the treatment is
made, the manner of administration of the compound, the health and
condition of the patient, and the judgment of the prescribing
physician. The proportion or concentration of a compound described
herein in a pharmaceutical composition can vary depending upon a
number of factors including dosage, chemical characteristics (e.g.,
hydrophobicity), and the route of administration. For example, the
compounds described herein can be provided in an aqueous
physiological buffer solution containing about 0.1 to about 10% w/v
of the compound for parenteral administration. Some typical dose
ranges are from about 1 .mu.g/kg to about 1 g/kg of body weight per
day. In some embodiments, the dose range is from about 0.01 mg/kg
to about 100 mg/kg of body weight per day. The dosage is likely to
depend on such variables as the type and extent of progression of
the disease or disorder, the overall health status of the
particular patient, the relative biological efficacy of the
compound selected, formulation of the excipient, and its route of
administration. Effective doses can be extrapolated from
dose-response curves derived from in vitro or animal model test
systems.
[0474] The compounds described herein can also be formulated in
combination with one or more additional active ingredients which
can include any pharmaceutical agent such as anti-viral agents,
vaccines, antibodies, immune enhancers, immune suppressants,
anti-inflammatory agents and the like.
EXAMPLES
General Synthetic Methodologies
[0475] Many general references providing commonly known chemical
synthetic schemes and conditions useful for synthesizing the
disclosed compounds are available (see, e.g., Smith and March,
March's Advanced Organic Chemistry: Reactions, Mechanisms, and
Structure, Fifth Edition, Wiley-Interscience, 2001; or Vogel, A
Textbook of Practical Organic Chemistry, Including Qualitative
Organic Analysis, Fourth Edition, New York: Longman, 1978).
[0476] Compounds as described herein can be purified by any of the
means known in the art, including chromatographic means, such as
HPLC, preparative thin layer chromatography, flash column
chromatography and ion exchange chromatography. Any suitable
stationary phase can be used, including normal and reversed phases
as well as ionic resins. Most typically the disclosed compounds are
purified via silica gel and/or alumina chromatography. See, e.g.,
Introduction to Modern Liquid Chromatography, 2nd Edition, ed. L.
R. Snyder and J. J. Kirkland, John Wiley and Sons, 1979; and Thin
Layer Chromatography, ed E. Stahl, Springer-Verlag, New York,
1969.
[0477] During any of the processes for preparation of the subject
compounds, it may be necessary and/or desirable to protect
sensitive or reactive groups on any of the molecules concerned.
This may be achieved by means of conventional protecting groups as
described in standard works, such as J. F. W. McOmie, "Protective
Groups in Organic Chemistry," Plenum Press, London and New York
1973, in T. W. Greene and P. G. M. Wuts, "Protective Groups in
Organic Synthesis," Third edition, Wiley, New York 1999, in "The
Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic
Press, London and New York 1981, in "Methoden der organischen
Chemie," Houben-Weyl, 4.sup.th edition, Vol. 15/1, Georg Thieme
Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit,
"Aminosauren, Peptide, Proteine," Verlag Chemie, Weinheim,
Deerfield Beach, and Basel 1982, and/or in Jochen Lehmann, "Chemie
der Kohlenhydrate: Monosaccharide and Derivate," Georg Thieme
Verlag, Stuttgart 1974. The protecting groups may be removed at a
convenient subsequent stage using methods known from the art.
[0478] The compounds disclosed herein can be made using procedures
familiar to the person of ordinary skill in the art and as
described herein. For example, compounds of any one of structural
formula (V), (I) or (II) can be prepared according to the Schemes
herein, or analogous synthetic schemes.
[0479] One of skill in the art can adapt the reaction sequences of
the Schemes herein to fit the desired target molecule. Of course,
in certain situations one of skill in the art will use different
reagents to affect one or more of the individual steps or to use
protected versions of certain of the substituents. Additionally,
one skilled in the art would recognize that a compound or
pharmaceutically acceptable salt of structural formulae (I), (II),
or (I.degree.) can be synthesized using different routes
altogether.
[0480] Compounds suitable for use in the presently disclosed
pharmaceutical compositions include compounds of disclosed, above.
These compounds can be made according to the general schemes
described above, for example using a procedure similar to that
described below in the Examples.
[0481] The following examples are intended to further illustrate
certain embodiments and are not intended to limit the scope of the
presently disclosed compounds.
Methods of Treating Disease
[0482] The compounds of the present disclosure are useful to
prevent, diagnose, and treat various medical disorders in humans or
animals. The compounds are used to inhibit or reduce one or more
activities associated with the GDF protein, relative to a GDF
protein not bound by the same compounds. Optionally, the compounds
inhibit or reduce one or more of the activities of mature GDF-8
(regardless of whether in monomeric form, active dimeric form, or
complexed in a GDF-8 latent complex) relative to a mature GDF-8
protein that is not bound by the same compounds. In an embodiment,
the activity of the mature GDF-8 protein, when bound by one or more
of the presently disclosed compounds, is inhibited at least 50%,
optionally at least 60, 62, 64, 66, 68, 70, 72, 72, 76, 78, 80, 82,
84, 86, or 88%, optionally at least 90, 91, 92, 93, or 94%, and
optionally at least 95% to 100% relative to a mature GDF-8 protein
that is not bound by one or more of the presently disclosed
compounds.
[0483] The medical disorder being diagnosed, treated, or prevented
by the presently disclosed compounds is optionally a muscle and
neuromuscular disorder; an adipose tissue disorder such as obesity;
type 2 diabetes, impaired glucose tolerance, metabolic syndromes
(e.g., syndrome X), insulin resistance induced by trauma such as
burns; or bone degenerative disease such as osteoporosis. The
medical condition is optionally a muscle or neuromuscular disorder,
such as muscular dystrophy, muscle atrophy, congestive obstructive
pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia
and disorders associated with a loss of bone, which include
osteoporosis, especially in the elderly and/or postmenopausal
women, glucocorticoid-induced osteoporosis, osteopenia, and
osteoporosis-related fractures. Other target metabolic bone
diseases and disorders amendable to treatment with GDF-8 inhibitors
of the disclosure include low bone mass due to chronic
glucocorticoid therapy, premature gonadal failure, androgen
suppression, vitamin D deficiency, secondary hyperparathyroidism,
nutritional deficiencies, and anorexia nervosa. The antibodies are
optionally used to prevent, diagnose, or treat such medical
disorders in mammals, optionally in humans.
[0484] The compounds or compositions of the present disclosure are
administered in therapeutically effective amounts. As used herein,
an "effective amount" of the antibody is a dosage which is
sufficient to reduce the activity of GDF proteins to achieve a
desired biological outcome (e.g., increasing muscle mass or
strength). Generally, a therapeutically effective amount may vary
with the subject's age, condition, and sex, as well as the severity
of the medical condition in the subject. The dosage may be
determined by a physician and adjusted, as necessary, to suit
observed effects of the treatment. Generally, the compositions are
administered so that compounds are given at a dose between 1
.mu.g/kg and 20 mg/kg. Optionally, the compounds are given as a
bolus dose, to maximize the circulating levels of compounds for the
greatest length of time after the dose. Continuous infusion may
also be used after the bolus dose.
[0485] The methods of treating, diagnosing, or preventing the above
medical conditions with the presently disclosed compounds can also
be used on other proteins in the TGF-.beta. superfamily. Many of
these proteins, e.g., BMP-11, are related in structure to GDF-8.
Accordingly, in another embodiment, the disclosure comprises
methods of treating the aforementioned disorders by administering
to a subject a compound capable of inhibiting BMP-11 or activin,
either alone or in combination with other TGF-.beta. inhibitors,
such as a neutralizing antibody against GDF-8.
[0486] Accordingly, in one aspect, the disclosure. In provides
methods for inhibiting GDF-8 in a cell comprising contacting the
cell with an effective amount of a compound or pharmaceutically
acceptable salt of formula (I), (II), or (I.degree.) or any
embodiment thereof, or a pharmaceutical composition comprising the
same. In another aspect, the disclosure comprises methods for
treating a patient suffering from a disease or disorder, wherein
the patient would therapeutically benefit from an increase in mass
or strength of muscle tissue, comprising administering to a patient
a therapeutically effective amount of a compound or
pharmaceutically acceptable salt of formula (I), (II), or
(I.degree.) or any embodiment thereof, or a pharmaceutical
composition comprising the same. The disease or disorder can be a
muscular disorder, adipose tissue disorder, neuromuscular
disorders, metabolic disorder, diabetes, or bone degenerative
disorder. In certain embodiments, the disease or disorder is a
muscular disorder, such as, but not limited to, muscular dystrophy,
muscle atrophy, congestive obstructive pulmonary disease, muscle
wasting syndrome, sarcopenia, or cachexia. In certain other
embodiments, the disease or disorder is muscular dystrophy. In
other embodiments, the disease or disorder is obesity, type 2
diabetes, impaired glucose tolerance, syndrome X, insulin
resistance induced by trauma, or osteoporosis. In particular
embodiments, the disease or disorder is osteoporosis.
[0487] In yet other embodiments, the disease or disorder is low
bone mass due to chronic glucocorticoid therapy, premature gonadal
failure, androgen suppression, vitamin D deficiency, secondary
hyperparathyroidism, nutritional deficiencies, and anorexia
nervosa.
[0488] In another aspect, the disclosure comprises methods for
increasing muscle mass in a mammal comprising administering a
therapeutically effective amount of a compound or pharmaceutically
acceptable salt of formula (I), (II), or (I.degree.) or any
embodiment thereof, or a pharmaceutical composition comprising the
same. In another aspect, the disclosure comprises methods for
increasing muscle strength in a mammal comprising administering a
therapeutically effective amount of a compound or pharmaceutically
acceptable salt of formula (I), (II), or (I.degree.) or any
embodiment thereof, or a pharmaceutical composition comprising the
same. In another aspect, the disclosure comprises methods for
increasing trabecular bone density in a patient in need thereof,
comprising administering a therapeutically effective amount of a
compound or pharmaceutically acceptable salt of formula (I), (II),
or) (I.degree.) or any embodiment thereof, or a pharmaceutical
composition comprising the same. In any of the preceding methods
and embodiments, thereof, the subject can be a mammal. As used
herein, the terms"individual" or "patient" or "subject" are used
interchangeably, and refers to any animal, including mammals,
preferably mice, rats, other rodents, rabbits, dogs, cats, swine,
cattle, sheep, horses, or primates, and most preferably humans.
[0489] The following examples are intended to further illustrate
certain embodiments and are not intended to limit the scope of the
presently disclosed compounds.
EXAMPLES
Example 1
Synthesis and Characterization
##STR00241##
[0491] Catalyst 1:
[0492] Pd(PPh.sub.3).sub.4 or
Pd.sub.2(dba).sub.3/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(SPhos) or
Pd(OAc).sub.2/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(SPhos) or
Pd.sub.2(dba).sub.3/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(Xphos),
Pd(OAc).sub.2/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(Xphos) or
Chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-
-1,1'-biphenyl)]palladium(II)-(SPhos-Pd-G2) or
Chloro(2-dicyclohexylphosphino-2',4'-6'-triisopropyl-1,1'-biphenyl)[2-2'--
amino-1,1'-biphenyl)]palladium(II)-(XPhos-Pd-G2) or
Pd.sub.2(dba).sub.3/sodium
2'-dicyclohexylphosphino-2,6-dimethoxy-1,1'-biphenyl-3-sulfonate
hydrate or Pd(OAc).sub.2/sodium
2'-dicyclohexylphosphino-2,6-dimethoxy-1,1'-biphenyl-3-sulfonate
hydrate
[0493] Catalyst 2:
[0494] Pd(PPh.sub.3).sub.4 or
Pd.sub.2(dba).sub.3/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(SPhos) or
Pd(OAc).sub.2/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(SPhos) or
Pd.sub.2(dba).sub.3/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(Xphos),
Pd(OAc).sub.2/2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
(Xphos) or
Chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-
-1,1'-biphenyl)]palladium(II)-(SPhos-Pd-G2) or
Chloro(2-dicyclohexylphosphino-2',4'-6'-triisopropyl-1,1'-biphenyl)[2-2'--
amino-1,1'-biphenyl)]palladium(II)-(XPhos-Pd-G2)
##STR00242##
##STR00243##
LC/MS: rt (Method A or Method B), rt=Peak Retention Time
[0495] Method A: Column: Luna 5 .mu.m C8 (100.times.4.6 mm), Flow
rate 1.0 mL/min, Mobile phase: A: H.sub.2O 0.05% TFA, B: CH.sub.3CN
0.05% TFA
[0496] Method B: Column: Gemini 5 .mu.m C18 (100.times.4.6 mm),
Flow rate 1.5 mL/min, Mobile phase: A: H.sub.2O 0.05% HCOOH, B:
CH.sub.3CN 0.05% HCOOH
Compound 1: 4-(6'-Methyl-[2,2'-bipyridin]-3-yl)quinolone
##STR00244##
[0498] 4-(2-Chloropyridin-3-yl)quinolone (200 mg, 0.83 mmol),
Pd.sub.2(dba).sub.3 (30 mg, 0.03 mmol) and
2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPHOS, 62
mg, 0.13 mmol) were transferred to a microwave vial (20 mL)
containing a stir bar under argon atmosphere. Subsequently the vial
was sealed and air was evacuated by vacuum. 6-Methyl-2-pyridylzinc
bromide (0.5 M in THF, 4.0 mL, 2.0 mmol) was added to above
reactants and degassed under vacuum followed by introducing argon
via balloon. After three degas cycles, the reaction mixture was
heated in a microwave (150.degree. C.) for 40 min. The reaction
mixture was diluted with saturated aqueous solution of Rochelle
salt (5 mL) and concentrated to remove volatiles under reduced
pressure. The crude concentrate was diluted with EtOAc (30 mL) and
separated the organic layer. Aqueous layer was further extracted
with EtOAc (30 mL). Combined organic layers were washed with aq.
NaCl (10 mL), stirred over MgSO.sub.4, filtered through a pad of
Fluorosil.RTM./Celite.RTM., concentrated and purified by revere
phase preparative HPLC. Product fractions were concentrated,
diluted with water and neutralized with aq. NaHCO.sub.3. The
resultant solid was collected by filtration and dried to provide
4-(6'-methyl-[2,2'-bipyridin]-3-yl)quinolone (78 mg, 31%) as a
white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.84 (dd,
J=4.7, 1.7 Hz, 1H), 8.81 (d, J=4.3 Hz, 1H), 7.99 (dt, J=8.4, 0.9
Hz, 1H), 7.89 (dd, J=7.7, 1.7 Hz, 1H), 7.78 (d, J=8.0 Hz, 1H),
7.70-7.52 (m, 3H), 7.34 (dd, J=4.4, 0.9 Hz, 2H), 7.26 (d, J=4.4 Hz,
1H), 6.90 (d, J=7.6 Hz, 1H), 1.59 (s, 3H).
Compound 3:
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00245##
[0500]
6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (175
mg, 0.69 mmol),
chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-
-1,1'-biphenyl)]palladium(II)-(SPhos-Pd-G2, 35 mg, 0.05 mmol), dry
THF (10 mL) and stir bar were transferred to a screw cap vial and
sealed with a peaceable teflon cap. The stirring contents in the
vial were degassed by application of vacuum and argon introduction
in three degas cycles. Subsequently, degassed heterogeneous slurry
was treated with 6-methyl-2-pyridylzinc bromide (0.5 M in THF, 2.77
mL, 1.38 mmol) under argon over a period of 3 min. The brown clear
homogeneous reaction mixture was degassed again and heated to stir
at 70.degree. C. for 24 h. Multiple peaks were noticed along with
90% consumption of
6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile upon
analyzing cooled reaction mixture to room temperature by LC/MS. At
this stage, brown homogeneous reaction mixture was concentrated
under reduced pressure and quenched with saturated aq.
Na.sub.2CO.sub.3 solution (10 mL). The heterogeneous slurry was
diluted with CH.sub.2Cl.sub.2 (50 mL), stirred and separated
organic layer from semi-separable heterogenous mixture. Remaining
aqueous layer was extracted with CH.sub.2Cl.sub.2 (2.times.50 mL).
Combined organic layers were stirred over MgSO.sub.4/Celite.RTM.,
filtered and concentrated. The resultant crude was purified by
Combiflash.RTM. on a Redifsep.RTM. 24G silica gel column and eluted
with 100% CH.sub.2Cl.sub.2-1% 7N NH.sub.3 MeOH/CH.sub.2Cl.sub.2.
Fractions containing product and MH.sup.+185 impurity (MH.sup.+185)
were concentrated under reduced pressure. The resulting pale yellow
solid (100 mg) was stirred in EtOAc (4 mL), filtered and suction
dried to provide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
(68 mg, 31%) as off-white solid. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.74 (dd, J=4.7, 1.6 Hz, 1H), 8.55 (dd,
J=1.6, 1.0 Hz, 1H), 8.44 (d, J=0.4 Hz, 1H), 8.05 (dd, J=7.8, 1.6
Hz, 1H), 7.77-7.63 (m, 3H), 7.59 (dd, J=7.8, 4.7 Hz, 1H), 7.21 (dd,
J=9.3, 1.7 Hz, 1H), 7.15 (d, J=7.5 Hz, 1H), 2.08 (s, 3H). LCMS: rt
3.80 min (A), purity 96%, MS (m/e) 312 (MH.sup.+).
Compound 4:
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
##STR00246##
[0502] A two necked round bottom flask containing a stir bar was
fitted with reflux condenser to one of the necks and rubber septa
to other neck. A three way stopcock was attached to reflux
condenser and remaining two inlets were connected to argon balloon
and vacuum pump hose.
6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (1.0 g,
4.34 mmol), and Pd(PPh.sub.3).sub.4 (0.15 g, 0.13 mmol) were
transferred into reaction flask, introduced dry THF (20 mL) under
vacuum and degassed by vacuum application followed by introduction
of argon in three cycles. Subsequently, degassed heterogenous
slurry was treated with 6-methyl-2-pyridylzinc bromide (0.5 M in
THF, 17 mL, 8.5 mmol) under argon over a period of 3 min. The
resulting dark heterogeneous suspension was degassed again and
stirred at 70.degree. C. overnight. Multiple peaks were noticed
with 77% consumption of
6-(2-chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine upon
analyzing cooled reaction mixture to room temperature by LC/MS. At
this stage, brown reaction mixture was concentrated under reduced
pressure and quenched with saturated aq. Na.sub.2CO.sub.3 (35
mL)/CH.sub.2Cl.sub.2 (130 mL) and stirred for 20 min. Organic layer
from heterogeneous slurry was separated and extracted aqueous layer
with CH.sub.2Cl.sub.2 (2.times.75 mL). Combined organic layers were
stirred over MgSO.sub.4/Celite.RTM., filtered and concentrated. The
resultant crude mixture was adsorbed on silica gel and purified by
Combiflash.RTM. on a RediSep.RTM. 40G silica gel column and eluted
with 100% CH.sub.2Cl.sub.2-2% 7N NH.sub.3 MeOH/CH.sub.2Cl.sub.2.
Product fractions containing MH.sup.+185 impurity were concentrated
under reduced pressure. Thus obtained off-white solid (370 mg) was
stirred in EtOAc (25 mL) for 5 min at 70.degree. C., filtered hot
mixture and suction dried to provide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
(315 mg, 25%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.90
(dd, J=1.7, 0.9 Hz, 1H), 8.74 (dd, J=4.7, 1.6 Hz, 1H), 8.47 (s,
1H), 8.01 (dd, J=7.8, 1.7 Hz, 1H), 7.79-7.69 (m, 2H), 7.66 (dd,
J=9.2, 0.8 Hz, 1H), 7.58 (dd, J=7.8, 4.8 Hz, 1H), 7.26 (dd, J=9.2,
1.8 Hz, 1H), 7.13 (dd, J=7.2, 1.4 Hz, 1H), 2.02 (s, 3H). LCMS: rt
3.06 min (A), purity 97%, MS (m/e) 288 (MH.sup.+).
Compound 5:
7-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
##STR00247##
[0504]
7-(6'-Methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
was prepared and isolated (229 mg, 18%) in an analogous manner to
the preparation of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
by the reaction of
7-(2-chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (1.0 g,
4.34 mmol) and 6-methyl-2-pyridylzinc bromide (0.5 M in THF, 17 mL,
8.5 mmol) in the presence of Pd(PPh.sub.3).sub.4 (0.15 g, 0.13
mmol). White solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.77 (dd, J=7.1, 0.8 Hz, 1H), 8.74 (dd, J=4.8, 1.6 Hz, 1H), 8.46
(s, 1H), 8.00 (dd, J=7.8, 1.6 Hz, 1H), 7.78-7.66 (m, 3H), 7.59 (dd,
J=7.8, 4.7 Hz, 1H), 7.14 (dd, J=7.3, 1.3 Hz, 1H), 6.78 (dd, J=7.1,
1.9 Hz, 1H), 2.01 (s, 3H). LCMS: rt 3.08 min (A), purity 99%, MS
(m/e) 288 (MH.sup.+).
Compound 6:
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00248##
[0506] Conc. H.sub.2SO.sub.4 (0.2 mL) was added to stirring TFA
(0.8 mL) in a microwave vial (20 mL) for 3 min at room temperature
and stirred pale brown homogeneous acidic mixture for additional
period of 5 min. Solid
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboni-
trile (125 mg, 0.40 mmol) was added in portions to above acidic
solution at room temperature for 5 min and stirred heterogeneous
mixture for 10 min. Subsequently, the mixture was heated at
85.degree. C. Reaction mixture was analyzed by LC/MS after 2 h
which indicated complete consumption of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile.
Reaction mixture was cooled to room temperature and poured onto
ice-water. Subsequently, aqueous acidic homogenous solution was
basified (pH>9) with 50% aq. NaOH and stirred at room
temperature for 2 h. The resulting off-white precipitous solid was
collected by suction filtration, washed with water, dried and
purified by Combiflash.RTM. on a RediSep.RTM. 12G silica gel column
and eluted with 100% CH.sub.2Cl.sub.2 followed by 7% 7N NH.sub.3
MeOH/CH.sub.2Cl.sub.2. A white solid (60 mg, 45%) of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xamide was isolated upon drying the solid obtained after
concentrating product fractions. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.37 (d, J=1.5 Hz, 1H), 8.73 (dd, J=4.7, 1.6
Hz, 1H), 8.30 (s, 1H), 8.02-7.85 (overlapped br s, 1H), 7.96 (dd,
J=7.8, 1.6 Hz, 1H), 7.69 (t, J=7.7 Hz, 1H), 7.60 (app s, 1H),
7.59-7.55 (m, 1H), 7.53 (d, J=9.8 Hz, 1H), 7.45-7.28 (br s, 1H),
7.11 (d, J=8.1 Hz, 1H), 7.08 (dd, J=9.3, 1.9 Hz, 1H), 2.08 (s, 3H).
LCMS: rt 1.88 min (A), purity 96%, MS (m/e) 330 (MH.sup.+).
Compound 7:
6-([2,2'-Bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00249##
[0508]
6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile was
prepared and isolated in an analogous manner to the preparation of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
by the reaction of
-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (1.0
g, 3.93 mmol) and 2-pyridylzinc bromide (0.5 M in THF, 13 mL, 6.5
mmol) in the presence of Pd(PPh.sub.3).sub.4 (0.14 g, 0.12 mmol).
Off-White solid (435 mg, 37%). .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.75 (dd, J=4.7, 1.6 Hz, 1H), 8.56 (dd, J=1.7, 1.0 Hz, 1H),
8.43 (s, 1H), 8.28 (dt, J=4.8, 1.4 Hz, 1H), 8.09 (dd, J=7.8, 1.6
Hz, 1H), 7.89 (app d, J=1.4 Hz, 1H), 7.88 (app d, J=1.2 Hz, 1H),
7.64 (dd, J=9.2, 0.8 Hz, 1H), 7.61 (app dd, J=7.8, 4.8 Hz, 1H),
7.29 (app dd, J=9.2, 4.8 Hz, 1H), 7.14 (dd, J=9.3, 1.7 Hz, 1H).
LCMS: rt 3.85 min (A), purity 95%, MS (m/e) 330 (MH.sup.+).
Compound 8:
6-([2,2'-Bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
##STR00250##
[0510] 6-([2,2'-Bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine was
prepared and isolated (395 mg, 31%) in an analogous manner to the
preparation of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
by the reaction of
6-(2-chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (1.0 g,
4.34 mmol) and 2-pyridylzinc bromide (0.5 M in THF, 17 mL, 8.5
mmol) in the presence of Pd(PPh.sub.3).sub.4 (0.15 g, 0.13 mmol).
Off-white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.93
(dd, J=1.8, 0.9 Hz, 1H), 8.74 (dd, J=4.8, 1.6 Hz, 1H), 8.47 (s,
1H), 8.25 (dt, J=4.8, 1.5 Hz, 1H), 8.04 (dd, J=7.8, 1.6 Hz, 1H),
7.90 (d, J=1.3 Hz, 1H), 7.88 (app d, J=1.2 Hz, 1H), 7.64 (dd,
J=9.2, 0.8 Hz, 1H), 7.60 (app dd, J=7.8, 4.8 Hz, 1H), 7.29 (app dd,
J=9.2, 4.8 Hz, 1H), 7.21 (dd, J=9.2, 1.8 Hz, 1H). LCMS: rt 3.11 min
(A), purity 96%, MS (m/e) 274 (MH.sup.+).
Compound 9:
6-([2,2'-Bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00251##
[0512]
6-([2,2'-Bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide was
prepared and isolated in an analogous manner to the preparation of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
from 6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
(200 mg, 0.67 mmol). White solid (98 mg, 46%). .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 9.39 (dd, J=1.8, 0.9 Hz, 1H), 8.74 (dd,
J=4.7, 1.6 Hz, 1H), 8.31 (s, 1H), 8.26 (dt, J=4.8, 1.4 Hz, 1H),
8.00-7.92 (overlapped br s, 1H), 7.99 (dd, J=7.8, 1.6 Hz, 1H), 7.87
(dd, J=7.9, 1.7 Hz, 1H), 7.85-7.79 (m, 1H), 7.59 (dd, J=7.8, 4.8
Hz, 1H), 7.51 (dd, J=9.3, 0.9 Hz, 1H), 7.37 (br s, 1H), 7.28 (ddd,
J=6.7, 4.8, 2.1 Hz, 1H), 7.02 (dd, J=9.3, 1.9 Hz, 1H). LCMS: rt
1.88 min (A), purity 97%, MS (m/e) 316 (MH.sup.+).
Compound 10:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
##STR00252##
[0514]
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
was prepared as depicted in the following Scheme:
##STR00253##
6-Chloro-4-methoxypyrido[3,2-d]pyrimidine
[0515] 4,6-Dichloropyrido[3,2-d]pyrimidine (prepared from PCT Int.
Appl., 2005058913, PCT Int. Appl., 2011131741, PCT Int. Appl.,
201009469)-(2.5 g, 12.4 mmol) and NaHCO.sub.3 (3.1 g, 31 mmol) in
MeOH (20 mL) were heated at 70.degree. C. for 12 h under nitrogen
atmosphere. The reaction mixture was filtered and concentrated the
filtrate. The crude concentrate was diluted with water and
filtered. The suction dried solid was stirred in EtOAc (20 mL) and
filtered to obtain 6-chloro-4-methoxypyrido[3,2-d]pyrimidine (1.8
g) as an off-white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.88 (s, 1H), 8.37 (d, J=8.8 Hz, 1H), 8.00 (d, J=8.8 Hz,
1H), 4.14 (s, 3H).
6-(2-Chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine
[0516] A reaction flask was charged
6-chloro-4-methoxypyrido[3,2-d]pyrimidine (3.5 g, 17.8 mmol),
2-chloro-3-pyridineboronic acid pinacol ester (4.35 g, 18.2 mmol),
Na.sub.2CO.sub.3 (4.0 g, 38.2 mmol) and 1,4-dioxane (100 mL) and a
stir bar. The contents were degassed by vacuum and back filled with
argon three times while stirring. Subsequently, Pd(PPh.sub.3).sub.3
(0.87 g, 0.75 mmol) was added to the reaction contents, repeated
degassing cycles, and heated for overnight under argon at
98.degree. C. The yellow heterogeneous reaction mixture was cooled
to room temperature and suction filtered on a Buchner funnel. The
collected solid on the funnel was washed with additional amount of
dioxane (30 mL). The pale yellow clear filtrate solution was passed
through a pad of Celite.RTM. and concentrated. The crude pale
yellow solid residue thus obtained was partitioned between
CH.sub.2Cl.sub.2 (150 mL)/water (50 mL). The organic layer was
separated, dried over MgSO.sub.4, filtered and concentrated. The
crude concentrate was stirred in EtOAc (30 mL) and suction
filtered. The filter cake was washed with EtOAc (10 mL) and dried
to obtain 1.6 g of
6-(2-chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine (purity:
95%) as a white solid. The filtrate was concentrated and purified
the concentrate by flash column chromatography (Combiflash.RTM.
companion system.RTM. with RediSep.RTM. silica gel column 40 g,
0-30-60% EtOAC/hexanes eluting solvent gradient) to obtain
additional 0.65 g of titled compound. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 8.92 (s, 1H), 8.57 (dd, J=4.8, 2.0 Hz, 1H),
8.45 (d, J=8.7 Hz, 1H), 8.28 (d, J=8.7 Hz, 1H), 8.13 (dd, J=7.6,
2.0 Hz, 1H), 7.63 (dd, J=7.6, 4.8 Hz, 1H), 4.16 (s, 3H).
4-Methoxy-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine
[0517] A two necked round bottom flask containing a stir bar was
fitted with reflux condenser to one of the necks and rubber septa
to other neck. A three way stopcock was attached to reflux
condenser and remaining two inlets were connected to argon balloon
and vacuum pump hose.
6-(2-chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine (2.0 g,
7.3 mmol), and SPhos-Pd-G2 (0.16 g, 0.22 mmol) were transferred
into reaction flask, introduced dry THF (20 mL) under vacuum,
degassed by vacuum application followed by introduction of argon in
three cycles and initiated heating yellow suspension reaction
mixture simultaneously. Subsequently, 6-methyl-2-pyridylzinc
bromide (0.5 M in THF, 22 mL, 11 mmol) was added under argon over a
period of 10 min at 34.degree. C. The resulting pale brown
heterogeneous mixture was degassed again and stirred at 45.degree.
C. After 1 h, reaction mixture was turned to homogenous solution
and indicated 7% of unreacted
6-(2-chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine as
analyzed by LC/MS. Reaction mixture was cooled to room temperature
after 5 h (<3% of unreacted
6-(2-chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine),
concentrated under reduced pressure and stirred in a mixture of
saturated aq. Na.sub.2CO.sub.3 (100 mL)/CH.sub.2Cl.sub.2 (300 mL).
Organic layer was separated from semi-separable heterogeneous
mixture and extracted aqueous layer with CH.sub.2Cl.sub.2
(3.times.200 mL). Combined organic layers were stirred over
MgSO.sub.4/Celite.RTM., filtered and concentrated. The resultant
crude mixture was adsorbed on silica gel, purified by
Combiflash.RTM. on a RediSep.RTM. 40G silica gel column and eluted
with 100% CH.sub.2Cl.sub.2-1% 7N NH.sub.3 MeOH/CH.sub.2Cl.sub.2-3%
7N NH.sub.3 MeOH/CH.sub.2Cl.sub.2. Two peaks were observed on UV
trace containing product. Impure product fractions corresponding to
low retention time peak were concentrated (1.2 g) and crystallized
from EtOAc. Resulting crystalline white solid was collected by
filtration and suction dried to provide 0.60 g of
4-methoxy-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine
with 96% purity. Filtrate was combined with impure product
fractions from higher retention time peak and purified the
concentrate (1.4 g) once again in a similar manner as above to
obtain another lot of (0.78 g, 94% purity, white solid)
4-methoxy-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine.
Combined yield (61%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.84 (s, 1H), 8.80 (dd, J=4.7, 1.7 Hz, 1H), 8.10-8.07 (m, 2H), 7.90
(ddd, J=7.8, 1.2, 0.6 Hz, 1H), 7.77 (t, J=7.7 Hz, 1H), 7.61 (dd,
J=7.8, 4.7 Hz, 1H), 7.53 (d, J=8.8 Hz, 1H), 7.12 (ddd, J=7.6, 1.1,
0.6 Hz, 1H), 4.12 (s, 3H), 1.81 (s, 3H). LCMS: rt 3.65 min (A), MS
(m/e) 330 (MH.sup.+).
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one
hydrochloride salt
[0518] Conc. HCl (0.0.5 ml) was added to a stirring heterogeneous
slurry of
4-methoxy-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine
(1.1 g, 3.33 mmol) in EtOH (6 mL) at room temperature and heated
the slurry gradually to 58.degree. C. and monitored the progress of
reaction. Additional amounts of conc. HCl were added to
heterogeneous reaction mixture at 1 h (0.05 mL), 1 h 30 min (0.1
mL) and 2 h 30 min (0.05 mL) respectively to realize consumption of
4-methoxy-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine.
Upon conc.HCl addition at 2 h 30 min, reaction mixture was turned
to homogeneous solution and converted back to heterogeneous mixture
over a period of 30 min. At this stage, heating was continued for
additional period of 2 h and cooled to room temperature.
Crystalline solid from reaction mixture was collected by filtration
and suction dried to provide 200 mg of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-
-one as an HCl salt. Upon concentration of filtrate under reduced
pressure provided pale yellow solid which was stirred in 10%
EtOH/EtOAc (50 mL) for 20 min and collected by filtration to
provide another lot of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one
hydrochloride salt (0.81 g). Combined yield (1.1 g, 93%). LCMS: rt
2.80 min (A), purity 96%, MS (m/e) 316 (MH.sup.+).
4-Chloro-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine
[0519] To a stirring mixture of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one
hydrochloride salt (1.0 g, 2.8 mmol) and dry CH.sub.2Cl.sub.2 (30
mL) under argon was added oxalyl chloride (2 mL, 3.0 g, 23.6 mmol)
at room temperature. After 10 min of stirring the reaction
contents, cat. DMF (0.1 mL) dissolved in dry CH.sub.2Cl.sub.2 (2
mL) was added to reaction mixture over a period of 10 min and
heated at 65.degree. C. for 3 h. Dark reaction mixture thus formed
was analyzed to notice complete consumption of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one
with minor product formation. Reaction mixture was cooled,
concentrated, diluted with EtOAc (75 mL) and stirred in solid
Na.sub.2CO.sub.3 (5.0 g) for 30 min. The dark slurry was diluted
with ice water (30 mL), stirred for 20 min, separated organic layer
and extracted aqueous layer with EtOAc (2.times.50 mL). Combined
organic layers were dried over MgSO.sub.4, filtered and
concentrated. Crude concentrate was subjected to purification by
Combiflash.RTM. on a RediSep.RTM. 40 g silica gel column and eluted
with 30-60% EtOAc/hexanes to obtain
4-chloro-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine
as a off-white solid (120 mg, 12%). LCMS: rt 4.00 min (A), purity
95%, MS (m/e) 334 (MH.sup.+).
6-(6'-Methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
[0520]
4-Chloro-6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidine
(120 mg, 0.36 mmol), THF (3 mL) and 4% NH.sub.3/i-PrOH (3 mL) in a
screw capped vial was stirred at 70.degree. C. for 4 h. Pale purple
reaction mixture was concentrated and purified by Combiflash.RTM.
on a RediSep.RTM. 4G silica gel column and eluted with 100%
CH.sub.2Cl.sub.2-3% 7N NH.sub.3 MeOH/CH.sub.2Cl.sub.2 to provide
6-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
(53 mg, 47%) as an off-white solid. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.76 (dd, J=4.7, 1.7 Hz, 1H), 8.38 (s, 1H),
8.23 (dd, J=7.8, 1.7 Hz, 1H), 7.88-7.72 (m, 4H), 7.61 (dd, J=7.8,
4.7 Hz, 1H), 7.50 (br s, 1H), 7.38 (d, J=8.7 Hz, 1H), 7.14 (dd,
J=6.4, 2.3 Hz, 1H), 1.92 (s, 3H). LCMS: rt 1.93 min (A), purity
99%, MS (m/e) 315 (MH.sup.+).
Preparation of 2-chloro-3-(heteroaryl)pyridines
Preparation of 5-(2-chloropyridin-3-yl)-1H-indazole
##STR00254##
[0521] tert-Butyl 5-bromo-1H-indazole-carboxylate
[0522] A single necked round bottom flask containing a with a
magnetic stir bar was charged with 5-bromo-1H-indazole (3.0 g, 15.2
mmol), di-tert-butyl dicarbonate (4.2 g, 19.2 mmol) and
acetonitrile (30 mL) under mild stream of nitrogen at room
temperature. Triethylamine (1.8 g, 2.5 mL, 17.7 mmol) was added in
one portion to above stirred homogeneous solution followed by
4-(dimethylamino)pyridine (2.2 g, 18 mmol) over a period of 15 min
in portions. The homogenous off-brown clear reaction mixture was
stirred at room temperature under nitrogen and the progress of
reaction monitored by TLC (50% EtOAc/hexanes). Stirring was
discontinued after 3 h and the reaction mixture concentrated by
rotary evaporator under vacuum. A clear viscous liquid was obtained
and dissolved in EtOAc/hexanes (7:3, 200 mL), and diluted with
water (75 mL). Organic layer was separated and the aqueous layer
extracted with EtOAc/hexanes (1:1, 125 mL). The combined organic
layers were washed with water (100 mL) followed by 1N aq. HCl
(2.times.75 mL) to remove 4-(dimethylamino)pyridine. The combined
organic layers were washed with water (2.times.75 mL), saturated
aq. NaHCO.sub.3 (2.times.75 mL) and saturated aqueous NaCl.
Separated organic layers were dried over anhydrous MgSO.sub.4,
filtered, concentrated and dried under vacuum to provide tert-butyl
5-bromo-1H-indazole-carboxylate (4.5 g, purity 97%) as a pale
yellow viscous liquid which was used without further purification.
.sup.1H NMR (DMSO-d6): .delta. 8.36 (d, J=0.8 Hz, 1H), 8.11 (app d,
J=0.8 Hz, 1H), 8.00 (d, J=8.8 Hz, 1H), 7.71 (app dd, J=8.8, 0.8 Hz,
1H), 1.62 (s, 9H). LCMS: 97%, MS (m/e) 241 (MH.sup.+-t-Bu). A
single necked round bottom flask (250 mL) equipped with a magnetic
stir bar was charged with tert-butyl
5-bromo-1H-indazole-carboxylate (4.0 g, 13.4 mmol) dissolved in
1,4-dioxane (130 mL), 2-chloro-3-pyridine boronic acid pinacol
ester (4 g, 16.7 mmol), Pd(PPh.sub.3).sub.4 (1.5 g, 1.3 mmol) and
2M aq.Na.sub.2CO.sub.3 (20 mL, 40 mmol) under nitrogen atmosphere.
The rubber septum was replaced with reflux condenser containing
three-way stopcock equipped with argon filled balloon. The reaction
contents were stirred and air was removed from the closed reaction
system by vacuum and back filled with argon. Following three cycles
of degassing, the reaction mixture was heated at 100.degree. C.
(oil-bath) under argon. Inflated argon balloon was emptied,
refilled with argon and remounted in the course of reaction. The
initial pale yellow heterogeneous reaction mixture turned to clear
biphasic off-brown solution. After 18 h with no additional change
in the proportion of the product (62%) as analyzed by LC/MS, the
reaction mixture was cooled to room temperature. Upon concentration
of the reaction mixture, EtOAc/water (200 mL/75 mL) was transferred
to the concentrate and stirred for 30 min. The organic layer was
separated and the aqueous layer extracted with EtOAc (100
mL.times.2). MgSO.sub.4 (20 g) and Celite.RTM. (20 g) were added to
combined organic layers and the contents suction filtered after
stirring for 1 h. The filter cake was washed with EtOAc (300 mL)
and the combined filtrates concentrated by rotary evaporator under
vacuum. The crude concentrate was dissolved in 1%
MeOH/CH.sub.2Cl.sub.2 and absorbed on silica gel (20 g) by
evaporating the solvent followed by drying. Subsequent purification
by flash silica gel column purification of the dry powder
(Combiflash.RTM. companion system.RTM. with RediSep.RTM. silica gel
column 120 g, 30-70% EtOAc/hexanes eluting solvent) provided
5-(2-chloropyridin-3-yl)-1H-indazole (1.5 g, 47%) as a white
crystalline solid after concentration of the desired product
fractions. .sup.1H NMR (DMSO-d6): .delta. 13.2 (s, 1H), 8.41 (dd,
J=1.8 and 4.7 Hz, 1H), 8.13 (s, 1H), 7.90 (dd, J=4.7, 1.7 Hz, 1H),
7.84 (s, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.51 (dd, J=7.3, 4.7 Hz, 1H),
7.42 (dd, J=8.5, 1.4 Hz, 1H). LCMS: 95%, MS (m/e) 230
(MH.sup.+).
4-(2-Chloropyridin-3-yl)quinoline
##STR00255##
[0524] 4-(2-Chloropyridin-3-yl)quinolone was prepared in the
similar manner to the preparation of
5-(2-chloropyridin-3-yl)-1H-indazole by reacting 4-bromoquinoline
(2.5 g, 12 mmol), 2-chloro-3-pyridine boronic acid pinacol ester
(3.4 g, 14.4 mmol), Pd(PPh.sub.3).sub.4 (0.7 g, 0.60 mmol) and 2M
aq.Na.sub.2CO.sub.3 (21 mL, 42 mmol) in 1,4-dioxane (100 mL) at
100.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 9.01
(d, J=4.4 Hz, 1H), 8.60 (dd, J=4.8, 1.9 Hz, 1H), 8.13 (d, J=8.5 Hz,
1H), 7.98 (dd, J=7.5, 1.9 Hz, 1H), 7.81 (ddd, J=8.4, 6.9, 1.4 Hz,
1H), 7.64 (dd, J=7.5, 4.8 Hz, 1H), 7.58 (dd, J=6.9, 1.3 Hz, 1H),
7.51 (d, J=4.4 Hz, 1H), 7.42 (dd, J=8.1, 1.1 Hz, 1H).
6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00256##
[0526]
6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile was
prepared in an analogous manner to
5-(2-chloropyridin-3-yl)-1H-indazole preparation from
6-bromoimidazo[1,2-a]pyridine-3-carbonitrile [JMC 54(7), 2455-2466,
2011] (1.5 g, 6.7 mmol), 2-chloro-3-pyridine boronic acid pinacol
ester (1.9 g, 8.0 mmol), Pd(PPh.sub.3).sub.4 (0.54 g, 0.46 mmol)
and 2M aq.Na.sub.2CO.sub.3 (9.2 mL, 18.4 mmol) in 1,4-dioxane (100
mL) at 100.degree. C. overnight. After extractive workup with
CH.sub.2Cl.sub.2 followed by drying over MgSO.sub.4/Celite.RTM. and
filtration, filtrate was concentrated under reduced pressure. The
resultant pale brown solid was stirred in EtOAc (25 mL) and
filtered to provide
6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile as a
white solid. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.82 (d,
J=1.9 Hz), 8.54-8.45 (m, 2H), 8.07 (dd, J=7.6, 1.9 Hz, 1H), 7.94
(d, J=9.3 Hz, 1H), 7.75 (dd, J=9.3, 1.7 Hz, 1H), 7.58 (dd, J=7.6,
4.8 Hz, 1H). LCMS: rt 5.34 min (B), purity 95%, MS (m/e)
MH.sup.+255.
6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
##STR00257##
[0528] 6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine was
prepared and isolated in the similar to
6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
preparation by the reaction of
6-bromo-[1,2,4]triazolo[1,5-a]pyridine (2.5 g, 12.5 mmol),
2-chloro-3-pyridine boronic acid pinacol ester (3.6 g, 15.0 mmol),
Pd(PPh.sub.3).sub.4 (0.58 g, 0.50 mmol) and 2M aq.Na.sub.2CO.sub.3
(17 mL, 34 mmol) in 1,4-dioxane (100 mL) at 100.degree. C.
overnight. White fluffy solid (1.76 g, 61%). .sup.1H NMR (DMSO-d6):
.delta. 9.18 (dd, J=1.7, 0.8 Hz, 1H), 8.57 (s, 1H), 8.50 (dd,
J=4.9, 2.0 Hz, 1H), 8.05 (dd, J=7.6, 1.7 Hz, 1H), 7.97 (dd, J=9.1,
0.9 Hz, 1H), 7.80 (dd, J=9.1, 1.7 Hz, 1H), 7.57 (dd, J=7.6, 4.7 Hz,
1H). LCMS: rt 4.88 min (A), purity 95%, MS (m/e) MH.sup.+231.
7-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine
##STR00258##
[0530] 7-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine was
prepared and isolated as in an analogous manner to
6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
preparation by the reaction of
7-bromo-[1,2,4]triazolo[1,5-a]pyridine (1.0 g, 5.0 mmol),
2-chloro-3-pyridine boronic acid pinacol ester (3.6 g, 8.3 mmol),
Pd(PPh.sub.3).sub.4 (0.3 g, 0.26 mmol) and 2M aq.Na.sub.2CO.sub.3
(8 mL, 16 mmol) in 1,4-dioxane (100 mL) at 100.degree. C.
overnight. White fluffy solid (0.67 g, 58%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 9.06 (d, J=6.5 Hz, 1H), 8.58 (s, 1H), 8.51
(dd, J=4.8, 1.9 Hz, 1H), 8.03 (dd, J=7.6, 1.9 Hz, 1H), 7.99 (s,
1H), 7.58 (dd, J=7.6, 4.8 Hz, 1H), 7.34 (dd, J=7.1, 1.8 Hz, 1H).
LCMS: rt 4.83 min (A), purity 98%, MS (m/e) MH.sup.+231.
Compound 2:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00259##
[0532] LCMS: rt 2.15 min (A), MS (m/e) 314 MH.sup.+.
[0533] .sup.1H NMR (CD.sub.3OD, 300 MHz): 8.71 (dd, J=5.1, 1.8 Hz,
1H),): 8.55 (dd, J=7.8, 1.5 Hz, 1H), 8.35 (s, 1H), 8.09-8.06 (m,
2H), 7.69-7.62 (m, 2H), 7.51 (d, J=8.7 Hz, 1H), 7.40 (dd, J=8.7,
1.8 Hz, 1H), 7.31 (d, J=7.5 Hz, 1H), 7.20 (d, J=7.5 Hz, 1H), 2.31
(m, 3H).
Compound 11:
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00260##
[0535] LCMS: rt 3.43 min (A), MS (m/e) 318 MH.sup.+.
[0536] .sup.1H NMR (CD.sub.3OD, 300 MHz): 8.77 (m, 1H), 8.65 (m,
1H), 8.32 (m, 1H), 8.07-7.94 (m, 2H), 7.76-7.73 (m, 2H), 7.71-7.63
(m, 2H), 7.00 (dd, J=8.4, 2.7 Hz, 1H).
Compound 12: 6-([2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00261##
[0538] LCMS: rt 1.07 min (A), MS (m/e) 300 MH.sup.+.
[0539] .sup.1H NMR (CD.sub.3OD, 300 MHz): 8.72 (m, 1H), 8.38 (m,
2H), 8.12-8.06 (m, 2H), 7.85-7.80 (m, 1H), 7.67-7.58 (m, 2H),
7.52-7.49 (m, 1H), 7.44-7.40 (m, 1H), 7.37-7.32 (m, 1H).
Example 2
AlphaScreen.RTM. SureFire.RTM. SMAD3 (p-Ser423/425) Assay
[0540] The p-SMAD-3 (Ser423/425) SureFire.RTM. assay has been
designed to measure the phosphorylation of endogenous cellular
p-SMAD-3 (Ser423/425) in cell lysates and is a system for the
screening of both modulators of receptor activation (e.g. agonists
and antagonists) as well as agents acting intracellularly, such as
small molecule inhibitors of upstream events. The assay will
measure p-SMAD-3 (Ser423/425) activation by either cloned or
endogenous receptors, and can be applied to primary cells.
P-SMAD-3 (Ser423/425) SureFire.RTM. Assay Protocols
Step A: Preparation of Buffers
[0541] 1.times. Lysis buffer: 1 ml of 5.times. Lysis buffer was
diluted with 4 ml of sterile water. After dilution, excess 1.times.
Lysis buffer can be frozen and thawed up to 5 times without loss in
activity.
[0542] Activation buffer: The buffer was warmed slowly to
37.degree. C. and gently mixed to re-suspend. Activation buffer can
be stored at room temperature with no loss in activity.
[0543] Reaction buffer: The buffer was kept at 4.degree. C. while
in use.
[0544] AlphaScreen.RTM. Protein A IgG Kit: The kit was stored at
4.degree. C. in the dark.
[0545] Reaction buffer+Activation buffer+AlphaScreen.RTM. Acceptor
beads: Reaction buffer (40 parts), Activation Buffer (10 parts) and
Acceptor beads (1 part) were mixed and the mixture was stored at
room temperature and used the same day. Mixture was added to
384-well plates; excess mixture was discarded.
[0546] Dilution buffer+AlphaScreen.RTM. Donor beads: Dilution
buffer (20 parts) and Donor beads (1 part) were mixed and the
mixture was stored at room temperature and used the same day.
Excess mixture was discarded.
[0547] Assay control samples: After reconstitution in 250 .mu.l of
water, lysates were at -20.degree. C. in single use aliquots.
Step B: Preparation of Samples and Cells
[0548] 96-well Assay Protocol for 293FT and RMS13 adherent cells
can be carried out manually or in high throughput with liquid
handling robots.
[0549] The cells (80 .mu.L of cells for 96 well plates) were plated
in collagen coated tissue culture plates in RPMI or FreeStyle
medium (Invitrogen) and incubated overnight. For manual analysis, 6
plates for GDF8, 6 plates for TGF.beta., and optionally 6 plates
for Alk5ca (ALK5 constitutively active) were used.
[0550] The compound dilution plates were prepared as follows: 12
.mu.L of DMSO was transferred into first column of 96-well plate,
and 16 .mu.L of DMSO was transferred into columns 2-12 of the
96-well plate. 12 .mu.L of compound solution was transferred into
first column of the DMSO-containing 96-well plate. Three-fold
dilution was performed up to column 10 of the DMSO-containing
96-well plate.
Step C: Treatment and Analysis
[0551] The plate containing cells were treated with compounds for
about 10 minutes, and then ligand was added. GDF8 or TGFb was added
to plates to stimulate. 293FL cells were stimulated for 90 minutes
at 37.degree. C.; and RMS13 cells were stimulated for 60 minutes at
37.degree. C. The medium was then removed from the cells, and
1.times. Lysis Buffer (about 25 .mu.L) was added and the plate was
gently agitated on plate shaker for 5-10 minutes.
[0552] The lysate (5 .mu.L) was then placed into 384-well shallow
plates avoiding the generation of bubbles. To this, the Reaction
Buffer+Activation Buffer+AlphaScreen.RTM. Acceptor beadsmixture (5
.mu.L) was added. The plate was sealed with adhesive cover and
shielded from light (e.g., with metal foil), and agitated gently on
plate shaker for 2 hours at room temperature.
[0553] Dilution buffer+AlphaScreen.RTM. Donor beads (2 .mu.L) was
then added, and the plate was intubated on the plate shaker for an
additional 11/2 hours. After completion, the plate was read on
Synergy-4 or Enspire plate reader, using AlphaScreen.RTM.
pSMAD3.RTM. settings.
[0554] Representative results for inhibition of TGF-.beta.
(data=TGF-.beta. pSMAD (MPC-11) (.mu.M)) and GDF8 (data=GDF pSMAD
(MPC11)-(.mu.M)) signaling are shown in Table 1:
TABLE-US-00005 No. TGF-.beta. GDF8 1 10.58 19.66 2 -- -- 2A 0.2506
0.129 2B 0.1115 -- 3 1.707 0.7339 4 0.5014 0.2148 5 1.069 0.2803 6
0.0538 0.0286 7 -- 8.509 8 23.56 8.058 9 0.2807 0.1194 10 -- -- 11
-- -- 11A 1.172 0.2288 12 -- -- 12A 5.477 1.307
Example 3
Synthesis and Characterization 2
[0555] Analytical LC-MS/HPLC retention time reported for each of
the following compounds was generated using one of the following
general analytical LC-MS/HPLC conditions:
LCMS Conditions:
[0556] A: Column: Waters Acquity UPLC BEH C18 (2.1.times.50 mm),
1.7.mu.; Mobile phase A: 0.1% TFA in water; Mobile phase B: 0.1%
TFA in Acetonitrile; Gradient=20-90% B over 1.1 minute, then a 0.6
minute hold at 90% B; Temperature: 50.degree. C.; Flow rate: 0.7
mL/min; Detection: UV at 220 nm.
[0557] B: Column: Waters Acquity UPLC BEH C18 (2.1.times.50 mm)
1.7.mu., Mobile phase A: 10 mM NH.sub.4OAc, Acetonitrile (95:5);
Mobile phase B: 10 mM NH.sub.4OAc: Acetonitrile (5:95),
Gradient=20-90% B over 1.1 minute, then a 0.6 minute hold at 90% B;
Temperature: 50.degree. C.; Flow rate: 0.7 mL/min; Detection: UV at
220 nm
[0558] C: Column: Ascentis Express C18 (2.1.times.50 mm), 2.7.mu.;
Mobile phase A: 10 mM NH.sub.4OAc, Acetonitrile (95:5), Mobile
phase B: 10 mM NH.sub.4OAc, Acetonitrile (5:95), Gradient=0-100% B
over 3 minutes; Temperature: 50.degree. C.; Flow rate: 1.1 mL/min;
Detection: UV at 220 nm.
[0559] D: Column: Ascentis Express C18 (50.times.2.1) mm, 2.7.mu.;
Mobile phase A: 0.1% TFA: Acetonitrile (95:5), Mobile phase B: 0.1%
TFA: Acetonitrile (5:95), Gradient=0-100% B over 3 minutes;
Temperature: 50.degree. C.; Flow rate: 1.1 mL/min; Detection: UV at
220 nm.
[0560] E: Column: Kinetex XB-C18 (75.times.3 mm) 2.6.mu.; Mobile
phase A: 10 mM Ammonium formate: Acetonitrile (98:2), Mobile phase
B: 10 mM Ammonium formate: Acetonitrile (2:98), Gradient=20-100% B
over 4 minutes, then a 0.6 minute hold at 100% B; Temperature:
27.degree. C.; Flow rate: 1.0 mL/min; Detection: UV at 220 nm.
Preparative HPLC Conditions:
[0561] F: Column: Waters X-Bridge C18, 19.times.150 mm, 5.mu.;
Mobile Phase A: 0.1% TFA in water; Mobile Phase B: Acetonitrile;
Gradient: 10-100% B over 25 minutes, then a 5 minute hold at 100%
B; Flow: 15 mL/min.
[0562] G: Column: Inertsil ODS, 250.times.20 mm ID, 5.mu.; Mobile
Phase A: 0.1% TFA in water; Mobile Phase B: Acetonitrile; Gradient:
10-100% B over 25 minutes, then a 5 minute hold at 100% B; Flow: 17
mL/min.
[0563] H: Column: Inertsil ODS, 250.times.20 mm ID, 5.mu.; Mobile
Phase A: 10 mM NH.sub.4OAc in water; Mobile Phase B: Methanol;
Gradient: 10-100% B over 25 minutes, then a 5 minute hold at 100%
B; Flow: 17 mL/min.
[0564] I: Column: DAD-1.times.-Bridge phenyl, 150.times.4.6 mm
5.mu.; DAD-2 Sunfire C18, 150.times.4.6 mm 5.mu.; Mobile Phase A:
10 mM NH.sub.4OAc in water; Mobile Phase B: Acetonitrile; Gradient:
0-100% B over 18 minutes, then a 5 minute hold at 100% B; Flow: 1
mL/min.
[0565] J: Column: Sunfire C18, 150.times.4.6 mm, 5.mu.; Mobile
Phase A: 0.05% TFA in water; Mobile Phase B: Acetonitrile;
Gradient: 0-100% B over 18 minutes, then a 5 minute hold at 100% B;
Flow: 1 mL/min.
[0566] K: Column: Inertsil ODS, 150.times.4.6 mm, 5.mu.; Mobile
Phase A: 10 mM NH.sub.4OAc in water; Mobile Phase B: Acetonitrile;
Gradient: 0-100% B over 18 minutes, then a 5 minute hold at 100% B;
Flow: 17 mL/min.
[0567] L: Column: Sunfire C18, 150.times.19 mm ID, 5.mu.; Mobile
Phase A: 10 mM NH.sub.4OAc in water; Mobile Phase B: Acetonitrile;
Gradient: 0-100% B over 18 minutes, then a 5 minute hold at 100% B;
Flow: 17 mL/min.
[0568] M: Column: Synergy Polar, 250.times.21.2 ID, 4.mu.; Mobile
Phase A: 0.1% TFA in water; Mobile Phase B: Acetonitrile; Gradient:
0-100% B over 18 minutes, then a 5 minute hold at 100% B; Flow: 17
mL/min.
[0569] N: Column: Waters X-Bridge C18, 19.times.150 mm, 5.mu.;
Mobile Phase A: 10 mM NH.sub.4OAc in water; Mobile Phase B:
Acetonitrile; Gradient: 0-100% B over 18 minutes, then a 5 minute
hold at 100% B; Flow: 17 mL/min.
[0570] O: Column: Symmetry C8, 300.times.19 mm ID, 7.mu.; Mobile
Phase A: 10 mM NH.sub.4OAc in water; Mobile Phase B: Acetonitrile;
Gradient: 0-100% B over 18 minutes, then a 5 minute hold at 100% B;
Flow: 17 mL/min.
[0571] P: Column: X-Bridge Phenyl, 250.times.19 mm ID, 5.mu.;
Mobile Phase A: 10 mM NH.sub.4OAc in water; Mobile Phase B:
Acetonitrile; Gradient: 0-100% B over 18 minutes, then a 5 minute
hold at 100% B; Flow: 17 mL/min.
[0572] Q: Column: DAD1--X-Bridge Phenyl, 4.6.times.250 mm, 5.mu.;
DAD2--X-Terra RP18, 4.6.times.250 mm, 5.mu.; Mobile Phase A: 0.05%
TFA in water; Mobile Phase B: Acetonitrile; Gradient: 0-100% B over
18 minutes, then a 5 minute hold at 100% B; Flow: 2 mL/min.
General Experimental Procedures for Stille Coupling
##STR00262##
[0574] To a solution of compound 1A (reference: WO 2015157093 A1
and WO2014055955 A1)-(200 mg, 0.785 mmol) in 1,4-dioxane (10 mL)
was added 2-(tributylstannyl)pyridine (318 mg, 0.864 mmol). The
reaction mixture was degassed with argon. Then, Pd(PPh.sub.3).sub.4
(91 mg, 0.079 mmol) was added and the reaction mixture was degassed
once again and stirred at 110.degree. C. for 36 h. It was then
cooled to room temperature and the volatiles were removed under
reduced pressure to give a brown solid. The crude residue was
purified by preparative HPLC (condition N) to furnish
6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile 13
(205 mg, 0.690 mmol, 88% yield). LCMS: m/z=298.1 [M+H].sup.+; ret.
time 0.99 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.78 (dd, J=1.6, 4.8 Hz, 1H), 8.59 (dd, J=1.2, 1.6 Hz,
1H), 8.46 (s, 1H), 8.30-8.31 (m, 1H), 8.11 (dd, J=1.6, 7.6 Hz, 1H),
7.90-7.92 (m, 2H), 7.62-7.68 (m, 2H), 7.33-7.34 (m, 1H), 7.16 (dd,
J=2.0, 9.6 Hz, 1H).
##STR00263##
[0575] To a stirred solution of compound 1A (200 mg, 0.785 mmol)
and 2-bromo-6-(trifluoromethyl)pyridine (195 mg, 0.864 mmol) in
1,4-dioxane (2 mL) was added hexamethylditin (0.326 mL, 1.571 mmol)
and the reaction mixture was purged with nitrogen for 5 minutes.
Then Pd(PPh.sub.3).sub.4 (0.091 g, 0.079 mmol) was added and the
mixture was again purged for 10 minutes. It was then heated at
110.degree. C. for 16 h. The reaction mixture was filtered through
syringe filter and the filtrate was concentrated. The crude residue
was purified by preparative HPLC (condition N) to give
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-ca-
rbonitrile 14 (0.15 g, 0.411 mmol, 52.3% yield) as a yellow solid.
LCMS: m/z=366.1 [M+H].sup.+; ret. time 1.67 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.81-8.85 (m, 1H)
8.58-8.62 (m, 1H) 8.44-8.48 (m, 1H) 8.29-8.36 (m, 1H) 8.17-8.24 (m,
1H) 8.08-8.13 (m, 1H) 7.78-7.83 (m, 1H) 7.66-7.72 (m, 2H) 7.22-7.28
(m, 1H).
##STR00264##
[0576] To a solution of compound 1A (50 mg, 0.196 mmol) and
6-bromo-3-fluoro-2-methylpyridine (37.3 mg, 0.196 mmol) in
1,4-dioxane (2 mL) was added hexamethylditin (0.041 mL, 0.196
mmol). The solution was degassed with argon and then
Pd(PPh.sub.3).sub.4 (22.69 mg, 0.020 mmol) was added. The reaction
mixture was stirred at 140.degree. C. for 1 h in a CEM microwave
instrument. The reaction mixture was cooled, filtered off and the
filtrate was evaporated under reduced pressure. The crude residue
was purified by preparative HPLC (Method N) to yield
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
bonitrile 15 (15.9 mg, 0.047 mmol, 24.1% yield). LCMS: m/z=330.1
[M+H].sup.+; ret. time 1.28 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.76 (dd, J=4.6, 1.7 Hz, 1H), 8.58 (dd,
J=1.7, 1.0 Hz, 1H), 8.48-8.44 (m, 1H), 8.07 (dd, J=7.7, 1.6 Hz,
1H), 7.80 (dd, J=8.6, 3.7 Hz, 1H), 7.73-7.65 (m, 2H), 7.61 (dd,
J=7.8, 4.6 Hz, 1H), 7.23 (dd, J=9.3, 1.7 Hz, 1H), 2.07 (d, J=2.9
Hz, 3H).
##STR00265##
[0577] To a stirred solution of 2-bromo-4-fluoropyridine (0.3 g,
1.71 mmol) in 1,4-dioxane (5 mL) was added hexamethylditin (0.43
mL, 2.1 mmol). The reaction mixture was purged with N.sub.2 for 10
min. and to it was added Pd(Ph.sub.3P).sub.4 (0.20 g, 0.17 mmol).
The reaction mixture was purged once again with N.sub.2 for another
10 min and heated at 110.degree. C. for 2 h. Then, after cooling to
room temperature, compound 1A (0.43 g, 1.71 mmol) was added and the
mixture was purged with N.sub.2 for 5 min., followed by the
addition of Pd(Ph.sub.3P).sub.4 (0.2 g, 0.17 mmol). The reaction
was again heated at 110.degree. C. for 18 h. The reaction mixture
was concentrated under vacuum to give a crude residue, which was
purified by preparative HPLC (Condition N) to provide
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
16 (0.38 mg, 0.89 mmol, 52.3% yield). LC-MS: m/z=317.1 [M+H].sup.+;
ret. time 1.41 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.93-8.89 (m, 1H), 8.60-8.57 (m, 1H),
8.27-8.19 (m, 3H), 8.03-7.97 (m, 1H), 7.77-7.72 (m, 1H), 7.42-7.37
(m, 1H), 7.34-7.27 (m, 1H).
##STR00266##
[0578] To a stirred solution of compound 1A (0.2 g, 0.79 mmol) and
2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
1B (0.24 g, 1.02 mmol) in 1,4-dioxane (10 mL)/H.sub.2O (2 mL) was
added K.sub.3PO.sub.4 (0.5 g, 2.36 mmol). The reaction mixture was
degassed for 3 min. and then to it was added the
PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (0.032 g, 0.039 mmol), and
the resultant mixture was heated at 100.degree. C. for 12 h. The
reaction mixture was then filtered through a Celite.RTM. pad, the
filter cake washed with ethyl acetate and the combined filtrate
evaporated under reduced pressure to give the crude compound, which
was purified by preparative HPLC (condition N) to yield
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
17 (0.2 mg, 0.054 mmol, 68.5% yield). LCMS: m/z=328.1 [M+H].sup.+;
ret. time 1.49 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.78 (dd, J=4.6, 1.7 Hz, 1H), 8.63 (dd,
J=1.7, 1.0 Hz, 1H), 8.48 (s, 1H), 8.07 (dd, J=7.7, 1.6 Hz, 1H),
7.86-7.70 (m, 2H), 7.66-7.55 (m, 2H), 7.25 (dd, J=9.2, 1.8 Hz, 1H),
6.79-6.66 (m, 1H), 3.04 (s, 3H).
General Experimental Procedures for Hydrolysis of Nitrile to
Amide
##STR00267##
[0580] Compound 14 was added to a stirred solution of
H.sub.2SO.sub.4 (0.066 mL, 1.232 mmol) in TFA (0.274 mL, 3.56 mmol)
at room temperature and the resultant mixture was stirred for 10
min. Then it was heated at 85.degree. C. for 2 h. After that,
ice-cold water (5 mL) was added and the solution was basified with
10% aq. NaOH solution. The precipitated solid was filtered and
purified by preparative HPLC (Condition H) to furnish
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide 18 (50 mg, 0.130 mmol, 47.6% yield) as an
off-white solid. LCMS: m/z=384.0 [M+H].sup.+; ret. time 1.82 min;
condition E. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
9.32-9.36 (m, 1H) 8.80-8.84 (m, 1H) 8.31-8.34 (m, 1H) 8.22-8.27 (m,
2H) 8.15-8.21 (m, 1H) 8.04-8.09 (m, 1H) 7.76-7.81 (m, 1H) 7.63-7.71
(m, 1H) 7.54-7.59 (m, 1H) 7.10-7.17 (m, 2H).
##STR00268##
[0581] In a 25 mL round bottom flask was added 15 (140 mg, 0.425
mmol) and K.sub.2CO.sub.3 (176 mg, 1.275 mmol) in DMSO (2 mL). The
mixture was cooled to 0.degree. C. and H.sub.2O.sub.2 (0.977 mL,
12.75 mmol, 30% v/v) was added drop-wise. The reaction mixture was
brought to room temperature and stirred for another 3 h. The
reaction mixture was then diluted with ice water and the solid
obtained was filtered, washed with water and dried to yield
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
boxamide 19 (73 mg, 0.205 mmol, 48.2% yield) as an off-white solid.
LCMS: m/z 348.2 [M+H].sup.+; ret. time 1.34 min; condition E.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.37 (dd, J=2.0,
1.0 Hz, 1H), 8.74 (dd, J=4.8, 1.8 Hz, 1H), 8.35-8.31 (m, 1H),
8.01-7.87 (m, 2H), 7.76-7.69 (m, 1H), 7.69-7.55 (m, 3H), 7.35 (br.
s., 1H), 7.16-7.10 (m, 1H), 2.07 (d, J=3.0 Hz, 3H).
Compound 20:
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00269##
[0583] Compound 20 was synthesized by reacting 1A and
6-bromo-3-fluoropyridine and employing the experimental procedure
described in Scheme 3 (Method C). The crude residue was purified by
preparative HPLC (condition N) to yield
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
20 (14 mg, 0.044 mmol, 34.7% yield). LCMS: m/z=316.1 [M+H].sup.+;
ret. time 1.49 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.76 (dd, J=4.6, 1.7 Hz, 1H), 8.60 (dd,
J=1.7, 1.0 Hz, 1H), 8.45 (s, 1H), 8.30 (s, 1H), 8.13-8.07 (m, 1H),
8.03-7.95 (m, 1H), 7.87-7.78 (m, 1H), 7.70-7.56 (m, 2H), 7.15 (dd,
J=9.3, 2.0 Hz, 1H).
Compound 21:
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00270##
[0585] Compound 21 was synthesized from 20 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
21 (57.3 mg, 0.172 mmol, 24.8% yield). LCMS m/z=334.1 [M+H].sup.+;
ret. time 0.98 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.39 (dd, J=1.8, 0.9 Hz, 1H), 8.77-8.72
(m, 1H), 8.34-8.26 (m, 2H), 8.03 (d, J=1.7 Hz, 1H), 7.94 (d, J=0.5
Hz, 2H), 7.82 (td, J=8.7, 2.9 Hz, 1H), 7.65-7.59 (m, 1H), 7.54 (s,
1H), 7.37 (d, J=7.3 Hz, 1H), 7.08 (d, J=2.0 Hz, 1H).
Compound 22:
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00271##
[0587] Compound 22 was synthesized from 16 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
compound 22. (3.9 mg, 0.012 mmol, 0.96% yield). LCMS: m/z=334.1
[M+H].sup.+; ret. time 0.86 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.40 (dd, J=2.0, 1.0 Hz, 1H), 8.77 (dd,
J=4.8, 1.6 Hz, 1H), 8.34-8.22 (m, 2H), 8.05 (d, J=1.7 Hz, 1H), 7.94
(d, J=4.4 Hz, 1H), 7.78 (d, J=2.7 Hz, 1H), 7.66 (d, J=4.6 Hz, 1H),
7.55 (dd, 1.0 Hz, 1H), 7.38 (br. s., 1H), 7.26 (ddd, J=8.9, 5.7,
2.4 Hz, 1H), 7.11 (dd, J=9.3, 2.0 Hz, 1H).
Compound 23:
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carbonitrile
##STR00272##
[0589] Compound 23 was synthesized by reacting 1A and
6-bromo-2-(difluoromethyl)-3-fluoropyridine employing the
experimental procedure described in Scheme 4 (Method-D). The crude
residue was purified by preparative HPLC (condition-N) to yield
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carbonitrile 23 (250 mg, 0.438 mmol, 33% yield). LCMS:
m/z=366.1 [M+H].sup.+; ret. time 1.62 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.79 (dd, J=4.8, 1.6 Hz, 1H),
8.60 (d, J=1.0 Hz, 1H), 8.45 (s, 1H), 8.24 (dd, J=8.9, 3.8 Hz, 1H),
8.12-8.06 (m, 1H), 8.05-7.97 (m, 1H), 7.69-7.57 (m, 2H), 7.21 (dd,
J=9.3, 1.7 Hz, 1H), 6.85-6.55 (m, 1H).
Compound 24:
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carboxamide
##STR00273##
[0591] Compound 24 was synthesized from 23 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carboxamide 24. (37.6 mg, 0.098 mmol, 25.6% yield). LCMS
m/z=384.1 [M+H].sup.+; ret. time 1.24 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.66-9.58 (m, 1H), 9.06 (d,
J=1.5 Hz, 1H), 8.59 (s, 1H), 8.40 (d, J=3.9 Hz, 1H), 8.33-8.22 (m,
2H), 8.20-8.09 (m, 1H), 7.93 (d, J=7.8 Hz, 1H), 7.83 (dd, J=9.3,
0.7 Hz, 1H), 7.66-7.55 (m, 1H), 7.41 (dd, J=9.2, 1.8 Hz, 1H),
7.13-6.96 (m, 1H).
Compound 25: methyl
3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carboxylate
##STR00274##
[0593] Compound 25 was synthesized by reacting 1A and methyl
6-bromonicotinate employing the experimental procedure described in
Scheme 4 (Method-D). The crude residue was purified by preparative
HPLC (condition-N) to yield methyl
3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carboxylate
25 (150 mg, 0.35 mmol, 25.2% yield). LCMS m/z=356.2 [M+H].sup.+;
ret. time 1.14 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.81 (dd, 1.5 Hz, 1H), 8.78-8.73 (m, 1H),
8.68-8.62 (m, 1H), 8.47 (s, 1H), 8.40 (dd, J=8.3, 2.3 Hz, 1H),
8.19-8.13 (m, 1H), 8.11-8.06 (m, 1H), 7.71-7.62 (m, 2H), 7.19-7.12
(m, 1H), 3.86 (s, 3H).
Compounds 26 and 27: methyl
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carboxylat-
e and
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carbo-
xylic acid
##STR00275##
[0595] Compounds 26 and 27 were obtained from 25 when employing
experimental procedure similar to the synthesis of 19 as described
in Scheme 7 (Method B). The crude residue was purified by
preparative HPLC (condition-N) to yield methyl
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carboxylat-
e 26 (4 mg, 10.71 .mu.mol, 3.8% yield) and
3'-(3-carbamoylimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridine]-5-carboxylic
acid 27 (20.1 mg, 0.056 mmol, 19.9% yield). Analysis of 26: LCMS:
m/z=374.1 [M+H].sup.+; ret. time 0.88 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.70-9.67 (m, 1H), 9.08-9.02
(m, 2H), 8.66-8.62 (m, 1H), 8.60 (s, 1H), 8.36-8.27 (m, 2H),
8.25-8.19 (m, 1H), 7.94 (dd, J=7.8, 4.6 Hz, 1H), 7.82 (s, 1H), 7.65
(br. s., 1H), 7.33 (dd, J=9.0, 1.7 Hz, 1H), 4.12 (s, 3H). Analysis
of 27: LCMS m/z=360.1 [M+H].sup.+; ret. time 0.57 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 13.68 (br. s., 1H),
9.72-9.64 (m, 1H), 9.09-8.97 (m, 2H), 8.62 (d, J=2.2 Hz, 2H),
8.35-8.18 (m, 3H), 7.93 (dd, J=7.7, 4.8 Hz, 1H), 7.81 (d, J=9.0 Hz,
1H), 7.66 (br. s., 1H), 7.32 (dd, J=9.2, 1.8 Hz, 1H).
Compound 28:
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
bonitrile
##STR00276##
[0597] Compound 28 was synthesized by reacting 1A and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described in Scheme 4 (Method-D). The crude residue was
purified by preparative HPLC (method-N) to yield
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
bonitrile 28 (0.22 g, 0.633 mmol, 81% yield) as a yellow solid.
LCMS: m/z=348.1 [M+H].sup.+; ret. time 1.35 min; conditions C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.79-8.83 (m, 1H)
8.53-8.57 (m, 1H) 8.41-8.47 (m, 1H) 8.07-8.13 (m, 3H) 7.56-7.72 (m,
3H) 7.18-7.24 (m, 1H) 6.33-6.66 (m, 1H).
Compound 29:
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
boxamide
##STR00277##
[0599] Compound 29 was synthesized from 28 in a manner similar to
18 employing the experimental procedure described in Scheme 6
(Method A). The crude residue was purified by preparative HPLC
(condition-H) to yield
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-car-
boxamide 29 (45 mg, 0.123 mmol, 28.5% yield) as an off-white solid.
LCMS m/z=366.2 [M+H].sup.+; ret. time 1.58 min; conditions E.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.36-9.43 (m, 1H)
8.76-8.82 (m, 1H) 8.32 (s, 1H) 7.98-8.11 (m, 3H) 7.8 (s, 1H)
7.63-7.70 (m, 1H) 7.51-7.62 (m, 2H) 7.4 (s, 1H) 7.09-7.15 (m, 1H)
6.36-6.69 (m, 1H).
Compound 30:
6-(6'-ethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00278##
[0601] Compound 30 was synthesized by reacting 1A and
2-bromo-6-ethylpyridine employing the experimental procedure
described in Scheme 4 (Method-D). The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(6'-ethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
30 (2.4 mg, 1% yield). LCMS m/z=326.1 [M+H].sup.+; ret. time 1.46
min; conditions C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
9.02-9.05 (m, 1H) 8.75-8.78 (m, 1H) 8.70-8.72 (m, 1H) 8.31-8.36 (m,
1H) 8.04-8.08 (m, 2H) 7.94-7.99 (m, 1H) 7.85-7.90 (m, 1H) 7.49-7.52
(m, 1H) 7.41-7.44 (m, 1H) 2.57-2.66 (m, 2H) 0.76-0.83 (m, 3H).
Compound 31:
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitri-
le
##STR00279##
[0603] Compound 31 was synthesized by reacting 1A and
2-bromo-6-isopropylpyridine employing the experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitri-
le 31 (150 mg, 4.4 mmol, 45% yield) as a pale yellow solid. LCMS:
m/z=340.1 [M+H].sup.+; ret. time 1.58 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.76-8.80 (m, 1H), 8.43-8.50
(m, 2H), 8.05-8.11 (m, 1H), 7.83-7.88 (m, 2H), 7.70-7.75 (m, 1H),
7.59-7.66 (m, 1H), 7.26 (dd, J=1.76, 9.29 Hz, 1H), 7.19 (dd,
J=2.76, 5.77 Hz, 1H), 2.68 (td, J=1.63, 3.76 Hz, 1H), 0.64 (d,
J=7.03 Hz, 6H).
Compound 32:
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamid-
e
##STR00280##
[0605] Compound 32 was synthesized from 31 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamid-
e 32 (59.7 mg, 0.164 mmol, 55.6% yield) as a pale yellow solid.
LCMS: m/z=358.2 [M+H].sup.+; ret. time 1.15 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.40 (d, J=6.85 Hz,
6H), 7.44-7.36 (m, 1H), 2.96-2.87 (m, 2H), 2.49-2.38 (m, 2H),
2.28-2.18 (m, 2H), 2.03 (dd, J=1.59, 7.70 Hz, 1H), 1.71 (s, 1H),
1.26 (dd, J=1.71, 4.65 Hz, 1H), 0.69 (dd, J=0.98, 1.71 Hz, 1H).
Compound 33:
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00281##
[0607] Compound 33 was synthesized from 17 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
33 (53 mg, 0.150 mmol, 24.6% yield) as a pale yellow solid. LCMS:
m/z=346.1 [M+H].sup.+; ret. time 1.06 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.42 (dd, J=1.8, 0.9 Hz, 1H),
8.78-8.70 (m, 1H), 8.34 (s, 1H), 8.00-7.71 (m, 3H), 7.63-7.52 (m,
3H), 7.34 (br. s., 1H), 7.15 (dd, J=9.2, 1.8 Hz, 1H), 6.70 (dd,
J=8.3, 0.7 Hz, 1H), 3.03 (s, 3H).
Compound 34:
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonit-
rile
##STR00282##
[0609] Compound 34 was synthesized by reacting 1A and
2-bromo-6-cyclopropylpyridine the employing experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (condition-F) to yield
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonit-
rile 34 (100 mg, 2.96 mmol, 30.2% yield) as a pale yellow solid.
LCMS: m/z=338.1 [M+H].sup.+; ret. time 1.65 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.76 (dd, 1.5 Hz,
1H), 8.54 (s, 1H), 8.48 (s, 1H), 8.04 (dd, J=7.7, 1.6 Hz, 1H),
7.78-7.74 (m, 2H), 7.71 (d, J=9.3 Hz, 1H), 7.60 (dd, J=7.8, 4.6 Hz,
1H), 7.27-7.22 (m, 1H), 7.16 (dd, J=9.3, 1.7 Hz, 1H), 1.82 (ddd,
J=12.5, 8.3, 4.6 Hz, 1H), 0.48-0.41 (m, 2H), 0.03-0.08 (m, 2H).
Compound 35:
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxam-
ide
##STR00283##
[0611] Compound 35 was synthesized from 34 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxam-
ide 35 (16.3 mg, 0.045 mmol, 30.6% yield) as a pale yellow solid.
LCMS: m/z=356.1 [M+H].sup.+; ret. time 1.29 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.61 (d, J=0.7 Hz,
1H), 9.00 (dd, J=4.8, 1.6 Hz, 1H), 8.61 (s, 1H), 8.21 (dd, J=7.7,
1.6 Hz, 2H), 8.06-7.92 (m, 2H), 7.90-7.75 (m, 2H), 7.60 (br. s.,
1H), 7.53-7.41 (m, 1H), 7.29 (dd, J=9.3, 1.7 Hz, 1H), 2.13-1.94 (m,
1H), 0.72-0.56 (m, 2H), 0.22-0.13 (m, 2H).
Compound 36:
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00284##
[0613] Compound 36 was synthesized by reacting 1A and
6-bromo-2-fluoropyridine employing experimental procedure described
in Scheme-4 (Method D). The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
36 (130 mg, 4.12 mmol, 52.4% yield) as a pale yellow solid. LCMS:
m/z=316.1 [M+H].sup.+; ret. time 1.35 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.06 (dd, J=4.8, 1.6 Hz, 1H),
8.92 (s, 1H), 8.75 (s, 1H), 8.42-8.29 (m, 2H), 8.11 (dd, J=7.6, 2.2
Hz, 1H), 7.98 (d, J=9.3 Hz, 1H), 7.92 (dd, J=7.8, 4.9 Hz, 1H), 7.48
(dd, J=9.3, 1.7 Hz, 1H), 7.41 (dd, J=7.9, 2.6 Hz, 1H).
Compound 37:
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00285##
[0615] Compound 37 was synthesized from 36 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
37 (13.5 mg, 0.040 mmol, 12.6% yield) as a pale yellow solid. LCMS:
m/z=334.1 [M+H].sup.+; ret. time 1.06 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.39 (dd, J=0.98, 1.96 Hz, 1H),
8.77 (dd, J=1.59, 4.77 Hz, 1H), 8.34 (s, 1H), 8.01-8.09 (m, 2H),
7.89-7.99 (m, 1H), 7.77 (dd, J=2.32, 7.21 Hz, 1H), 7.56-7.68 (m,
2H), 7.36 (br. s., 1H), 7.06-7.15 (m, 2H).
Compound 38:
6-(6'-(benzyloxy)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonit-
rile
##STR00286##
[0617] Compound 38 was synthesized by reacting 1A and
2-(benzyloxy)-6-bromopyridine employing experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(6'-(benzyloxy)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonit-
rile 38 (24.1 mg, 0.06 mmol, 15.21%). LCMS m/z=404.1 [M+H].sup.+;
ret. time 1.97; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.78 (dd, J=4.9, 1.7 Hz, 1H), 8.66 (dd, J=1.7, 1.0 Hz,
1H), 8.50 (s, 1H), 8.07 (dd, J=7.7, 1.6 Hz, 1H), 7.86 (dd, J=8.1,
7.3 Hz, 1H), 7.71-7.79 (m, 2H), 7.60-7.63 (m, 1H), 7.29-7.20 (m,
4H), 6.95-6.87 (m, 2H), 6.81 (dd, J=8.3, 0.7 Hz, 1H), 4.31 (s,
2H).
Compound 39:
6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00287##
[0619] Compound 39 was synthesized from 13 in a manner similar to
18 employing the experimental procedure described in Scheme-6
(Method A). The crude compound was purified by preparative HPLC
(condition-H) to yield
6-([2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonoxamide 39
(14.3 g, 0.045 mmol, 13.3% yield). LCMS: m/z=316.2 [M+H].sup.+;
ret. time 1.22 min; condition E. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.40 (d, J=0.8 Hz, 1H), 8.75 (dd, J=1.6,
4.8 Hz, 1H), 8.32 (s, 1H), 8.27 (d, J=4.4 Hz, 1H), 8.01 (dd, J=1.6,
7.6 Hz, 1H), 7.95 (bs, 1H), 7.83-7.90 (m, 2H), 7.61 (dd, J=4.8, 8.0
Hz, 1H), 7.52 (d, J=9.2 Hz, 1H), 7.35 (bs, 1H), 7.28-7.31 (m, 1H),
7.03 (dd, J=2.0, 9.2 Hz, 1H)
Compound 40:
6-(6'-acetyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00288##
[0621] Compound 40 was synthesized by reacting 1A and
1-(6-bromopyridin-2-yl)ethanone employing the experimental
procedure described in Scheme-2 (Method B). The crude residue was
purified by preparative HPLC (condition-N) to yield
6-(6'-acetyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
40 (6.5 mg, 0.019 mmol, 4.9%). LCMS: m/z=340.1 [M+H].sup.+; ret.
time 1.38; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.83 (dd, J=4.6, 1.7 Hz, 1H), 8.73 (dd, J=1.7, 1.0 Hz, 1H),
8.47 (s, 1H), 8.33 (dd, J=7.8, 1.0 Hz, 1H), 8.16-8.10 (m, 2H), 7.86
(dd, J=7.7, 1.1 Hz, 1H), 7.73-7.65 (m, 2H), 7.24 (dd, J=9.3, 1.7
Hz, 1H), 1.72 (s, 3H).
##STR00289##
Compound 41:
6-(6'-6-(6'-(2-hydroxypropan-2-yl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]py-
ridine-3-carbonitrile
[0622] To a solution of compound 40 (0.09 g, 0.265 mmol) in THF (5
mL) at 0.degree. C. was added 3.4M solution of methylmagnesium
bromide (0.086 mL, 0.292 mmol) and the reaction was stirred for 2
h. It was then quenched with saturated aq. NH.sub.4Cl solution and
extracted with ethyl acetate (2.times.50 mL). The combined organic
layer was washed with water, brine, dried over anhydrous sodium
sulfate, filtered and the filtrate was concentrated under reduced
pressure to afford a crude residue. It was purified by preparative
HPLC (Condition N) to yield
6-(6'-6-(6'-(2-hydroxypropan-2-yl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]py-
ridine-3-carbonitrile 41 (7.1 mg, 0.020 mmol, 7.46% yield). LCMS:
m/z=356.1 [M+H].sup.+; ret. time 1.05; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.77 (s, 1H), 8.51-8.51 (m,
1H), 8.48 (dd, J=0.92, 1.59 Hz, 1H), 8.05 (d, J=7.76 Hz, 1H),
7.84-7.94 (m, 2H), 7.74-7.77 (m, 1H), 7.50-7.64 (m, 2H), 7.22-7.25
(m, 1H), 1.81 (s, 1H), 0.76 (s, 6H).
Compound 42:
6-(4',6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxam-
ide
##STR00290##
[0624] Compound 42 was synthesized by reacting 1A and
2-bromo-4,6-dimethylpyridine employing the experimental procedure
described in Scheme 4 (Method-D) and then the resultant cyano
compound was hydrolyzed similar to 19 employing experimental
procedures described in Scheme 7 (Method B). The crude residue was
purified by preparative HPLC (condition P) to yield
6-(4',6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxam-
ide 42 (42.6 mg, 0.122 mmol, 39.6% yield). LCMS: m/z=344.2
[M+H].sup.+; ret. time 1.56 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.39 (d, J=0.7 Hz, 1H), 8.73 (dd, 1.5 Hz,
1H), 8.32 (s, 1H), 7.96 (dd, J=7.7, 1.6 Hz, 2H), 7.58 (dd, J=7.7,
4.8 Hz, 1H), 7.55-7.49 (m, 2H), 7.37 (br. s., 1H), 7.12-7.06 (m,
1H), 6.96 (s, 1H), 2.29 (s, 3H), 2.02 (s, 3H).
Compound 44:
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridin]-6-yl)methanesu-
lfonamide
##STR00291##
[0626] Compound 44 was synthesized by reacting 1A and
N-(6-bromopyridin-2-yl)methanesulfonamide [Reference: WO2011141848
A1/Organic & Biomolecular Chemistry (2015), 13(25), 7050-7066]
employing experimental procedure described in Scheme-2 (Method B).
The crude residue was purified by preparative HPLC (Method: N) to
yield
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridin]-6-yl)methanesu-
lfonamide 44 (0.07 g, 0.179 mmol, 22.8% yield) as a yellow solid.
LCMS: m/z=391.1 [M+H].sup.+; ret. time 1.03 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.31 (s, 1H)
8.68-8.89 (m, 1H) 8.55-8.58 (m, 1H) 8.41-8.44 (m, 1H) 8.08-8.14 (m,
1H) 7.82-7.89 (m, 1H) 7.60-7.67 (m, 2H) 7.55-7.59 (m, 1H) 7.07-7.13
(m, 1H) 6.87-6.92 (m, 1H) 2.72-2.76 (m, 3H).
##STR00292##
Compound 3AA:
6-(6'-chloro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00293##
[0628] Compound 3AA was synthesized by reacting 1A and
2-chloro-6-(tributylstannyl)pyridine employing experimental
procedure described in Scheme 1 (Method A). The crude residue was
purified by silica gel chromatography (40 g RediSep.RTM. column,
eluted with a gradient of 20-30% ethyl acetate in petroleum ether)
to yield
6-(6'-chloro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
3AA (0.25 g, 0.460 mmol, 29.3% yield) as colorless liquid. LCMS:
m/z=332.2 [M+H].sup.+; ret. time 2.46 min; condition E.
Compound 45:
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridin]-6-yl)acetamide
##STR00294##
[0630] Tris(dibenzylideneacetone)dipalladium(O)-(27.6 mg, 0.030
mmol) was added to a stirred solution of
6-(6'-chloro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
3AA (100 mg, 0.301 mmol), acetamide (26.7 mg, 0.452 mmol),
4,5-bis(diphenylphosphino)-9,9-dimethylxantheneacetamide (34.9 mg,
0.060 mmol) and Cs.sub.2CO.sub.3 (196 mg, 0.603 mmol) in
1,4-dioxane (10 mL). The reaction mixture was heated at 100.degree.
C. for 12 h. The mixture was cooled to room temperature and
filtered through a Celite.RTM. pad, the filter cake was washed with
ethyl acetate and the combined filtrate was evaporated under
reduced pressure to give crude compound, which was purified by
preparative HPLC (condition N) to yield
N-(3'-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-[2,2'-bipyridin]-6-yl)acetamide
45 (17.4 mg, 0.048 mmol, 15.8% yield). LCMS: m/z=355.1 [M+H].sup.+;
ret. time 1.22 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.14 (s, 1H), 8.76 (d, J=4.5 Hz, 1H),
8.66-8.57 (m, 1H), 8.46 (s, 1H), 8.15 (d, J=9.5 Hz, 1H), 8.01 (d,
J=8.0 Hz, 1H), 7.79 (d, J=15.6 Hz, 1H), 7.67-7.50 (m, 2H), 7.35 (d,
J=7.5 Hz, 1H), 7.12-6.94 (m, 1H), 1.95 (s, 3H).
Compound 46:
6-(6'-chloro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
##STR00295##
[0632] Compound 46 was synthesized from 3AJ in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-H) to yield compound
6-(6'-chloro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
oxamide 46 (7.3 mg, 0.020 mmol, 5.6% yield). LCMS: m/z=350.1
[M+H].sup.+; ret. time 1.13 min; condition C. .sup.1H NMR .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.38 (d, J=0.7 Hz, 1H), 8.77
(dd, 1.5 Hz, 1H), 8.33 (s, 1H), 8.05-7.97 (m, 1H), 7.95-7.86 (m,
2H), 7.85-7.80 (m, 1H), 7.67-7.61 (m, 2H), 7.58 (s, 1H), 7.42 (dd,
J=7.8, 0.7 Hz, 1H), 7.12 (dd, J=9.2, 1.8 Hz, 1H).
##STR00296##
Compound 47:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine
##STR00297##
[0634] Compound 47 was synthesized by reacting 3AD (Reference: WO
2015157093 A1/WO 2014055955 A1) and
2-methyl-6-(tributylstannyl)pyridine in a manner similar to
compound 13 employing the experimental procedure described in
Scheme-1 (Method A). The crude residue was purified by preparative
HPLC (method: I) to yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine 47 (17
mg, 0.069 mmol, 15.80% yield). LCMS: m/z=287.1 [M+H].sup.+; ret.
time 1.16 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.72 (dd, 1.5 Hz, 1H), 8.53 (s, 1H), 7.97 (dd, 1.5 Hz,
1H), 7.89 (s, 1H), 7.75-7.69 (m, 1H), 7.60-7.53 (m, 3H), 7.36 (d,
J=9.3 Hz, 1H), 7.15 (d, J=7.6 Hz, 1H), 6.78 (dd, 1.7 Hz, 1H), 2.13
(s, 3H).
Compound 48:
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine
##STR00298##
[0636] Compound 48 was synthesized by reacting 3AD and
6-bromo-2-(difluoromethyl)-3-fluoropyridine employing the
experimental procedure described in Scheme-2 (Method B). The crude
residue was purified by preparative HPLC (method I) to yield
6-(6'-(difluoromethyl)-5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine 48 (6.8 mg, 0.020 mmol, 3.3% yield). LCMS: m/z=341.1
[M+H].sup.+; ret. time 1.43 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta.=8.76 (dd, J=4.6, 1.5 Hz, 1H), 8.56 (s, 1H),
8.10 (dd, J=8.7, 3.8 Hz, 1H), 8.05-7.99 (m, 2H), 7.89 (s, 1H), 7.64
(dd, J=7.7, 4.8 Hz, 1H), 7.56 (s, 1H), 7.42-7.34 (m, 1H), 6.92-6.56
(m, 2H).
##STR00299##
Compound 49:
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arbonitrile
##STR00300##
[0638] Compound 49 was synthesized by reacting 4 (reference: WO
2015157093 A1 and WO 2014055955 A1) and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described in Scheme 4 (Method-D). The crude residue was
purified by preparative HPLC (condition-H) to yield
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arbonitrile 49 (242 mg, 0.0604 mmol, 62.9% yield). LCMS: m/z=349.1
[M+H].sup.+; ret. time 1.53 min. condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.92 (dd, J=4.6, 1.7 Hz, 1H), 8.36 (dd,
J=8.1, 1.0 Hz, 1H), 8.25 (d, J=9.3 Hz, 1H), 8.21-8.18 (m, 2H), 8.16
(t, J=7.8 Hz, 1H), 7.74 (dd, J=7.7, 4.8 Hz, 1H), 7.61 (d, J=7.8 Hz,
1H), 7.43 (d, J=9.5 Hz, 1H), 6.26 (s, 1H).
##STR00301##
Compound 50:
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitri-
le
##STR00302##
[0640] Compound 50 was synthesized by reacting 4 and
2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
employing the experimental procedure described in Scheme-5 (Method
E). The crude product was purified by preparative HPLC (condition
L) to yield
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitri-
le 50 (125 mg, 0.35 mmol, 44.8% yield). LCMS: m/z=329.2
[M+1].sup.+; ret. time 1.54 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.48 (dd, J=4.8, 1.6 Hz, 1H), 8.21 (s,
1H), 7.89 (d, J=9.5 Hz, 2H), 7.77-7.63 (m, 1H), 7.45 (d, J=5.9 Hz,
1H), 7.33-7.21 (m, 1H), 6.98 (d, J=9.3 Hz, 1H), 6.42-6.19 (m, 1H),
2.91 (s, 3H).
Compound 51:
6-(6'-methoxy-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamid-
e
##STR00303##
[0642] Compound 51 was synthesized from 50 and employing the
experimental procedure described in Scheme 6 (Method A). The crude
residue was purified by preparative HPLC (condition L) to yield
compound 51. (28.9 mg, 0.083 mmol, 27.1% yield). LCMS: m/z=347.2
[M+H].sup.+; ret. time 1.02 min; condition E. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.88-8.82 (m, 1H), 8.29-8.19 (m, 3H),
7.89-7.82 (m, 1H), 7.79-7.73 (m, 2H), 7.70-7.65 (m, 1H), 7.63-7.59
(m, 1H), 7.37 (s, 1H), 6.77-6.71 (m, 1H), 2.89 (s, 3H).
Compound 52:
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arboxamide
##STR00304##
[0644] Compound 52 was synthesized from 5 in a manner similar to 19
employing the experimental procedure described in Scheme 7 (Method
B). The crude residue was purified by preparative HPLC (condition
H) to yield
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arboxamide 52 (38.7 mg, 0.105 mmol, 36.4% yield). LCMS: m/z=367.2
[M+H].sup.+; ret. time 1.18 min.; condition E. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 8.91 (dd, J=4.8, 1.8 Hz, 1H),
8.32-8.21 (m, 4H), 8.15 (s, 1H), 7.75 (dd, J=7.8, 4.8 Hz, 1H),
7.70-7.65 (m, 1H), 7.62 (s, 1H), 7.49-7.44 (m, 1H), 7.39 (d, J=9.5
Hz, 1H), 6.39 (s, 1H).
Compound 53:
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e
##STR00305##
[0646] Compound 53 was synthesized by reacting 4 and
2-bromo-5-fluoropyridine employing the experimental procedure
described in Scheme 4 (Method-D). The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e 53 (220 mg, 0.58 mmol, 34.3% yield). LCMS=m/z 317.1 [M+H].sup.+;
ret. time 1.24 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.89 (dd, J=4.8, 1.8 Hz, 1H), 8.60 (s,
1H), 8.27-8.22 (m, 3H), 8.20-8.16 (m, 1H), 7.94-7.87 (m, 1H), 7.71
(dd, J=7.8, 4.8 Hz, 1H), 7.33 (d, J=9.5 Hz, 1H).
Compound 54:
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
##STR00306##
[0648] Compound 54 was synthesized from 53 employing the
experimental procedure described in Scheme 6 (Method A). The crude
residue was purified by preparative HPLC (condition-M) to yield
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
54 (10.3 mg, 0.031 mmol, 6.4% yield). LCMS: m/z=335.1 [M+H].sup.+;
ret. time 0.77 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.86 (dd, J=4.8, 1.6 Hz, 1H), 8.26 (s,
3H), 8.22-8.18 (m, 1H), 8.17-8.12 (m, 1H), 7.87 (td, J=8.8, 2.9 Hz,
1H), 7.79 (br. s., 1H), 7.70 (dd, J=7.8, 4.9 Hz, 1H), 7.57 (br. s.,
1H), 7.30-7.26 (m, 1H).
Compound 55:
6-(5'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e
##STR00307##
[0650] Compound 55 was synthesized by reacting 4 and
2-bromo-5-methylpyridine employing the experimental procedure
described in Scheme 4 (Method-D). The crude residue was purified by
preparative HPLC (condition N) to yield
6-(5'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e 55 (65 mg, 0.2 mmol, 21.5% yield). LCMS: m/z=313.1 [M+H].sup.+;
ret. time 1.42 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.88 (dd, J=4.9, 1.7 Hz, 1H), 8.59 (s,
1H), 8.20 (s, 1H), 8.16-8.09 (m, 2H), 8.05-8.03 (m, 1H), 7.81-7.77
(m, 1H), 7.70-7.65 (m, 1H), 7.25 (d, J=9.5 Hz, 1H), 2.27 (s,
3H).
Compound 56:
6-(5'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
##STR00308##
[0652] Compound 56 was synthesized from 55 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition H) to yield
6-(5'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
56 (12 mg, 0.036 mmol, 28.4% yield). LCMS: m/z=331.1 [M+H].sup.+;
ret. time 1.04 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.86 (dd, J=5.0, 1.5 Hz, 1H), 8.28 (s,
1H), 8.24 (dd, J=8.0, 1.5 Hz, 1H), 8.18 (d, J=9.5 Hz, 1H), 8.07 (d,
J=1.5 Hz, 1H), 8.02 (d, J=8.0 Hz, 1H), 7.81 (br. s., 1H), 7.78 (dd,
J=8.0, 1.5 Hz, 1H), 7.68 (dd, J=7.8, 4.8 Hz, 2H), 7.21 (d, J=9.5
Hz, 1H), 2.27 (s, 3H).
Compound 57: 6-(6'-methyl-[2, 2'-bipyridin]-3-yl)
imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00309##
[0654] Compound 57 was synthesized by reacting 4 and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme 1 (Method-A). The crude residue was
purified by preparative HPLC (condition Q) to yield
6-(6'-methyl-[2, 2'-bipyridin]-3-yl)
imidazo[1,2-b]pyridazine-3-carbonitrile 57 (3.4 mg, 10.89 .mu.mol,
2.8% yield). LC-MS: m/z=313.2 [M+H].sup.+; ret. time 1.40 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
8.92-8.86 (m, 1H), 8.60-8.56 (m, 1H), 8.26-8.20 (m, 1H), 8.18-8.11
(m, 1H), 8.08-8.02 (m, 1H), 7.88-7.79 (m, 1H), 7.72-7.64 (m, 1H),
7.38-7.31 (m, 1H), 7.23-7.15 (m, 1H), 1.87 (s, 3H).
Compound 58:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
##STR00310##
[0656] Compound 58 was synthesized from 57 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
58 (5.1 mg, 0.015 mmol, 12.1% yield). LC-MS: m/z=331.1 [M+H].sup.+;
ret. time 1.01 min; condition C, .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.15-9.10 (m, 1H), 8.54-8.45 (m, 3H),
8.22-8.17 (m, 1H), 8.07 (s, 1H), 8.04-7.99 (m, 1H), 7.97-7.92 (m,
1H), 7.89-7.85 (m, 1H), 7.56 (d, J=9.5 Hz, 1H), 7.46-7.40 (m, 1H),
2.15 (s, 3H).
Compound 59:
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e
##STR00311##
[0658] Compound 59 was synthesized by reacting 4 and
2-bromo-4-fluoropyridine employing the experimental procedure
described in Scheme 4 (Method D). The crude residue was purified by
preparative HPLC (condition-N) to yield compound 59. (4.3 mg, 0.013
mmol, 3.1% yield), LC-MS: m/z=317 [M+H].sup.+; ret. time 1.41 min;
condition C, .sup.1H NMR (400 MHz, DMSO-d6) .delta. ppm 8.93-8.89
(m, 1H), 8.60-8.57 (m, 1H), 8.27-8.19 (m, 3H), 8.03-7.97 (m, 1H),
7.77-7.72 (m, 1H), 7.42-7.37 (m, 1H), 7.34-7.27 (m, 1H).
Compound 60:
6-(4'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide
##STR00312##
[0660] Compound 60 was synthesized from 59 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield compound 60 (7.9 mg, 0.023 mmol, 18.3%
yield). LC-MS: m/z=335.1 [M+H].sup.+; ret. time 1.03 min; condition
C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.93-8.87 (m,
1H), 8.32-8.20 (m, 4H), 7.98-7.92 (m, 1H), 7.85-7.80 (m, 1H),
7.78-7.72 (m, 1H), 7.68-7.61 (m, 1H), 7.34 (d, J=9.3 Hz, 2H).
Compound 61:
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arbonitrile
##STR00313##
[0662] Compound 61 was synthesized by reacting 4 and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme 3 (Method C). The crude residue was
purified by preparative HPLC (condition-N) to yield compound 61
(140 mg, 0.424 mmol, 54.2% yield). LCMS: m/z=331.1 [M+H].sup.+;
ret. time 1.59 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.88 (dd, J=4.8, 1.6 Hz, 1H), 8.60 (s,
1H), 8.25 (d, J=9.5 Hz, 1H), 8.17-8.09 (m, 2H), 7.77 (t, J=9.0 Hz,
1H), 7.68 (dd, J=7.8, 4.9 Hz, 1H), 7.38 (d, J=9.5 Hz, 1H), 1.86 (d,
J=2.7 Hz, 3H).
Compound 43:
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arboxamide
##STR00314##
[0664] Compound 43 was synthesized from 61 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-c-
arboxamide 43 (20 mg, 0.057 mmol, 19.0% yield). LCMS: m/z=349.1;
ret. time 1.13 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.86 (dd, J=4.8, 1.6 Hz, 1H), 8.28 (s,
1H), 8.26-8.20 (m, 2H), 8.03 (dd, J=8.7, 3.8 Hz, 1H), 7.82-7.58 (m,
4H), 7.32 (d, J=9.3 Hz, 1H), 1.88 (d, J=2.7 Hz, 3H).
Compound 63:
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonit-
rile
##STR00315##
[0666] Compound 63 was synthesized from 4 and
2-bromo-6-isopropylpyridine employing the experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (condition-F) to yield
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonit-
rile 63 (125 mg, 3.67 mmol, 37.5% yield) as a pale yellow solid.
LCMS: m/z=341.1 [M+H].sup.+; ret. time 1.64 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.87-8.91 (m, 1H),
8.58 (s, 1H), 8.28 (d, J=9.54 Hz, 1H), 8.12-8.17 (m, 1H), 8.01-8.06
(m, 1H), 7.84-7.91 (m, 1H), 7.65-7.73 (m, 1H), 7.39 (d, J=9.04 Hz,
1H), 7.16-7.24 (m, 1H), 2.68 (td, J=1.95, 3.64 Hz, 1H), 0.58 (d,
J=7.03 Hz, 6H).
Compound 64:
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxam-
ide
##STR00316##
[0668] Compound 64 was synthesized from 4 in a manner similar to 19
employing the experimental procedure described in Scheme 7 (Method
B). The crude residue was purified by preparative HPLC
(condition-N) to yield
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxam-
ide 64 (34.9 mg, 0.096 mmol, 32.8%) as a pale yellow solid. LCMS:
m/z=359.2 [M+H].sup.+; ret. time 1.13 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.15 (dd, J=1.59, 4.77 Hz, 1H),
1.82-1.72 (m, 3H), 2.09-2.04 (m, 1H), 2.20-2.12 (m, 1H), 2.33 (dd,
J=4.77, 7.70 Hz, 2H), 2.65-2.57 (m, 2H), 2.84 (dd, J=0.98, 7.83 Hz,
1H), 7.48-7.40 (m, 1H), 9.49 (d, J=6.85 Hz, 6H).
Compound 65:
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e
##STR00317##
[0670] Compound 65 was synthesized by reacting 4 and
6-bromo-2-fluoropyridine employing experimental procedure described
in Scheme 4 (Method D). The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(6'-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carbonitril-
e 65 (1.4 mg, 4.38 .mu.mol, 0.38% yield) as a pale yellow solid.
LCMS: m/z=317.1 [M+H].sup.+; ret. time 1.41 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.91 (dd, J=1.71,
4.65 Hz, 1H), 8.60 (s, 1H), 8.31 (d, J=9.54 Hz, 1H), 8.17-8.22 (m,
1H), 8.15 (d, J=8.07 Hz, 1H), 8.08-8.13 (m, 1H), 7.73 (dd, J=4.89,
7.83 Hz, 1H), 7.47 (d, J=9.54 Hz, 1H), 7.11-7.18 (m, 1H).
##STR00318##
Compound 6B:
N-(tert-butyl)-6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridin-3-amine
##STR00319##
[0672] Compound 6B was synthesized by reacting 6A (reference: WO
2013064984 A1) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(reference: WO 2015157093 A1/WO 2015044172 A1/WO 2014055955 A1)
employing the experimental procedure described in Scheme-5 compound
17. The crude product was purified by silica gel chromatography (24
g RediSep.RTM. column, eluting with a gradient of 20-60% ethyl
acetate in petroleum ether) to yield compound 6B (180 mg, 0.59
mmol, 16.1% yield) as a light yellow solid. LCMS: m/z=301.2
[M-H].sup.+; ret. time 2.13 min; condition-E.
Compound 6C:
N-(tert-butyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-3-
-amine
##STR00320##
[0674] Compound 6C was synthesized by reacting 6B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme 1 (Method A). The crude residue was
purified by silica gel chromatography (RediSep.RTM. column, eluting
with a gradient of 20% ethyl acetate in petroleum ether) to yield
N-(tert-butyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-3-
-amine 6C (0.07 g, 0.20 mmol, 39.3%). LCMS: m/z=358.2 [M+H].sup.+;
ret. time 1.73; conditions E.
Compound 66:
2,2,2-trifluoro-N-(6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
in-3-yl)acetamide
##STR00321##
[0676] A mixture of
N-(tert-butyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-3-
-amine 6C (0.05 g, 0.140 mmol) and TFA (2 mL, 26.0 mmol) was
stirred overnight at room temperature. TFA was evaporated under
reduced pressure and the residue was purified by preparative HPLC
(condition N). The fractions containing the product were combined
and concentrated under reduced pressure to yield
2,2,2-trifluoro-N-(6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
in-3-yl)acetamide 66 (5.7 mg, 0.14 mmol, 9.7% yield). LCMS:
m/z=398.1 [M+H].sup.+; ret. time 1.27; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 13.63 (br s, 1H), 8.75-8.81 (m,
1H), 8.39 (br s, 1H), 7.98-8.06 (m, 2H), 7.59-7.75 (m, 5H),
7.14-7.19 (m, 1H), 2.12 (s, 3H).
##STR00322##
Compound 67:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxylic
acid
[0677] To a solution of
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
7A (100 mg, 0.321 mmol) in 1,4-dioxane (5 mL) and H.sub.2O (2 mL)
mixture was added LiOH (61.5 mg, 2.57 mmol). The reaction mixture
was heated at 80.degree. C. for 4 h. The reaction mixture was then
diluted with water (20 mL), acidified with 1.5N aq. HCl solution to
pH-5.0 and passed through a Celite.RTM. bed. The filtrate was
evaporated to dryness. The crude residue was purified by
preparative HPLC (method N) to yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carboxylic
acid 67 (4.4 mg, 0.013 mmol, 4.1% yield) as a pale yellow solid.
LCMS: m/z=330.1 [M+H].sup.+; ret. time 1.02 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.39 (dd, J=0.98,
1.71 Hz, 1H), 8.75 (dd, J=1.59, 4.77 Hz, 1H), 8.32 (s, 1H), 7.98
(dd, J=1.47, 7.83 Hz, 1H), 7.67-7.76 (m, 1H), 7.50-7.64 (m, 3H),
7.05-7.16 (m, 2H), 2.09 (s, 3H).
Compound 68:
N-(2,2-difluoroethyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]py-
ridine-3-carboxamide
##STR00323##
[0679] To a stirred solution of compound 67 (0.0.1 g, 0.303 mmol)
in DMF (2 mL) was added HATU (0.23 g, 0.605 mmol) and DIPEA (0.16
mL, 0.908 mmol), followed by 2,2-difluoroethanamine (29.4 mg, 0.363
mmol). The reaction mixture was stirred at room temperature for 18
h. The reaction mixture concentrated under reduced pressure to give
a crude residue, which was purified by preparative HPLC (condition
N) to yield
N-(2,2-difluoroethyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]py-
ridine-3-carboxamide 68 (3.2 mg, 8.05 .mu.mol, 2.7% yield) as a
pale yellow solid. LCMS: m/z=394.1 [M+H].sup.+; ret. time 1.40 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.35
(dd, J=1.00, 2.01 Hz, 1H), 8.87 (t, J=6.02 Hz, 1H), 8.75 (dd,
J=1.51, 4.52 Hz, 1H), 8.40 (s, 1H), 7.95-8.01 (m, 1H), 7.68-7.75
(m, 1H), 7.53-7.65 (m, 3H), 7.08-7.17 (m, 1H), 5.95-6.29 (m, 1H),
3.63-3.76 (m, 2H), 2.09 (s, 3H).
Compound 69:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(2,2,2-trifluoroethyl)imidazo[1,2-a-
]pyridine-3-carboxamide
##STR00324##
[0681] Compound 69 was synthesized by reacting 67 and
2,2,2-trifluoroethanamine employing the experimental procedure
described for 68 in Scheme 14. The crude residue was purified by
preparative HPLC (condition-N) to yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(2,2,2-trifluoroethyl)imidazo[1,2-a-
]pyridine-3-carboxamide 69 (2.1 mg, 5.05 .mu.mol, 1.7% yield) as a
pale yellow solid. LCMS: m/z=412.1 [M+H].sup.+; ret. time 1.53 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
9.32-9.36 (m, 1H), 9.08 (t, J=6.53 Hz, 1H), 8.75 (dd, J=1.76, 4.77
Hz, 1H), 8.45 (s, 1H), 7.97-8.02 (m, 1H), 7.68-7.74 (m, 1H),
7.56-7.64 (m, 3H), 7.09-7.18 (m, 2H), 4.05-4.16 (m, 2H), 2.08 (s,
3H).
Compound 70:
N-(2-methoxyethyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
##STR00325##
[0683] Compound 70 was synthesized by reacting 67 and
2-methoxyethanamine employing the experimental procedure described
for 68 in Scheme 14. The crude residue was purified by preparative
HPLC (condition-N) to yield
N-(2-methoxyethyl)-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide 70 (1.7 mg, 4.34 .mu.mol, 1.4% yield) as a pale
yellow solid. LCMS: m/z=388.2 [M+H].sup.+; ret. time 1.3 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.39
(dd, J=1.00, 2.01 Hz, 1H), 8.73-8.76 (m, 1H), 8.56 (d, J=4.02 Hz,
1H), 8.33 (d, J=8.03 Hz, 1H), 7.95-8.01 (m, 1H), 7.68-7.75 (m, 1H),
7.57-7.63 (m, 2H), 7.51-7.56 (m, 1H), 7.14 (d, J=7.53 Hz, 1H),
7.04-7.10 (m, 1H), 3.40-3.49 (m, 4H), 3.28 (s, 3H), 2.10 (s,
3H).
Compound 71:
N--(.sup.2H.sub.3)methyl-6-[2-(6-methylpyridin-2-yl)pyridin-3-yl]imidazo[-
1,2-a]pyridine-3-carboxamide
##STR00326##
[0685] Compound 71 was synthesized by reacting 67 and
(.sup.2H.sub.3)methylamine employing the experimental procedure
described for 68 in Scheme 14. The crude residue was purified by
preparative HPLC (condition-N) to yield compound 71 (0.4 mg, 1.120
.mu.mol, 0.4% yield) as a pale yellow solid. LCMS: m/z=347.1
[M+H].sup.+; ret. time 0.90 min; condition D. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.36 (s, 1H), 8.74 (dd, J=1.59, 4.77 Hz,
1H), 8.41 (s, 1H), 8.25 (s, 1H), 7.97 (dd, J=1.59, 7.70 Hz, 1H),
7.67-7.75 (m, 1H), 7.56-7.63 (m, 2H), 7.53 (d, J=9.05 Hz, 1H), 7.13
(d, J=7.83 Hz, 1H), 7.06 (dd, J=1.71, 9.29 Hz, 1H), 2.08 (s,
3H).
Compound 72:
methyl-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbox-
amide
##STR00327##
[0687] Compound 72 was synthesized by reacting 67 and methylamine
employing experimental procedure described for 68 in Scheme 14. The
crude residue was purified by preparative HPLC (condition-N) to
yield compound 72 (2.4 mg, 6.64 .mu.mol, 2.2% yield) as a pale
yellow solid. LCMS: m/z=344.1 [M+H].sup.+; ret. time 1.22 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.38
(dd, J=1.00, 2.01 Hz, 1H), 8.73-8.76 (m, 1H), 8.40-8.46 (m, 1H),
8.26 (s, 1H), 7.98 (dd, J=1.76, 7.78 Hz, 1H), 7.69-7.75 (m, 1H),
7.57-7.63 (m, 2H), 7.50-7.56 (m, 1H), 7.14 (d, J=7.53 Hz, 1H),
7.04-7.10 (m, 1H), 2.79 (d, J=4.52 Hz, 3H), 2.09 (s, 3H).
##STR00328##
Compound 73:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carboxylic
acid
##STR00329##
[0689] To a solution of 57 (0.02 g, 0.064 mmol) in water (5 mL) was
added KOH (0.018 g, 0.32 mmol). The reaction mixture was heated up
to 95.degree. C. over 5 min. and was stirred for 18 h. The reaction
mixture was cooled to room temperature, the precipitated solid was
filtered off and the filtrate was acidified to pH 6 with 1N aq.
HCl. The precipitated product was filtered through a sintered
funnel and dried under vacuum to get a crude residue, which was
purified by preparative HPLC (condition N) to yield
(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-3-carb-
oxylic acid 73 (8.7 mg, 0.026 mmol, 41.0% yield). LCMS: m/z=332.1
[M+H].sup.+; ret. time 0.71 min; condition C, .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 12.94 (bs, 1H), 8.89-8.86 (m, 1H), 8.32
(s, 1H), 8.13 (s, 2H), 8.01-7.95 (m, 1H), 7.87-7.82 (m, 1H),
7.72-7.66 (m, 1H), 7.26-7.19 (m, 2H), 1.97 (s, 3H).
Compound 74:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)imidazo[1,2-b]pyridazi-
ne-3-carboxamide
##STR00330##
[0691] Compound 74 was synthesized by reacting 73 and
oxetan-3-amine employing the experimental procedure described for
68 in Scheme 14. The crude product was purified by preparative HPLC
(Condition N) to yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)imidazo[1,2-b]pyridazi-
ne-3-carboxamide 6M (11.3 mg, 0.029 mmol, 16.15% yield). LCMS:
m/z=387.2 [M+H].sup.+; ret. time 1.07 min; condition C, .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.89-8.86 (m, 1H), 8.69-8.66
(m, 1H), 8.28 (s, 2H), 8.26-8.21 (m, 1H), 7.99-7.95 (m, 1H),
7.86-7.81 (m, 1H), 7.73-7.68 (m, 1H), 7.37-7.31 (m, 1H), 7.21-7.15
(m, 1H), 4.95-4.88 (m, 1H), 4.76 (s, 2H), 4.38 (s, 2H), 1.86 (s,
3H).
Compound 75:
N-cyclopropyl-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-
-3-carboxamide
##STR00331##
[0693] Compound 75 was synthesized by reacting 73 and cyclopropyl
amine employing the experimental procedure described for 68 in
Scheme 14. The crude residue was purified by HPLC (condition N) to
yield
N-cyclopropyl-6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-b]pyridazine-
-3-carboxamide 75 (7.6 mg, 0.020 mmol, 16.8% yield). LCMS:
m/z=371.2 [M+H].sup.+; ret. time 1.26 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.90-8.83 (m, 1H), 8.25 (d,
J=2.4 Hz, 3H), 8.15-8.10 (m, 1H), 7.98-7.93 (m, 1H), 7.87-7.81 (m,
1H), 7.73-7.68 (m, 1H), 7.37-7.31 (m, 1H), 7.19-7.13 (m, 1H),
2.77-2.70 (m, 1H), 1.85 (s, 3H), 0.75-0.69 (m, 2H), 0.39-0.33 (m,
2H).
##STR00332##
Compound 9B:
N-(6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide
##STR00333##
[0695] To a stirred solution of compound 9A (reference: US
2009/0163489 A1)-(0.315 g, 1.24 mmol) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(Reference WO 2015157093 A1/WO 2015044172 A1/WO 2014055955
A1)-(0.445, 1.86 mmol) in 1,4-dioxane (9 mL) and water (3 mL) was
added Na.sub.2CO.sub.3 (0.394 g, 3.72 mmol). The reaction mixture
was degassed for 3 min. and then to it was added
Pd(PPh.sub.3).sub.4 (0.143 g, 0.124 mmol), and the resultant
mixture was heated at 100.degree. C. for 12 h. The reaction mixture
was then filtered through a Celite.RTM. pad, the filter cake washed
with ethyl acetate and the combined filtrate evaporated under
reduced pressure to give the crude compound. It was purified via
silica gel chromatography (24 g RediSep.RTM. column, eluted with
60% ethyl acetate in petroleum ether) to furnish
N-(6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide 9B
(211 mg, 0.736 mmol, 59.4% yield) as a light yellow solid. LCMS:
m/z=385.0 [M+H].sup.+; ret. time 1.49 min; condition C.
Compound 76:
N-(6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamid-
e
##STR00334##
[0697] Compound 76 was synthesized by reacting 9B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme 1 (Method A). The crude compound was
purified by preparative HPLC (Condition-N) to yield
N-(6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamid-
e 76 (7.6 mg, 0.022 mmol, 12.4% yield). LCMS: m/z=344.1
[M+H].sup.+; ret. time 1.17 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.65 (s, 1H), 8.70-8.71 (m, 1H), 8.50
(s, 1H), 8.02 (s, 1H), 7.93-7.95 (m, 1H), 7.69-7.73 (m, 1H),
7.53-7.58 (m, 2H), 7.21 (d, J=9.2 Hz, 1H), 7.15 (d, J=7.6 Hz, 1H),
6.77 (d, J=1.6 Hz, 1H) 2.15 (s, 3H), 2.07 (s, 3H).
Compound 77:
N-(6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-2-y-
l)acetamide
##STR00335##
[0699] Compound 77 was synthesized by reacting 9B and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme-2 (Method B). The crude compound was
purified by preparative HPLC (Condition-G) to yield
N-(6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridin-2-y-
l)acetamide 77 (27.3 mg, 0.073 mmol, 21.0% yield). LCMS: m/z=362.1
[M+H].sup.+; ret. time 1.29 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.8 (s, 1H), 8.72 (dd, J=1.6, 4.8 Hz,
1H), 8.57 (s, 1H), 8.05 (s, 1H), 7.96 (dd, J=1.2, 7.6, 1H),
7.65-7.72 (m, 2H), 7.58-7.61 (m, 1H), 7.32 (d, J=9.2 Hz, 1H), 6.90
(d, J=8.8 Hz, 1H), 2.11 (s, 3H), 2.09 (s, 3H).
##STR00336##
Compound 10B: ethyl
6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-2-carboxylate
##STR00337##
[0701] Compound 10B was synthesized by reacting 10A (reference: WO
2015086526 A1, WO 2011050245 A1 and WO 2009112651 A1) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(reference: WO 2015157093 A1, WO 2015044172 A1 and WO 2014055955
A1) employing the experimental procedure described for 50 in
Scheme-12. The crude product was purified by silica gel
chromatography (24 g RediSep.RTM. column, eluting with 50% ethyl
acetate in petroleum ether). The fractions containing the product
were combined and concentrated under reduced pressure to yield
ethyl 6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-2-carboxylate
74 (0.5 g, 1.65 mmol, 55.7% yield). LCMS: m/z=302.1 [M+H].sup.+;
ret. time 2.21 min; condition E.
Compound 10C: ethyl
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxylate
##STR00338##
[0703] Compound 10C was synthesized by reacting 10B and
6-bromo-3-fluoro-2-methylpyridine and bis-(tributyltin) employing
the experimental procedure described in Scheme-2 (Method B). The
crude product was purified by silica gel chromatography (24 g
RediSep.RTM. column, eluting with 40% ethyl acetate in petroleum
ether). The fractions containing the product were combined and
concentrated under reduced pressure to yield ethyl
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxylate 10C (0.05 g, 0.133 mmol, 25.1% yield). LCMS: m/z=377.2
[M+H].sup.+; ret. time 1.50 min; condition E.
Compound 78:
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxamide
##STR00339##
[0705] To a solution of ethyl
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxylate 10C (0.05 g, 0.133 mmol) in THF (2 mL) was added ammonia
(1 mL of 2.5M) and the reaction was stirred overnight at room
temperature. The solvent was evaporated under reduced pressure and
the residue was purified by preparative HPLC (condition N) to yield
compound 8D (1.5 mg, 4.32 .mu.mol 3.3% yield). LCMS: m/z=348.2
[M+H].sup.+; ret. time 1.13 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.74 (dd, J=1.31, 4.68 Hz, 1H), 8.57 (s,
1H), 8.30 (s, 1H), 7.99 (dd, J=1.35, 7.76 Hz, 1H), 7.75-7.81 (m,
1H), 7.66-7.72 (m, 2H), 7.59 (dd, J=4.71, 7.76 Hz, 1H), 7.36-7.46
(m, 2H), 6.92 (dd, J=9.45, 1.62 Hz, 1H), 2.07 (d, J=2.75 Hz,
3H).
Compound 10E: ethyl
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-ca-
rboxylate
##STR00340##
[0707] Compound 10E was synthesized by reacting 10B and
2-bromo-6-(trifluoromethyl)pyridine and bis-(tributyltin) employing
experimental procedure described in Scheme-2 (Method B). The crude
residue was purified by silica gel chromatography (12 g,
RediSep.RTM. column, eluting with 40% ethyl acetate in petroleum
ether). The fractions containing the product were combined and
evaporated under reduced pressure to yield ethyl
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-ca-
rboxylate 10E (0.2 g, 48.7% yield). LCMS: m/z=413.3 [M+H].sup.+;
ret. time 1.14 min.; condition B.
Compound 79:
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-ca-
rboxamide
##STR00341##
[0709] Compound 79 was synthesized by reacting 10E and ammonia
employing the experimental procedure described for the synthesis of
78. The crude residue was purified by preparative HPLC (method-N)
to yield compound 79 (6.5 mg, 0.017 mmol, 6.9%). LCMS m/z=384.1
[M+H].sup.+; ret. time 1.40 min; conditions C. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 8.78-8.83 (m, 1H), 8.57-8.60 (m,
1H), 8.26 (s, 2H), 8.17-8.23 (m, 1H), 8.03-8.07 (m, 1H), 7.79-7.84
(m, 1H), 7.64-7.74 (m, 2H), 7.37-7.43 (m, 2H), 6.88-6.94 (m,
1H).
Compound 10G: ethyl
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-carboxylate
##STR00342##
[0711] Compound 10G was synthesized by reacting 10B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme-1 (Method A). The crude product was
purified by silica gel chromatography (12 g RediSep.RTM. column,
eluting with 40% ethyl acetate in petroleum ether). The fractions
containing the product were combined and concentrated under reduced
pressure to yield compound 10G (0.06 g, 0.17 mmol, 38.9% yield).
LCMS: m/z=359.2 [M+H].sup.+; ret. time 1.39 min; condition E.
Compound 80:
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-carboxamide
##STR00343##
[0713] Compound 80 was synthesized by reacting 10G and ammonia
employing experimental procedure described for the synthesis of 78.
The crude residue was purified by preparative HPLC (method N) to
yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-carboxamide
80 (21.5 mg, 11.46% yield). LCMS: m/z=330.1 [M+H].sup.+; ret. time
1.13 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.73-8.77 (m, 1H), 8.58 (s, 1H), 8.30 (s, 1H), 7.97-8.02 (m,
1H), 7.64-7.79 (m, 3H), 7.57-7.63 (m, 1H), 7.40 (d, J=9.35 Hz, 2H),
7.18 (s, 1H), 6.88-6.93 (m, 1H), 2.11 (s, 3H).
##STR00344##
Compound 11C:
6-(2-chloro-5-fluoropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00345##
[0715] Compound 11C was synthesized by reacting 11A' (reference:
WO2013171640 A1) and 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile
11B employing the experimental procedure described for 9B in
Scheme-16. The crude product was purified via silica gel
chromatography (24 g RediSep.RTM. column, eluting with 50% ethyl
acetate in petroleum ether). Fractions containing the product were
combined and evaporated to get compound 11C (0.32 g, 1.17 mmol,
45.3% yield) as a white solid. LCMS: m/z=273.2 [M+H].sup.+; ret.
time 1.73 min; conditions E.
Compound 81:
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile
##STR00346##
[0717] To a degassed solution of
6-(2-chloro-5-fluoropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
11C (0.05 g, 0.183 mmol) and 2-methyl-6-(tributylstannyl)pyridine
(0.070 g, 0.183 mmol) in 1,4-dioxane (2 mL),
tetrakis(triphenylphosphine)palladium(O)-(0.127 g, 0.110 mmol) was
added under nitrogen. The reaction mixture was stirred at
120.degree. C. for 1 h in a microwave oven to obtain a crude
residue, which was purified by preparative HPLC (condition-N) to
yield
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile 81 as an off-white solid (4.5 mg, 0.014 mmol, 7.5% yield).
LCMS m/z=330.1 [M+H].sup.+; ret. time 1.55 min; conditions C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.77-8.80 (m, 1H)
8.68-8.71 (m, 1H) 8.48 (s, 1H) 8.11 (dd, J=9.29, 2.76 Hz, 1H)
7.61-7.78 (m, 3H) 7.15-7.24 (m, 2H) 2.10 (s, 3H).
Compound 82:
6-(5-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
oxamide
##STR00347##
[0719] Compound 82 was synthesized from 81 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-I) to yield compound 82 (22 mg, 0.063 mmol, 17.38%
yield). LCMS m/z=348.1 [M+H].sup.+; ret. time 0.84 min; condition
C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.39 (d, J=0.73
Hz, 1H) 8.32 (s, 1H) 8.02 (dd, J=9.29, 2.93 Hz, 1H) 7.86-7.96 (m,
1H) 7.94 (br. s., 1H) 7.70 (d, J=15.41 Hz, 1H) 7.28-7.45 (m, 1H)
7.36 (br. s., 1H) 7.07-7.09 (m, 2H) 2.08 (s, 3H).
Compound 83:
6-(6'-(difluoromethyl)-5-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carbonitrile
##STR00348##
[0721] Compound 9F was synthesized by reacting 11C and
2-bromo-6-(difluoromethyl)pyridine employing experimental procedure
described in Scheme 3 (Method C). The crude residue was purified by
preparative HPLC (condition-N) to yield compound 83 (65 mg, 0.18
mmol, 97% yield). LCMS: m/z=366.1 [M+H].sup.+; ret. time 1.73 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.79
(d, J=2.69 Hz, 1H) 8.65 (d, J=0.73 Hz, 1H) 8.47 (s, 1H) 8.00-8.14
(m, 3H) 7.55-7.66 (m, 2H) 7.16 (dd, J=9.17, 1.83 Hz, 1H) 6.32-6.62
(m, 1H).
Compound 84:
6-(6'-(difluoromethyl)-5-fluoro-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
##STR00349##
[0723] Compound 84 was synthesized from 83 employing the
experimental procedure described in Scheme-7 (Method B). The crude
residue was purified by preparative HPLC (condition-N) to yield
compound 84 (7 mg, 0.018 mmol, 13.3% yield). LCMS: m/z=384.1
[M+H].sup.+; ret. time 1.12 min; conditions C. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 9.41 (s, 1H) 8.81 (d, J=2.69 Hz, 1H)
8.32 (s, 1H) 8.03-8.12 (m, 2H) 7.97 (d, J=7.83 Hz, 2H) 7.52-7.62
(m, 2H) 7.36 (br. s., 1H) 7.15 (dd, J=9.17, 1.83 Hz, 1H) 6.35-6.68
(m, 1H).
Compound 85:
6-(5,5'-difluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-
-carboxamide
##STR00350##
[0725] Compound 85 was synthesized by reacting 11C and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme 3 (Method C), and the resultant cyano
compound was hydrolyzed similar to 19 employing experimental
procedures described in Scheme 7 (Method B). The crude residue was
purified by preparative HPLC (condition-N) to yield compound 85 (12
mg, 0.033 mmol, 19.1% yield). LCMS: m/z=366.1 [M+H].sup.+; ret.
time 1.32 min; conditions C. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 9.39 (d, J=0.73 Hz, 1H)) 8.77 (d, J=2.4 Hz, 1H) 8.32
(s, 1H) 8.02 (dd, J=9.29, 2.93 Hz, 1H) 7.86-7.96 (br. s., 1H) 7.70
(m, 1H) 7.36 (br. s., 1H) 7.07-7.09 (m, 1H) 2.08 (s, 3H)
##STR00351##
Compound: 12A':
6-(2-chloro-6-methylpyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile
##STR00352##
[0727] Intermediate 12A' was synthesized by reacting 11B and
(2-chloro-6-methylpyridin-3-yl)boronic acid employing the
experimental procedure described for 9B as shown in Scheme-16. The
crude product was purified by silica gel chromatography (40 g
RediSep.RTM. column, eluted with a gradient of 20-30% ethyl acetate
in petroleum ether) to yield compound 12A' (150 mg, 0.497 mmol,
31.5% yield) as an off-white solid. LCMS: m/z=269 [M+H].sup.+; ret.
time 1.7 min; condition E
Compound 86:
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitr-
ile
##STR00353##
[0729] Compound 86 was synthesized by reacting 12A' and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme-1 (Method A). The crude residue was
purified by preparative HPLC (condition-H) to yield
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitr-
ile 86 (85 mg, 0.149 mmol, 57.2% yield). LCMS: m/z=326.1
[M+H].sup.+; ret. time 1.45 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.49 (dd, J=1.7, 1.0 Hz, 1H), 8.44 (s,
1H), 7.95 (d, J=7.8 Hz, 1H), 7.74-7.65 (m, 2H), 7.62 (s, 1H), 7.47
(d, J=8.1 Hz, 1H), 7.23-7.14 (m, 2H), 2.61 (s, 3H), 2.13 (s,
3H).
Compound 87:
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitr-
ile
##STR00354##
[0731] Compound 87 was synthesized from 86 similar to 19 employing
experimental procedure described in Scheme 7 (Method B). The crude
residue was purified by preparative HPLC (condition-0) to yield
6-(6,6'-dimethyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbonitr-
ile 87 (16.9 mg, 0.049 mmol, 24.6% yield). LCMS: m/z=344.2
[M+H].sup.+; ret. time 1.17 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.36 (d, J=1.0 Hz, 1H), 8.31 (s, 1H),
7.91-7.81 (m, 1H), 7.71-7.64 (m, 1H), 7.56-7.49 (m, 2H), 7.46 (s,
1H), 7.34 (br. s., 1H), 7.15-7.03 (m, 2H), 2.60 (s, 3H), 2.12 (s,
3H).
Compound 88:
6-(6'-(difluoromethyl)-6-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
##STR00355##
[0733] Compound 88 was synthesized by reacting 12A' and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described in Scheme-2 (Method B) and then the resultant
cyano compound was hydrolyzed similar to 19 employing experimental
procedures described in Scheme 7 (Method B). The crude residue was
purified by preparative HPLC (condition-H) to yield compound 88
(14.1 mg, 0.036 mmol, 19.8% yield). LCMS: m/z=380.2 [M+H].sup.+;
ret. time 1.33 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.36 (s, 1H), 8.30 (s, 1H), 8.06 (s, 1H),
7.97-7.85 (m, 3H), 7.61-7.45 (m, 3H), 7.38-7.25 (m, 1H), 7.08 (dd,
J=9.3, 1.7 Hz, 1H), 6.69-6.32 (m, 1H), 2.62 (s, 3H).
##STR00356##
Compound 13B:
N-(4-((2-(6-(difluoromethyl)pyridin-2-yl)-5-methyl-7H-pyrrolo[2,3-d]pyrim-
idin-4-yl)amino)pyridin-2-yl)acetamide
##STR00357##
[0735] In a 50 mL flask, a solution of
3-bromo-2-chloro-6-(trifluoromethyl)pyridine 13A (reference: WO
2015052264 A1)-(0.3 g, 1.15 mmol), bis(pinacolato)diborane (0.44 g,
173 mmol) and potassium acetate (0.19 g, 2.3 mmol) in 1,4-dioxane
(3 mL) was degassed under nitrogen for 10 min, prior to the
addition of PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (0.094 g,
0.115 mmol) under nitrogen. The reaction mixture was stirred at
80.degree. C. for 16 h. It was quenched with water (8 mL) and the
organic layer separated. The aqueous layer was back extracted with
diethyl ether (3.times.20 mL). The combined organic layer was
washed with water (2.times.20 mL), brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and the filtrate concentrated under
reduced pressure to afford compound 13B (0.25 g, 0.813 mmol, 70.6%
yield) as a brown solid, which was carried to the next step without
purification. .sup.1H NMR (400 MHz, CDCl3) .delta. ppm 7.76-7.90
(m, 1H) 7.47-7.56 (m, 1H) 1.27 (s, 12H).
Compound 13C:
6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile
##STR00358##
[0737] Compound 13C was synthesized by reacting 13B and
6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 11B employing
experimental procedure described for 67 in Scheme 16. The crude
residue was purified by silica gel chromatography (24 g
RediSep.RTM. column, eluting with 50% ethyl acetate in petroleum
ether) to afford
6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile 13C (0.2 g, 062 mmol, 57.2% yield) as a white solid. LCMS:
m/z=323.0 [M+H].sup.+; ret. time 2.43 min; conditions E.
Compound 89:
6-(6'-methyl-6-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carbonitrile
##STR00359##
[0739] Compound 89 was synthesized by reacting 13C and
2-methyl-6-(tributylstannyl)pyridine employing experimental
procedure described for 81 in Scheme 18. The crude residue was
purified by preparative HPLC (condition-N) to yield compound 89
(0.15 g, 0.395 mmol, 63.8%). LCMS m/z=380.1 [M+H].sup.+; ret. time
1.95 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
8.72 (s, 1H) 8.48 (s, 1H) 8.37 (d, J=8.07 Hz, 1H) 8.13 (d, J=8.07
Hz, 1H) 7.66-7.82 (m, 3H) 7.20-7.31 (m, 2H) 2.14 (s, 3H).
Compound 90:
6-(6'-methyl-6-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyri-
dine-3-carboxamide
##STR00360##
[0741] Compound 90 was synthesized from 89 similar to 19 employing
experimental procedure described in Scheme 7 (Method B). The crude
residue was purified by preparative HPLC (condition K) to yield
compound 90 (11 mg, 0.027 mmol, 8.66% yield). LCMS m/z=398.1
[M+H].sup.+; ret. time 1.19 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) 9.45 (s, 1H) 8.30-8.35 (m, 2H) 8.10 (d, J=8.07 Hz,
1H) 7.95 (br. s., 1H) 7.72-7.79 (m, 1H) 7.60 (dd, J=8.56, 6.11 Hz,
2H) 7.39 (br. s., 1H) 7.10-7.23 (m, 2H) 2.14 (s, 3H).
##STR00361## ##STR00362##
Compound 14B: methyl 3-bromo-2-chloroisonicotinate
##STR00363##
[0743] To a stirred solution of 3-bromo-2-chloroisonicotinic acid
14A (1 g, 4.23 mmol) in MeOH (20 mL) at 0.degree. C. under nitrogen
was added SOCl.sub.2 (2.0 mL, 27.4 mmol) drop-wise and the reaction
mixture was allowed to stir at 80.degree. C. for 5 h. The reaction
mixture was evaporated under reduced pressure, basified with
saturated aqueous sodium bicarbonate and extracted with ethyl
acetate (2.times.200 mL), the organic layer washed with brine (20
mL), dried over sodium sulfate and concentrated under reduced
pressure to get compound-14B (0.8 g, 3.19 mmol, 76% yield) as a
pale brown oil. LCMS: m/z=252.2 [M+H].sup.+; ret. time 0.9 min;
condition B.
Compound 14D: methyl
2-chloro-3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)isonicotinate
##STR00364##
[0745] Compound 14D was synthesized by reacting 14B and
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-3-c-
arbonitrile 14C employing the experimental procedure described in
Scheme 5 (Method-E). The crude compound was purified by silica gel
chromatography (24 g RediSep.RTM. column, eluting with a gradient
of 2-4% methanol in chloroform) to get compound 14D (0.25 g, 0.799
mmol, 40.0% yield) as pale yellow solid. LCMS m/z 313.3
[M+H].sup.+; ret. time 0.75 min; condition B.
Compound 91: methyl
3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridine]-4-carbo-
xylate
##STR00365##
[0747] Compound 91 was synthesized by reacting 14D and
2-methyl-6-(tributylstannyl)pyridine employing experimental
procedure described in Scheme 1 (Method A). The crude residue was
purified by preparative HPLC (Method: N) to yield compound 91 (215
mg, 77% yield). LCMS: m/z=370.1 [M+H].sup.+; ret. time 1.22 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. ppm
8.93-8.91 (m, 1H), 8.40 (s, 1H), 7.92-7.91 (m, 1H), 7.73-7.67 (m,
2H), 7.61-7.59 (m, 1H), 7.43-7.40 (m, 1H), 7.08-7.07 (m, 1H), 7.40
(d, J=8.00 Hz, 1H), 3.65 (s, 3H), 2.00 (s, 3H).
Compound 92:
6-(4-(hydroxymethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridi-
ne-3-carbonitrile
##STR00366##
[0749] To a stirred solution of methyl
3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridine]-4-carbo-
xylate 91 (0.05 g, 0.135 mmol) in a mixture of methanol (0.5 mL)
tetrahydrofuran (0.5 mL) was added NaBH.sub.4 (5.12 mg, 0.135 mmol)
at 0.degree. C. stirred for 10 minutes, and the reaction mixture
was allowed to stir at room temperature for 1 h. The reaction
mixture was diluted with water (5 mL) and extracted with ethyl
acetate (2.times.25 mL). The organic layer was washed with brine
(1.times.10 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered
and concentrated under reduced pressure. The residue was purified
by preparative HPLC (condition N) to yield
6-(4-(hydroxymethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridi-
ne-3-carbonitrile 92 (6 mg, 12% yield); LCMS: m/z=342.1
[M+H].sup.+; ret. time 1.11 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. ppm 8.74 (d, J=4.00 Hz, 1H), 8.43 (s, 2H),
7.76-7.60 (m, 4H), 7.37-7.40 (m, 1H), 7.02-7.04 (m, 1H), 5.4 (bs,
1H) 4.37-4.40 (m, 2H), 1.99 (s, 3H).
Compound 14G:
6-(4-formyl-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile
##STR00367##
[0751] To a stirred solution of
6-(4-(hydroxymethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridi-
ne-3-carbonitrile 92 (0.05 g, 0.527 mmol) in CH.sub.2Cl.sub.2 (1
mL) was added Dess-Martin periodinane (0.093 g, 0.22 mmol) at
0.degree. C. under nitrogen and the reaction mixture was allowed to
stir at room temperature for 1 h. The reaction mixture was quenched
with saturated aqueous sodium bicarbonate, extracted with DCM
(2.times.250 mL), dried over sodium sulfate and concentrated to
yield crude
6-(4-formyl-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile 14G (0.053 g, 0.016 mmol, 11.5% yield), which was used
without further purification in the next step. LCMS: m/z=340.1
[M+H].sup.+; ret. time 0.54 min; condition B.
Compound 93:
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carbonitrile
##STR00368##
[0753] To a stirred solution of
6-(4-formyl-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carb-
onitrile 14G (0.2 g, 0.589 mmol) in CH.sub.2Cl.sub.2 (2 mL) was
added DAST (0.156 mL, 1.179 mmol) drop-wise at -78.degree. C. under
nitrogen. The reaction mixture was allowed to stir at room
temperature for 4 h. The reaction mixture was cooled to 0.degree.
C., quenched with saturated aqueous sodium bicarbonate solution and
extracted with ethyl acetate (2.times.200 mL). The organic layer
was washed with brine (25 mL), dried over sodium sulfate and
concentrated to obtain crude product, which was purified by
preparative HPLC using (condition-N) to provide
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carbonitrile 93 (115 mg, 0.30 mmol, 53% yield); LCMS:
m/z=362.1 [M+H].sup.+; ret. time 1.54 min; condition C.; .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 8.96 (d, J=4.00 Hz, 1H), 8.57
(s, 1H), 8.46 (s, 1H), 7.83 (d, J=4.00 Hz, 1H), 7.67-7.70 (m, 3H),
7.35-7.37 (m, 1H), 6.88-7.14 (m, 2H), 2.00 (s, 3H).
Compound 94:
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide
##STR00369##
[0755] Compound 94 was synthesized from 93 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude product was purified by preparative HPLC
(condition N) to yield
6-(4-(difluoromethyl)-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyrid-
ine-3-carboxamide 94 (9.1 mg, 0.024 mmol, 8.7% yield). LCMS:
m/z=380.1 [M+H].sup.+; ret. time 1.09 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 9.26 (s, 1H) 8.94 (d, J=8.00 Hz,
1H), 8.31 (s, 1H), 8.01-7.82 (m, 2H), 7.57-7.68 (m, 3H), 7.25-7.40
(m, 2H), 6.77-7.01 (m, 2H), 2.01 (s, 3H).
##STR00370##
Compound 15B: 5-bromo-6-chloropyridin-2-amine
##STR00371##
[0757] To a solution of 6-chloropyridin-2-amine 13A (reference:
WO2014055955A1)-(1.0 g, 7.78 mmol) in DMF (10 mL) was added NBS
(1.384 g, 7.78 mmol) portion-wise at room temperature and stirring
was continued for 2 h. The reaction mixture was then evaporated
under reduced pressure to give a crude residue. To this was added
aqueous ammonia (60 mL, 25% solution) and the mixture was extracted
with ethyl acetate (3.times.100 mL). The combined organic layer was
dried over anhydrous sodium sulfate, filtered and the filtrate was
evaporated under reduced pressure to give crude residue which was
purified by silica gel chromatography (24 g RediSep.RTM. column,
eluting with a gradient of 27-29% ethyl acetate in petroleum ether)
to yield 5-bromo-6-chloropyridin-2-amine 15B (0.4 g, 1.928 mmol,
24.79% yield) as a brown solid. LCMS: m/z=207.0 [M+H].sup.+; ret.
time 1.74 min; condition-E. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 7.63 (d, J=8.5 Hz, 1H), 6.59 (s, 2H), 6.36 (d, J=9.0
Hz, 1H).
Compound 15C: N-(5-bromo-6-chloropyridin-2-yl)acetamide
##STR00372##
[0759] A solution of 5-bromo-6-chloropyridin-2-amine 15B (0.37 g,
1.784 mmol) in Ac.sub.2O (5 mL, 53.0 mmol) was stirred at room
temperature for 1 h. The reaction was then poured into ice-cold
water, stirred for 20 min. and the precipitate obtained was
filtered to yield N-(5-bromo-6-chloropyridin-2-yl)acetamide 15C
(0.33 g, 1.323 mmol, 74.2% yield). LCMS: m/z=249.0 [M+H].sup.+;
ret. time 1.86 min; condition E. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.94 (s, 1H), 8.16 (d, J=8.5 Hz, 1H),
8.01 (d, J=8.5 Hz, 1H), 2.09 (s, 3H).
Compound 15D:
N-(6-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)a-
cetamide
##STR00373##
[0761] Compound 89 was synthesized from
N-(5-bromo-6-chloropyridin-2-yl)acetamide 15C similar to 13B as
shown in Scheme 20. The crude product
N-(6-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)a-
cetamide 15D (0.29 g, 46.2% yield) was taken for the next step
without further purification. LCMS: m/z=295.2 [M-H].sup.+; ret.
time 1.27 min; condition-C.
Compound 15E:
N-(6-chloro-5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)acetamide
##STR00374##
[0763] Compound 15E was synthesized by reacting
N-(6-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)a-
cetamide 15D and 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 11B
employing the experimental procedure described for compound 9B as
shown in Scheme 16. The crude product 15E (0.18 g, 16% yield) was
used for next reaction without further purification. LCMS:
m/z=310.2 [M-H].sup.+; ret. time 0.65 min; condition C.
Compound 15F:
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridin]-6-yl)-
acetamide
##STR00375##
[0765] Compound 15F was synthesized by reacting
N-(6-chloro-5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)acetamide
15E and 2-methyl-6-(tributylstannyl)pyridine employing experimental
procedure described in Scheme 1 (Method A). The crude product
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridin]-6-yl)-
acetamide 15F (0.04 g, 18.8% yield) was used for next reaction
without further purification. LCMS: m/z=369.5 [M-H].sup.+; ret.
time 0.54 min; condition D.
Compound 95:
6-(6-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-c-
arboxamide
##STR00376##
[0767] Compound 95 was synthesized from 15F in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude product was purified by preparative HPLC
(method N) to yield
6-(6-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-c-
arboxamide 95 (6.6 mg, 0.017 mmol, 15.7% yield). LC-MS: m/z=387.2
[M+H].sup.+; ret. time 1.08 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.79-10.73 (m, 1H), 9.38-9.32 (m, 1H),
8.31 (s, 1H), 8.26-8.21 (m, 1H), 7.97 (s, 1H), 7.67 (s, 1H),
7.57-7.50 (m, 1H), 7.48-7.28 (m, 2H), 7.19-7.05 (m, 2H), 2.19 (s,
3H), 2.14 (s, 3H).
##STR00377## ##STR00378##
Compound 16B: N-(5-bromo-6-chloropyridin-3-yl) acetamide
##STR00379##
[0769] Compound 16B was synthesized from
5-bromo-6-chloropyridin-3-amine 16A employing experimental
procedure for compound 15C in Scheme 22 to yield
N-(5-bromo-6-chloropyridin-3-yl)acetamide 16B (0.25 g, 1.002 mmol,
49.5% yield) as a brown solid. LCMS: m/z=249.0 [M+H].sup.+; ret.
time 1.53 min; condition E.
Compound 16C:
N-(6-chloro-5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)acetamide
##STR00380##
[0771] Compound 16C was synthesized by reacting
bromo-6-chloropyridin-3-yl)acetamide 16B and
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-3-c-
arbonitrile employing the experimental procedure described in
Scheme 5 (Method-E). The crude compound was purified by silica gel
chromatography (24 g RediSep.RTM. column, eluting with a gradient
of 42-48% ethyl acetate in petroleum ether) to yield
N-(6-chloro-5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)acetamide
16C (0.3 g, 0.962 mmol, 48.0% yield) as a brown solid. LCMS:
m/z=312.2 [M+H].sup.+; ret. time 1.23 min; condition E.
Compound 96:
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridin]-5-yl)-
acetamide
##STR00381##
[0773] Compound 96 was synthesized by reacting 16C and
2-methyl-6-(tributylstannyl)pyridine employing experimental
procedure described in Scheme 1 (Method A). The crude residue was
purified by preparative HPLC (condition-N) to yield compound 96
(12.5 mg, 0.033 mmol, 17.3% yield). LCMS: m/z=369.2 [M+H].sup.+;
ret. time 1.12 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.45 (s, 1H), 8.90 (d, J=2.2 Hz, 1H),
8.61-8.49 (m, 1H), 8.47-8.39 (m, 1H), 8.23 (d, J=2.4 Hz, 1H),
7.76-7.61 (m, 3H), 7.26 (dd, J=9.3, 1.7 Hz, 1H), 7.12 (d, J=7.3 Hz,
1H), 2.14 (s, 3H), 2.06 (s, 3H).
Compound 97:
6-(5-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-c-
arboxamide
##STR00382##
[0775] Compound 97 was synthesized from 96 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition-N) to yield compound 97 (15.6 mg, 0.040 mmol, 13.5%
yield). LCMS: m/z=387.1 [M+H].sup.+; ret. time 0.94 min; condition
C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 10.45 (s, 1H),
9.40 (s, 1H), 8.88 (d, J=2.2 Hz, 1H), 8.30 (s, 1H), 8.18 (d, J=2.4
Hz, 1H), 7.95 (br. s., 1H), 7.73-7.64 (m, 1H), 7.63-7.57 (m, 1H),
7.54 (d, J=9.3 Hz, 1H), 7.36 (br. s., 1H), 7.12-7.01 (m, 2H), 2.12
(s, 3H), 2.06-2.01 (s, 3H).
Compounds 98 and 99:
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xamide 98 and
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xylic acid 99
##STR00383##
[0777] To a solution of
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridin]-5-yl)-
acetamide 97 (0.055 g, 0.149 mmol) in MeOH (4 mL) was added LiOH (1
mL, 2.0 mmol). The reaction mixture was heated at 80.degree. C. for
18 h. It was then filtered through Celite.RTM. bed and the filtrate
was concentrated under high vacuum to get a brown oil, which was
purified by preparative HPLC (condition-N) to provide compounds 98
and 99
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbox-
amide 98
[0778] (4.6 mg, 0.013 mmol, 8.95% yield). LCMS: m/z=345.1
[M+H].sup.+; ret. time 0.44 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.37 (s, 1H), 8.54 (s, 1H), 8.32 (s, 1H),
8.09 (s, 1H), 7.91 (br. s., 1H), 7.67-7.47 (m, 3H), 7.36 (s, 1H),
7.08-6.93 (m, 2H), 5.76 (s, 2H), 1.98 (s, 3H).
6-(5-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbox-
ylic acid 14G
[0779] (3.3 mg, 9.56 .mu.mol, 6.40% yield). LCMS: m/z 346.1
[M+H].sup.+; ret. time 0.5 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.72 (br. s, 1H), 8.41-8.28 (m, 1H), 8.14
(br. s., 1H), 7.91-7.82 (m, 1H), 7.79-7.71 (m, 1H), 7.65 (d, J=9.0
Hz, 1H), 7.32-7.21 (m, 2H), 7.17 (br. s., 1H), 6.01-5.84 (s, 2H),
2.33 (s, 3H).
##STR00384##
Compound 17B: 3-bromo-2-chloropyridin-4-amine
##STR00385##
[0781] To a stirred solution of 2-chloropyridin-4-amine 17A (2 g,
15.56 mmol) in acetic acid (20 mL) was added NB S (2.77 g, 15.56
mmol) portion-wise at 0.degree. C. under nitrogen. Then reaction
mixture was allowed to stir at room temperature for 1 h. The
solvent was removed under reduced pressure, followed by azeotropic
distillation with ethanol. The crude compound was purified by
silica gel chromatography (40 g RediSep.RTM. column, eluting with a
gradient of 10-20% ethyl acetate in petroleum ether) to yield
Compound 15B (2 g, 9.64 mmol, 62.0% yield) as a white solid. LCMS:
m/z=209.0 [M+H].sup.+; ret. time 0.84 min; condition B.
Compound 17C: N-(3-bromo-2-chloropyridin-4-yl)acetamide
##STR00386##
[0783] To a stirred solution of 3-bromo-2-chloropyridin-4-amine 17B
(1 g, 4.82 mmol) in DCM (20 mL) at 0.degree. C. was added DIPEA
(1.684 mL, 9.64 mmol), followed by acetyl chloride (0.514 mL, 7.23
mmol) under nitrogen. Then reaction mixture was allowed to stir at
room temperature for 1 h. The solvent was evaporated at reduced
pressure, diluted with ethyl acetate (300 mL). Ethyl acetate layer
was washed with saturated sodium bicarbonate (50 mL) and brine (50
mL). The organic layer was dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure to yield crude
N-(3-bromo-2-chloropyridin-4-yl)acetamide 17C (0.8 g. 66% yield).
LCMS: m/z=251.3 [M+H].sup.+; ret. time 0.92 min; condition B, which
was used without further purification.
Compound 17D:
N-(2-chloro-3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-4-yl)acetamide
##STR00387##
[0785] Compound 17D was synthesized from 17C similar to 17
employing the experimental procedure described in Scheme 5
(Method-E). The crude product was purified by silica gel
chromatography (12 g RediSep.RTM. column, eluting with 4% methanol
in chloroform). The fractions containing the product were collected
and evaporated under reduced pressure to afford compound 17D (0.13
g, 0.417 mmol, 20.8% yield) as a white solid. LCMS: m/z=312.4
[M+H].sup.+; ret. time 0.85 min; condition B.
Compound 100:
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridin]-4-yl)-
acetamide
##STR00388##
[0787] Compound 100 was synthesized by reacting 17D and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme 1 (Method-A). The crude residue was
purified by preparative HPLC (condition N) to yield
N-(3-(3-cyanoimidazo[1,2-a]pyridin-6-yl)-6'-methyl-[2,2'-bipyridin]-4-yl)-
acetamide 100 (110 mg, 65% yield). LCMS: m/z=369.2 [M+H].sup.+;
ret. time 1.19 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.02 (s, 1H), 8.62 (d, J=4.00 Hz, 1H),
8.46 (s, 2H), 8.16 (d, J=4.00 Hz, 1H), 7.74 (d, J=8.00 Hz, 1H),
7.64 (t, J=16.00 Hz, 1H), 7.53 (d, J=8.00 Hz, 1H), 7.27-7.25 (m,
1H), 7.04 (d, J=8.00 Hz, 1H), 2.03 (s, 3H), 1.97 (s, 3H).
Compound 101:
6-(4-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xamide
##STR00389##
[0789] Compound 101 was synthesized from 100 in a manner similar to
3A employing the experimental procedure described in Scheme 6
(Method A). The crude residue was purified by preparative HPLC
(condition N) to yield
6-(4-amino-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-carbo-
xamide 101 (10 mg, 34% yield). LCMS: m/z=345.1 [M+H].sup.+; ret.
time 0.66 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. ppm 9.17 (s, 1H), 8.26 (s, 1H), 8.10-8.13 (m, 1H), 7.8 (bs,
1H), 7.53-7.58 (m, 2H), 7.41-7.43 (m, 1H), 7.25 (bs, 1H) 7.12-7.14
(m, 1H), 6.94 (d, J=8.00 Hz, 1H), 6.73 (d, J=4.00 Hz, 1H), 5.8 (s,
2H) 2.01 (s, 3H).
Compound 102:
6-(4-acetamido-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-3-c-
arboxamide
##STR00390##
[0791] Compound 102 was synthesized from 100 in a manner similar to
19 employing the experimental procedure described in Scheme 7
(Method B). The crude residue was purified by preparative HPLC
(condition N) to yield 102 (14 mg, 32% yield). LCMS: m/z=387.1
[M+H].sup.+; ret. time 0.86 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.21-9.20 (m, 1H), 9.10 (s, 1H), 8.60 (d,
J=4.00 Hz, 1H), 8.29 (s, 1H), 8.11 (d, J=8.00 Hz, 1H) 8.1 (bs, 1H),
7.61-7.57 (m, 2H), 7.40 (d, J=8.00 Hz, 1H), 7.14 (dd, J=12.00, Hz,
1H), 7.00 (d, J=8.00 Hz, 1H), 6.9 (m, 1H) 2.05 (s, 3H), 1.96 (s,
3H).
##STR00391##
Compound 18B:
6-(2-chloropyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine
##STR00392##
[0793] Compound 18B was synthesized by reacting 18A (reference:
Journal of Medicinal Chemistry, 2014, 57, 3484-3493) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(reference: WO 2015157093 A1, WO 2015044172 A1 and WO 2014055955
A1) employing experimental procedure described in Scheme 5
(Method-E). The crude residue was purified by silica gel
chromatography (24 g RediSep.RTM. column, eluting with a gradient
of 3-10% methanol in chloroform). The fractions containing the
product were combined and concentrated under reduced pressure to
yield compound 18B (320 mg, 1.242 mmol, 37.4% yield) as a yellow
solid. LCMS: m/z=258.0 [M+H].sup.+; ret. time 1.08 min; condition
E.
Compound 103:
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-ami-
ne
##STR00393##
[0795] Compound 103 was synthesized by reacting 18B and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described for compound 15 as shown in Scheme 3 (Method
C). The crude residue was purified by preparative HPLC (condition
K) to yield 103 (13.9 mg, 0.041 mmol, 14.23% yield). LCMS:
m/z=333.2 [M+H].sup.+; ret. time 1.24 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.77 (dd, J=4.77, 1.59 Hz, 1H)
8.40 (s, 1H) 8.25 (dd, J=7.70, 1.59 Hz, 1H) 7.76-7.87 (m, 4H) 7.63
(dd, J=7.83, 4.65 Hz, 1H) 7.52 (br. s., 1H) 7.40 (d, J=8.80 Hz, 1H)
1.94 (s, 3H).
Compound 104:
6-(5'-fluoro-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
##STR00394##
[0797] Compound 104 was synthesized by reacting 18B and
6-bromo-3-fluoropyridine employing the experimental procedure
described for compound 15 as shown in Scheme 3 (Method C). The
crude residue was purified by preparative HPLC (method Q) to yield
compound 104 (35.6 mg, 0.111 mmol, 36% yield). LCMS: m/z=319.2
[M+H].sup.+; ret. time 1.09 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.78 (dd, J=4.65, 1.47 Hz, 1H) 8.40 (s,
1H) 8.27-8.32 (m, 1H) 8.21 (d, J=2.69 Hz, 1H) 8.09 (dd, J=8.80,
4.65 Hz, 1H) 7.84-7.91 (m, 3H) 7.65 (dd, J=7.83, 4.89 Hz, 1H) 7.49
(br. s., 1H) 7.44 (d, J=8.56 Hz, 1H).
Compound 105:
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-ami-
ne
##STR00395##
[0799] Compound 105 was synthesized by reacting 18B and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described for compound 15 as shown in Scheme 3 (Method
C). The crude residue was purified by preparative HPLC (method K)
to yield compound 105. (30.1 mg, 0.085 mmol, 28% yield). LCMS:
m/z=351.1 [M+H].sup.+; ret. time 1.32 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.82 (dd, J=4.77, 1.59 Hz, 1H)
8.38 (s, 1H) 8.30 (dd, J=7.83, 1.71 Hz, 1H) 8.09-8.18 (m, 2H) 7.89
(d, J=8.56 Hz, 1H) 7.80 (br. s., 1H) 7.69 (dd, J=7.83, 4.89 Hz, 1H)
7.60 (d, J=6.85 Hz, 1H) 7.53 (d, J=8.80 Hz, 1H) 7.32 (br. s., 1H)
6.19-6.48 (t, J=54.8 Hz, 1H).
Compound 106:
6-(6'-cyclopropyl-[2,2'-bipyridin]-3-yl)pyrido[3,2-d]pyrimidin-4-amine
##STR00396##
[0801] Compound 106 was synthesized by reacting 18B and
2-bromo-6-cyclopropylpyridine employing experimental procedure
described for compound 15 as shown in Scheme 3 (Method C). The
crude residue was purified by preparative HPLC (method: K) to yield
compound 106 (48 mg, 0.141 mmol, 45% yield). LCMS: m/z=341.1
[M+H].sup.+; ret. time 1.42 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.76 (dd, J=4.77, 1.59 Hz, 1H) 8.41 (s,
1H) 8.17 (dd, J=7.83, 1.71 Hz, 1H) 7.87 (d, J=8.80 Hz, 1H)
7.75-7.85 (m, 3H) 7.61 (dd, J=7.83, 4.65 Hz, 1H) 7.55 (br. s., 1H)
7.34 (d, J=8.80 Hz, 1H) 7.25 (dd, J=7.34, 1.22 Hz, 1H) 1.73-1.77
(m, 1H) 0.402-0.358 (m, 2H) 0.137-0.164 (m, 2H).
##STR00397##
Compound 19B: 6-(2-chloropyridin-3-yl)quinazolin-4-amine
##STR00398##
[0803] Compound 19B was synthesized by reacting 19A (reference:
Angew. Chem. Int. Ed. 2014, 53, 305-309) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
employing the experimental procedure described for compound 9B as
shown in Scheme 16. The crude residue was purified by silica gel
chromatography (40 g RediSep.RTM. column, eluting with a gradient
of 35% ethyl acetate in petroleum ether) to yield
6-(2-chloropyridin-3-yl)quinazolin-4-amine 18B (0.6 g, 2.337 mmol,
52.4% yield). LCMS: m/z=257.2 [M+H].sup.+; ret. time 1.06 min;
condition E.
Compound 107:
6-(6'-ethyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00399##
[0805] Compound 107 was synthesized by reacting 19B and
6-bromo-2-ethylpyridine employing the experimental procedure
described in Scheme 2 (Method B). The crude residue was purified by
preparative HPLC (method: F) to yield compound 107 (4.2 mg, 0.012
mmol, 2.09% yield). LCMS: m/z=328.2 [M+H].sup.+; ret. time 1.21
min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
8.83 (s, 1H), 8.80-8.76 (m, 1H), 8.41 (s, 1H), 7.97 (dd, J=7.9, 1.6
Hz, 1H), 7.83-7.78 (m, 2H), 7.67-7.61 (m, 3H), 7.26-6.93 (m, 3H),
2.30 (d, J=7.6 Hz, 2H), 0.60-0.50 (m, 3H).
Compound 108:
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00400##
[0807] Compound 108 was synthesized by reacting 19B and
2-bromo-6-isopropylpyridine employing the experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (method N) to yield compound 108 (14.6 mg, 0.04
mmol, 7.03% yield). LCMS: m/z=342.2 [M+H].sup.+; ret. time 1.36
min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
8.75-8.67 (m, 1H), 8.33 (s, 1H), 8.17 (d, J=1.5 Hz, 1H), 8.00-7.90
(m, 1H), 7.83-7.71 (m, 2H), 7.69-7.52 (m, 3H), 7.43 (d, J=8.6 Hz,
1H), 7.25 (dd, J=8.6, 1.7 Hz, 1H), 7.10 (d, J=7.3 Hz, 1H),
2.65-2.54 (m, 1H), 0.62 (d, J=6.8 Hz, 6H).
Compound 109:
6-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00401##
[0809] Compound 109 was synthesized by reacting 19B and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described in Scheme-2 (Method B). The crude residue was
purified by preparative HPLC (method K) to yield compound 109
(0.015 g, 0.042 mmol, 10.7% yield). LCMS: m/z=350.2 [M+H].sup.+;
ret. time 1.08 min; condition E. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.77 (dd, 1.5 Hz, 1H), 8.36 (s, 1H), 8.21
(d, J=1.5 Hz, 1H), 8.08-8.00 (m, 2H), 7.93 (d, J=8.0 Hz, 1H), 7.67
(dd, J=8.0, 4.5 Hz, 3H), 7.59 (d, J=8.0 Hz, 1H), 7.44 (d, J=9.0 Hz,
1H), 7.29 (dd, J=8.8, 1.8 Hz, 1H), 1.82 (s, 1H).
Compound 110:
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)imidazo[1,2-a]pyridine-2-car-
boxamide
##STR00402##
[0811] Compound 110 was synthesized by reacting 19B and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme-2 (Method B). The crude residue was
purified by preparative HPLC (method K) to yield compound 110 (15
mg, 0.044 mmol, 11.3% yield). LCMS: m/z=332.2 [M+H].sup.+; ret.
time 1.03 min; condition E. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.72 (dd, J=4.8, 1.8 Hz, 1H), 8.37 (s, 1H), 8.20 (d,
J=2.0 Hz, 1H), 7.97 (dd, J=7.8, 1.8 Hz, 1H), 7.74-7.63 (m, 4H),
7.60 (dd, J=7.5, 4.5 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 7.30 (dd,
J=8.5, 2.0 Hz, 1H), 2.03 (d, J=3.0 Hz, 3H).
Compound 111:
6-(6'-isopropyl-[2,2'-bipyridin]-3-yl)quinazolin-4-amine
##STR00403##
[0813] Compound 111 was synthesized by reacting 19B and
2-bromo-6-cyclopropylpyridine employing the experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (method: N) to yield compound 111 (31.2 mg, 0.091
mmol, 11.7% yield). LCMS: m/z=340.1 [M+H].sup.+; ret. time 1.38
min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
8.68-8.72 (m, 1H), 8.35-8.38 (m, 1H), 8.15-8.19 (m, 1H), 7.89-7.94
(m, 1H), 7.62-7.77 (m, 4H), 7.55-7.61 (m, 1H), 7.43-7.47 (m, 1H),
7.16-7.23 (m, 2H), 1.70-1.79 (m, 1H), 0.33-0.41 (m, 2H), -0.13-0.06
(m, 2H).
##STR00404##
Compound 20B: 6-(2-chloropyridin-3-yl)quinoxaline
##STR00405##
[0815] Compound 20B was synthesized by reacting 20A and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(reference: WO 2015157093 A1, WO 2015044172 A1 and WO 2014055955
A1) employing the experimental procedure described in Scheme-5
(Method E). The crude product was purified by silica gel
chromatography (40 g RediSep.RTM. column, eluting with 50% ethyl
acetate in petroleum ether) to yield compound 20B (2.32 g, 9.61
mmol, 67.0% yield) as a light yellow solid. LCMS: m/z=242.0
[M+H].sup.+; ret. time 1.66 min; condition C.
Compound 112:
6-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)quinoxaline
##STR00406##
[0817] Compound 112 was synthesized by reacting 20B and
2-methyl-3-Flouro-6-bromopyridine employing experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
preparative HPLC (method: N) to yield compound 112 (79.9 mg, 0.253
mmol, 40.7% yield). LCMS: m/z=317.2 [M+H].sup.+; ret. time 1.51
min.; condition-C. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. ppm
8.94 (s, 2H), 8.76 (dd, J=1.2, 4.8 Hz, 1H), 8.05-8.07 (m, 1H),
7.92-7.97 (m, 2H), 7.74-7.77 (m, 1H), 7.61-7.69 (m, 2H), 7.51-7.53
(m, 1H), 1.93 (d, J=2.8 Hz, 3H).
Compound 113: 6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinoxaline
##STR00407##
[0819] Compound 113 was synthesized by reacting 20B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described in Scheme 1 (Method A). The crude residue was
purified by preparative HPLC (method: N) to yield
6-(6'-methyl-[2,2'-bipyridin]-3-yl)quinoxaline 113 (68.6 mg, 0.230
mmol, 55.6% yield). LCMS: m/z=299.1 [M+H].sup.+; ret. time 1.41
min; conditions-C. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. ppm
8.92 (s, 2H), 8.74-8.76 (m, 1H), 8.05-8.07 (m, 1H), 7.90-7.94 (m,
2H), 7.69-7.73 (m, 1H), 7.60-7.63 (m, 2H), 7.51 (dd, J=2.0, 8.8 Hz,
1H), 7.11 (d, J=7.6 Hz, 1H), 1.97 (s, 3H).
Compound 114:
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)quinoxaline
##STR00408##
[0821] Compound 114 was synthesized by reacting 20B and
2-bromo-6-(trifluoromethyl)pyridine employing the experimental
procedure described in Scheme-2 (Method B). The crude residue was
purified by preparative HPLC (method: H) to yield
6-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)quinoxaline 114 (56.9
mg, 0.162 mmol, 39.0% yield). LCMS: m/z=353.1 [M+H].sup.+; ret.
time 1.75 min; condition C. 1H NMR (400 MHz, DMSO-d.sub.6): .delta.
ppm 8.93 (s, s, 2H), 8.83-8.84 (m, 1H), 8.26 (d, J=8.0 Hz, 1H),
8.12-8.20 (m, 2H), 7.96 (d, J=8.4 Hz, 1H), 7.98 (d, J=1.6 Hz, 1H),
7.76 (d, 7.6 Hz, 1H), 7.71 (dd, J=4.8, 7.6 Hz, 1H), 7.54 (dd,
J=2.0, 8.8 Hz, 1H).
##STR00409##
Compound 21B:
5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole
##STR00410##
[0823] To a solution of 5-bromo-1H-indazole 20 (5 g, 25.4 mmol) in
THF (100 mL) was added LiHMDS (30.5 mL, 30.5 mmol) at -78.degree.
C. and the reaction mixture was stirred at the same temperature for
30 min. Then 2-(trimethylsilanyl)ethoxymethyl chloride (6.75 mL,
38.1 mmol) was added and the reaction mixture was slowly allowed to
attain room temperature and stirred for 16 h. The reaction mixture
was quenched with saturated NH.sub.4Cl. The aqueous layer was back
extracted with ethyl acetate (3.times.100 mL). The combined organic
layers was washed with 10% NaHCO.sub.3 (3.times.150 mL) solution
and brine. The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated to afford crude product as pale yellow
liquid. The crude residue was purified by silica gel chromatography
(120 g RediSep.RTM. column, eluted with a gradient of 1-5% ethyl
acetate in petroleum ether) to yield
5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole 21B (8.13
g, 24.84 mmol, 98% yield) as a light yellow liquid. LCMS: m/z=327.0
[M+H].sup.+; ret. time 3.76 min; condition E.
Compound 21C:
5-(2-chloropyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole
##STR00411##
[0825] Compound 21C was synthesized by reacting 21B and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) employing
the experimental procedure described for compound 9B as shown in
Scheme 16. The crude residue was purified by silica gel
chromatography (40 g RediSep.RTM. column, eluted with a gradient of
5-10% ethyl acetate in petroleum ether) to yield
5-(2-chloropyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole
21C (1.925 g, 5.35 mmol, 50.0% yield) as light yellow solid. LCMS:
m/z=360.3 [M+H].sup.+; ret. time 1.21 min; condition B.
Compound 21D:
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole
##STR00412##
[0827] Compound 21D was synthesized by reacting 21C and
2-bromo-6-(difluoromethyl)pyridine (95 mg, 0.458 mmol) employing
the experimental procedure described in Scheme-2 (Method B). The
crude residue was purified by silica gel chromatography (24 g
RediSep.RTM. column, eluted with a gradient of 5-10% methanol in
chloroform) to yield
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole 21D (93 mg, 0.205 mmol, 49.3% yield). LCMS:
m/z=453.7 [M+H].sup.+; ret. time 1.1 min; condition B.
Compound 115:
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1H-indazole
##STR00413##
[0829]
5-(6'-(Difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl-
)ethoxy)methyl)-1H-indazole 21D (110 mg, 0.243 mmol) was treated
with TFA (8 mL, 104 mmol) and the reaction mixture was stirred at
room temperature for 12 h. The volatiles were removed under reduced
pressure and the residue was dissolve in methanol (10 mL) and
ammonium hydroxide (8 mL, 205 mmol) and stirred for 12 h. After
that, the reaction mixture was evaporated under reduced pressure to
obtain the crude compound, which was purified by preparative HPLC
(method: H) to yield
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1H-indazole 115 (37.5
mg, 0.116 mmol, 47.9% yield). LCMS: m/z=323.1 [M+H].sup.+; ret.
time 1.14 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 13.03 (s, 1H), 8.71 (dd, J=1.6, 4.8 Hz, 1H), 7.93-8.01
(m, 3H), 7.61-7.68 (m, 3H), 7.57 (d, J=7.6 Hz, 1H), 7.36 (d, J=8.8
Hz, 1H), 6.96-7.00 (m, 1H), 6.58 (t, J=55.2 Hz, 1H).
Compound 21F:
5-(5'-fluoro-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)--
1H-indazole
##STR00414##
[0831] Compound 21F was synthesized by reacting 21C and
2-bromo-5-fluoropyridine employing the experimental procedure
described in Scheme-2 (Method B). The crude residue was purified by
silica gel chromatography (24 g RediSep.RTM. column, eluted with a
gradient of 5-10% methanol in chloroform) to yield
5-(5'-fluoro-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)--
1H-indazole 21F (105 mg, 0.250 mmol, 59.9% yield). LCMS: m/z=421.1
[M+H].sup.+; ret. time 3.13 min; condition E.
Compound 116: 5-(5'-fluoro-[2,2'-bipyridin]-3-yl)-1H-indazole
##STR00415##
[0833] Compound 116 was synthesized by reacting 21F employing the
experimental procedure described in for compound 115 in Scheme 28.
The crude residue was purified by preparative HPLC (method: H) to
yield 5-(5'-fluoro-[2,2'-bipyridin]-3-yl)-1H-indazole 116 (23.2 mg,
0.080 mmol, 28.0% yield). LCMS: m/z=291.1 [M+H].sup.+; ret. time
1.32 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.65-8.67 (m, 1H), 8.29 (d, J=2.8 Hz, 1H), 8.02 (s, 1H),
7.92-7.95 (m, 1H), 7.68-7.76 (m, 2H), 7.60 (s, 1H), 7.55-7.58 (m,
1H), 7.37 (d, J=8.8 Hz, 1H), 6.95-6.98 (m, 1H).
Compound 21H:
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole
##STR00416##
[0835] Compound 21H was synthesized by reacting 21C and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme-2 (Method B). The crude residue was
purified by silica gel chromatography (24 g RediSep.RTM. column,
eluted with a gradient of 5-10% methanol in chloroform) to get
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole 21H (135 mg, 0.311 mmol, 74.5% yield) as a
light yellow solid. LCMS: m/z=435.4 [M+H].sup.+; ret. time 3.3 min;
condition E.
Compound 117:
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole
##STR00417##
[0837] Compound 117 was synthesized by reacting 21H employing the
experimental procedure described for compound 115 as shown in
Scheme 28. The crude residue was purified by preparative HPLC
(method: H) to yield
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-1H-indazole 117 (13
mg, 0.043 mmol, 14.28% yield). LCMS: m/z=305.1 [M+H].sup.+; ret.
time 1.24 min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 13.03 (s, 1H), 8.65 (dd, J=1.6, 4.8 Hz, 1H), 8.03 (s,
1H), 7.92 (dd, J=1.6, 8.0 Hz, 1H), 7.53-7.60 (m, 3H), 7.37-7.42 (m,
2H), 6.97-7.00 (m, 1H), 2.13 (d, J=2.8 Hz, 3H).
##STR00418##
Compound 22B:
5-(2-chloropyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-
-3-carbaldehyde
##STR00419##
[0839] Compound 22B was synthesized by reacting 22A (reference: US
20140194441 A1) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
employing the experimental procedure described for compound 9B as
shown in Scheme 16. The crude residue was purified by silica gel
chromatography (40 g RediSep.RTM. column, eluted with a gradient of
5-10% ethyl acetate in petroleum ether) to yield
5-(2-chloropyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-
-3-carbaldehyde 22B (1.202 g, 3.10 mmol, 73.4% yield). LCMS:
m/z=388.2 [M+H].sup.+; ret. time 3.52 min; condition E.
Compound 22C:
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole-3-carbaldehyde
##STR00420##
[0841] Compound 22C was synthesized by reacting 22B and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described in Scheme 2 (Method 2). The crude residue was
purified by silica gel chromatography (24 g RediSep.RTM. column,
eluted with a gradient of 5-10% ethyl acetate in petroleum ether)
to yield
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole-3-carbaldehyde 22C (335 mg, 0.697 mmol, 49.2%
yield). LCMS: m/z=481.2 [M+H].sup.+; ret. time 3.56 min; condition
E.
Compound 22D:
3-(difluoromethyl)-5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(t-
rimethylsilyl)ethoxy)methyl)-1H-indazole
##STR00421##
[0843] To a stirred solution of
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-indazole-3-carbaldehyde 22C (100 mg, 0.208 mmol) in
DCM (5 mL) was added DAST (0.055 mL, 0.416 mmol) at 0.degree. C.
The reaction mixture was warmed to room temperature and stirred for
16 h. The reaction mixture was diluted with DCM (20 mL) and poured
into an ice cooled 10% aq. NaHCO.sub.3 solution (20 mL). The
organic layer was separated and the aqueous layer was back
extracted with DCM (3.times.15 mL). The combined organic layer were
dried over Na.sub.2SO.sub.4, concentrated under reduced pressure to
give a light yellow semi-solid mass. The crude residue was purified
by silica gel chromatography (24 g RediSep.RTM. column, eluted with
a gradient of 10-30% ethyl acetate in petroleum ether) to yield
3-(difluoromethyl)-5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1-((2-(t-
rimethylsilyl)ethoxy)methyl)-1H-indazole 22D (72 mg, 0.143 mmol,
68.8% yield). LCMS: m/z=503.2 [M+H].sup.+; ret. time 3.47 min;
condition E.
Compound 118:
3-(difluoromethyl)-5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1H-indaz-
ole
##STR00422##
[0845] Compound 118 was synthesized from 22D employing the
experimental procedure described for compound 115 as shown in
Scheme 29. The crude residue was purified by preparative HPLC
(method: H) to yield
3-(difluoromethyl)-5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)-1H-indaz-
ole 115 (9.7 mg, 0.026 mmol, 12.35% yield). LCMS: m/z=373.1
[M+H].sup.+; ret. Time 1.8 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta.=13.57 (s, 1H), 8.72-8.74 (m, 1H), 7.97-8.00
(m, 2H), 7.74-7.76 (m, 1H), 7.56-7.64 (m, 4H), 7.27 (t, J=54.0 Hz,
1H), 7.14-7.18 (m, 1H), 6.52 (J=54.8 Hz, 1H).
##STR00423##
Compound 23B:
5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile
##STR00424##
[0847] Compound 23B was synthesized by reacting 23A [reference:
Heterocycles (2010), 80(2), 1359-1379] and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
employing experimental procedure described for compound 9B as shown
in Scheme 16. The crude was purified using silica gel
chromatography (24 g RediSep.RTM. column, eluting with a gradient
of 50% ethyl acetate in petroleum ether). The fractions containing
the product were combined and evaporated under reduced pressure to
afford compound
5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile
23B (900 mg, 3.52 mmol, 62.9% yield). LCMS: m/z=256.1 [M+H].sup.+;
ret. time 0.64 min; condition B.
Compound 119:
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitri-
le
##STR00425##
[0849] Compound 119 was synthesized by reacting 23B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described for compound 81 in Scheme 18. The crude
compound was purified by preparative HPLC (Condition-N) to yield
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitri-
le 119 (120 mg, 0.384 mmol, 49.1% yield). LCMS: m/z=313.1
[M+H].sup.+; ret. time 1.44 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta.=9.19 (d, J=7.3 Hz, 1H), 8.85 (dd, J=4.6, 1.7
Hz, 1H), 8.81 (s, 1H), 8.14 (dd, J=7.8, 1.7 Hz, 1H), 8.00 (d, J=7.8
Hz, 1H), 7.83 (t, J=7.7 Hz, 1H), 7.66 (dd, J=7.7, 4.8 Hz, 1H), 7.19
(d, J=7.6 Hz, 1H), 7.07 (d, J=7.1 Hz, 1H), 1.90 (s, 3H)
Compound 120:
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e
##STR00426##
[0851] Compound 120 was synthesized from 119 similar to 3A
employing experimental procedure described in Scheme-6 (Method A).
The crude compound was purified by preparative HPLC (Condition-N)
to yield
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e 120 (10.6 mg, 0.032 mmol, 10% yield). LCMS: m/z=332.1
[M+H].sup.+; ret. time 1.1 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.16 (d, J=7.1 Hz, 1H), 8.83 (dd, J=4.8,
1.6 Hz, 1H), 8.51 (s, 1H), 8.25 (dd, J=7.7, 1.6 Hz, 1H), 7.90-7.77
(m, 2H), 7.67 (dd, J=7.7, 4.8 Hz, 1H), 7.31 (br. s., 1H), 7.19 (d,
J=7.3 Hz, 1H), 7.08-6.98 (m, 2H), 1.95 (s, 3H).
Compound 121:
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-
-carbonitrile
##STR00427##
[0853] Compound 121 was synthesized by reacting 23B and
2-bromo-6-(trifluoromethyl)pyridine employing the experimental
procedure described in Scheme 2 (Method B). The crude compound was
purified by preparative HPLC (Condition-N) to yield
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-
-carbonitrile 121 (140 mg, 0.382 mmol, 48.9% yield). LCMS:
m/z=367.1 [M+H].sup.+; ret. time 1.72 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.30 (d, J=7.1 Hz, 1H), 8.92
(dd, J=4.6, 1.5 Hz, 1H), 8.79 (s, 1H), 8.49 (d, J=7.8 Hz, 1H),
8.29-8.19 (m, 2H), 7.83 (d, J=7.8 Hz, 1H), 7.75 (dd, J=7.7, 4.8 Hz,
1H), 7.31 (d, J=7.1 Hz, 1H).
Compound 122:
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carbonitrile
##STR00428##
[0855] Compound 122 was synthesized by reacting 23B and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme 3 (Method C). The crude compound was
purified by preparative HPLC (Condition-N) to yield
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-c]pyrimidine-3--
carbonitrile 122 (130 mg, 0.394 mmol, 50.3% yield). LCMS: m/z=331.2
[M+H].sup.+; ret. time 1.55 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.30 (d, J=7.1 Hz, 1H), 8.92 (dd, J=4.6,
1.5 Hz, 1H), 8.79 (s, 1H), 8.49 (d, J=7.8 Hz, 1H), 8.29-8.19 (m,
2H), 7.83 (d, J=7.8 Hz, 1H), 7.75 (dd, J=7.7, 4.8 Hz, 1H), 7.31 (d,
J=7.1 Hz, 1H).
##STR00429##
Compound 24B: ethyl
5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00430##
[0857] Compound 24B was synthesized by reacting 24A (reference: WO
2013059587 A1) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
employing the experimental procedure described for compound 9B as
shown in Scheme 16. The crude was purified using silica gel
chromatography (24 g RediSep.RTM. column, eluting with a gradient
of 50% ethyl acetate in petroleum ether). The fractions containing
the product were combined and evaporated under reduced pressure to
afford ethyl
5-(2-chloropyridin-3-yl)pyrazolo[1,5-c]pyrimidine-3-carboxylate 24B
(1 g, 3.30 mmol, 83% yield). LCMS: m/z=303.1 [M+H].sup.+; ret. time
0.82 min; condition B.
Compound 123: ethyl
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-
-carboxylate
##STR00431##
[0859] Compound 123 was synthesized by reacting 24B and
2-bromo-6-(trifluoromethyl)pyridine employing the experimental
procedure described in Scheme 3 (Method C). The crude compound was
purified by preparative HPLC (Condition-N) to yield ethyl
5-(6'-(trifluoromethyl)[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylate 123 (180 mg, 0.435 mmol, 65.9% yield). LCMS: m/z=414.1
[M+H].sup.+; ret. time 1.81 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.18 (d, J=7.1 Hz, 1H), 8.90 (dd, J=4.8,
1.6 Hz, 1H), 8.58 (s, 1H), 8.45 (d, J=8.1 Hz, 1H), 8.28-8.17 (m,
2H), 7.82-7.72 (m, 2H), 7.18 (d, J=7.1 Hz, 1H), 4.19 (q, J=7.1 Hz,
2H), 1.22 (t, J=7.1 Hz, 3H).
Compound 124:
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-
-carboxylic acid
##STR00432##
[0861] In a 8 mL vial, was added ethyl
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-
-carboxylate 23B (120 mg, 0.290 mmol) in THF (2 mL) and water (1
mL). The mixture was cooled to 0.degree. C. and LiOH (6.95 mg,
0.290 mmol) was added. Then, the reaction mixture was heated at
50.degree. C. for 12 h. The reaction mixture was acidified using 1N
aqueous HCl and evaporated completely to get the crude product,
which was purified by preparative HPLC (Condition-N) to yield
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 124 (22.5 mg, 0.058
mmol, 20.1% yield). LCMS: m/z=386.1 [M+H].sup.+; ret. time 0.97
min; condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
9.06 (d, J=7.3 Hz, 1H), 8.89 (d, J=3.7 Hz, 1H), 8.46 (d, J=7.6 Hz,
2H), 8.27-8.14 (m, 2H), 7.80 (d, J=7.6 Hz, 1H), 7.73 (dd, J=7.6,
4.9 Hz, 1H), 6.99 (d, J=6.6 Hz, 1H).
Compound 125:
N-methyl-5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyr-
imidine-3-carboxamide
##STR00433##
[0863] Compound 125 was synthesized by reacting 124 and
methylamine, employing the experimental procedure described for
compound 68 as shown in Scheme 14. The crude compound was purified
by preparative HPLC (Condition-N) to yield
N-methyl-5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyr-
imidine-3-carboxamide 125 (1.1 mg, 2.76 .mu.mol, 3.6% yield). LCMS:
m/z=399.1 [M+H].sup.+; ret. time 1.466 min; condition C. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.26 (d, J=7.3 Hz, 1H),
8.93-8.88 (m, 1H), 8.49 (s, 1H), 8.42 (d, J=8.1 Hz, 1H), 8.37-8.24
(m, 2H), 7.84-7.73 (m, 2H), 7.33-7.27 (m, 1H), 7.14 (d, J=4.6 Hz,
1H), 2.71-2.65 (m, 3H).
Compound 126:
N-cyclopropyl-5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00434##
[0865] Compound 126 was synthesized by reacting 124 and
cyclopropanamine, employing experimental procedure described for
compound 68 as shown in Scheme 14. The crude compound was purified
by preparative HPLC (Condition-N) to yield
N-cyclopropyl-5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)
pyrazolo[1,5-c]pyrimidine-3-carboxamide 126 (5.8 mg, 0.014 mmol,
17.55% yield. LCMS: m/z=425.1 [M+H].sup.+; ret. time 1.617 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.30
(d, J=7.1 Hz, 1H), 8.91 (dd, J=4.6, 1.5 Hz, 1H), 8.50 (s, 1H), 8.43
(d, J=7.8 Hz, 1H), 8.34-8.25 (m, 2H), 7.83 (d, J=7.8 Hz, 1H), 7.77
(dd, J=7.8, 4.9 Hz, 1H), 7.35 (d, J=7.3 Hz, 1H), 7.20 (d, J=3.2 Hz,
1H), 2.65-2.57 (m, 1H), 0.71-0.63 (m, 2H), 0.29-0.22 (m, 2H).
Compound 24G: ethyl
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylat-
e
##STR00435##
[0867] Compound 24G was synthesized by reacting 24B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described for compound 81 as sown in Scheme 18. The crude
compound was purified using silica gel chromatography (24 g
RediSep.RTM. column, eluting with a gradient of 50% ethyl acetate
in petroleum ether). The fractions containing the product were
combined and evaporated under reduced pressure to afford ethyl
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylat-
e 24G (200 mg, 0.557 mmol, 67.4% yield). LCMS: m/z=360.1
[M+H].sup.+; ret. time 0.84 min; condition B.
Compound 24H:
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR00436##
[0869] Compound 24H was synthesized from 24G employing the
experimental procedure described for compound 124 as shown in
Scheme 31. The crude compound was purified by preparative HPLC
(Condition-N) to yield
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid 23G (120 mg, 0.362 mmol, 100% yield). LCMS: m/z=332.1
[M+H].sup.+; ret. time 0.86 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.99 (d, J=7.1 Hz, 1H), 8.83 (dd, J=4.8,
1.6 Hz, 1H), 8.49 (s, 1H), 8.11 (dd, J=7.7, 1.6 Hz, 1H), 7.97 (d,
J=7.8 Hz, 1H), 7.81 (t, J=7.7 Hz, 1H), 7.65 (dd, J=7.8, 4.9 Hz,
1H), 7.18 (d, J=7.6 Hz, 1H), 6.78 (d, J=7.1 Hz, 1H), 1.93 (s,
3H).
Compound 127:
N-methyl-5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide
##STR00437##
[0871] Compound 127 was synthesized from 24H employing the
experimental procedure described for compound 68 as shown in Scheme
14. The crude compound was purified by preparative HPLC
(Condition-N) to yield
N-methyl-5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide 127 (1 mg, 2.90 .mu.mol, 3.2% yield). LCMS: m/z=345.2
[M+H].sup.+; ret. time 1.08 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.17 (d, J=7.3 Hz, 1H), 8.83 (dd, J=4.8,
1.6 Hz, 1H), 8.50 (s, 1H), 8.27 (dd, J=7.8, 1.7 Hz, 1H), 7.91-7.80
(m, 2H), 7.67 (dd, J=7.8, 4.6 Hz, 1H), 7.31 (d, J=4.9 Hz, 1H), 7.18
(d, J=7.3 Hz, 1H), 7.14-7.09 (m, 1H), 2.74 (d, J=4.9 Hz, 4H),
1.94-1.90 (m, 3H).
Compound 128:
N-cyclopropyl-5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide
##STR00438##
[0873] Compound 128 was synthesized from 24H employing the
experimental procedure described in Scheme 14 (compound 68). The
crude compound was purified by preparative HPLC (Condition-N) to
N-cyclopropyl-5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide 231 (3.4 mg, 9.18 .mu.mol, 10.1% yield). LCMS:
m/z=371.1 [M+H].sup.+; ret. time 1.13 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.21 (d, J=7.1 Hz, 1H), 8.84
(dd, J=4.8, 1.6 Hz, 1H), 8.51 (s, 1H), 8.24 (dd, J=7.7, 1.6 Hz,
1H), 7.94-7.80 (m, 2H), 7.68 (dd, J=7.7, 4.8 Hz, 1H), 7.41 (d,
J=3.4 Hz, 1H), 7.21-7.11 (m, 2H), 2.72-2.65 (m, 1H), 1.90 (s, 2H),
1.94-1.86 (m, 3H), 0.73-0.65 (m, 1H), 0.38-0.27 (m, 1H).
Compound 129:
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide
##STR00439##
[0875] Compound 129 was synthesized from 24H employing the
experimental procedure described for compound 68 as shown in Scheme
14. The crude compound was purified by preparative HPLC
(Condition-N) to yield
5-(6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide 129 (16.5 mg, 0.043 mmol, 47.2% yield). LCMS:
m/z=387.1 [M+H].sup.+; ret. time 0.99 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.22 (d, J=7.3 Hz, 1H), 8.85
(dd, J=4.8, 1.6 Hz, 1H), 8.54 (s, 1H), 8.31 (dd, J=7.8, 1.7 Hz,
1H), 7.95 (dd, J=12.2, 7.1 Hz, 2H), 7.87-7.80 (m, 1H), 7.70 (dd,
J=7.8, 4.9 Hz, 1H), 7.22-7.12 (m, 2H), 4.90 (dq, J=13.8, 6.6 Hz,
1H), 4.75 (t, J=7.0 Hz, 2H), 4.36 (t, J=6.5 Hz, 2H), 1.91 (s,
3H).
Compound 130: ethyl
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylate
##STR00440##
[0877] Compound 130 was synthesized by reacting 24B and
6-bromo-3-fluoro-2-methylpyridine employing the experimental
procedure described in Scheme 3 (Method C). The crude compound was
purified by preparative HPLC (Condition-N) to yield ethyl
5-(5'-fluoro-6'-methyl-[2, 2'-bipyridin]-3-yl)
pyrazolo[1,5-a]pyrimidine-3-carboxylate 130 (180 mg, 0.477 mmol,
72.2% yield). LCMS: m/z=378.1 [M+H].sup.+; ret. time 1.66 min;
condition C. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.=9.37 (d,
J=7.1 Hz, 1H), 9.10 (dd, J=4.8, 1.6 Hz, 1H), 8.87 (s, 1H), 8.40
(dd, J=7.8, 1.7 Hz, 1H), 8.32 (dd, J=8.4, 4.0 Hz, 1H), 8.03 (t,
J=9.0 Hz, 1H), 7.93 (dd, J=7.8, 4.9 Hz, 1H), 7.25 (d, J=7.3 Hz,
1H), 4.51 (q, J=7.1 Hz, 2H), 2.16 (d, J=2.7 Hz, 3H), 1.53 (t, J=7.1
Hz, 3H).
Compound 131:
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylic acid
##STR00441##
[0879] Compound 131 was synthesized from 130 employing the
experimental procedure described for Compound 124 as shown in
Scheme 31. The crude compound was purified by preparative HPLC
(Condition N) to yield
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylic acid 131 (15.4 mg, 0.044 mmol, 13.8% yield). LCMS:
m/z=350.2 [M+H].sup.+; ret. time 0.67 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.87 (d, J=7.1 Hz, 1H), 8.80
(dd, J=4.6, 1.7 Hz, 1H), 8.32 (s, 1H), 8.11 (dd, J=7.7, 1.6 Hz,
1H), 8.02 (dd, J=8.6, 3.7 Hz, 1H), 7.74 (t, J=9.0 Hz, 1H), 7.63
(dd, J=7.7, 4.8 Hz, 1H), 6.63 (d, J=7.1 Hz, 1H), 1.96 (d, J=2.7 Hz,
3H).
Compound 132:
N-cyclopropyl-5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide
##STR00442##
[0881] Compound 132 was synthesized from 131 employing the
experimental procedure described for compound 68 as shown in Scheme
14. The crude compound was purified by preparative HPLC
(Condition-N) to yield
N-cyclopropyl-5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide 132 (1.8 mg, 4.63 .mu.mol, 5.40% yield).
LCMS: m/z=389.1 [M+H].sup.+; ret. time 1.475 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.21 (d, J=7.3 Hz,
1H), 8.84 (dd, J=4.6, 1.2 Hz, 1H), 8.53 (s, 1H), 8.26 (d, J=7.6 Hz,
1H), 8.00 (dd, J=8.7, 3.8 Hz, 1H), 7.80 (t, J=9.0 Hz, 1H), 7.69
(dd, J=7.8, 4.6 Hz, 1H), 7.45 (d, J=3.7 Hz, 1H), 7.16 (d, J=7.1 Hz,
1H), 1.90 (d, J=2.7 Hz, 3H), 0.77-0.67 (m, 2H), 0.38-0.30 (m,
2H).
Compound 133:
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)pyrazolo[1,5-
-a]pyrimidine-3-carboxamide
##STR00443##
[0883] Compound 133 was synthesized from 131 employing the
experimental procedure described for compound 68 as shown in Scheme
14. The crude compound was purified by preparative HPLC
(Condition-N) to yield
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)-N-(oxetan-3-yl)pyrazolo[1,5-
-a]pyrimidine-3-carboxamide 133 (2.2 mg, 5.44 .mu.mol, 6.3% yield).
LCMS: m/z=405.1 [M+H].sup.+; ret. time 1.31 min; condition C.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.02 (d, J=7.3 Hz,
1H), 8.83 (dd, J=4.8, 1.6 Hz, 1H), 8.53 (s, 1H), 8.13-8.03 (m, 2H),
7.76 (t, J=9.2 Hz, 1H), 7.66 (dd, J=7.8, 4.6 Hz, 1H), 6.86 (d,
J=7.3 Hz, 1H), 4.80 (t, J=5.5 Hz, 1H), 4.38-4.31 (m, 1H), 4.28-4.12
(m, 2H), 3.59 (dt, J=10.0, 5.0 Hz, 1H), 3.46-3.37 (m, 1H), 1.91 (d,
J=2.7 Hz, 3H).
Compound 134: ethyl
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylate
##STR00444##
[0885] Compound 134 was synthesized by reacting 24B and
2-bromo-6-(difluoromethyl)pyridine employing the experimental
procedure described in Scheme 3 (Method C). The crude compound was
purified by preparative HPLC (Condition-N) to yield ethyl
5-(6'-(difluoromethyl)[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxylate 134 (26 mg, 0.066 mmol, 19.91% yield). LCMS: m/z=396.1
[M+H].sup.+; ret. time 1.63 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta.=9.10 (d, J=7.3 Hz, 1H), 8.88 (dd, J=4.8, 1.6
Hz, 1H), 8.57 (s, 1H), 8.30 (d, J=7.1 Hz, 1H), 8.22-8.10 (m, 2H),
7.72 (dd, J=7.8, 4.6 Hz, 1H), 7.59 (d, J=7.6 Hz, 1H), 7.04 (d,
J=7.1 Hz, 1H), 6.58-6.24 (m, 1H), 4.21 (q, J=7.1 Hz, 1H), 1.24 (t,
J=7.1 Hz, 3H).
Compound 135:
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylic acid
##STR00445##
[0887] Compound 135 was synthesized from 134 employing experimental
procedure described for compound 124 as shown in Scheme 31. The
crude compound was purified by preparative HPLC (Condition-N) to
yield
5-(6'-(difluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxylic acid 135 (6.2 mg, 0.017 mmol, 35.1% yield). LCMS:
m/z=368.1 [M+H].sup.+; ret. time 0.91 min; condition C. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.92 (d, J=7.5 Hz, 1H),
8.88-8.85 (m, 1H), 8.40 (s, 1H), 8.31-8.26 (m, 1H), 8.19-8.11 (m,
2H), 7.70 (dd, J=7.8, 4.8 Hz, 1H), 7.61 (d, J=7.5 Hz, 1H), 6.75 (d,
J=7.5 Hz, 1H), 6.59-6.26 (m, 1H).
##STR00446##
Compound 25B: 5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine
##STR00447##
[0889] Compound 25B was synthesized by reacting 25A (reference: WO
2014074657 A1) and
2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
employing the experimental procedure described for compound 9B as
shown in Scheme 16. The crude product was purified using silica gel
chromatography (24 g RediSep.RTM. column, eluting with a gradient
of 50% ethyl acetate in petroleum ether). The fractions containing
the product were combined and evaporated under reduced pressure to
afford 5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine 24A (1 g,
4.34 mmol, 66.6% yield). LCMS: m/z=231.3 [M+H].sup.+; ret. time
0.76 min; condition B.
Compound 136:
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
##STR00448##
[0891] Compound 136 was synthesized by reacting 25B and
2-bromo-6-(trifluoromethyl)pyridine employing the experimental
procedure described in Scheme 2 (Method B). The crude compound was
purified by preparative HPLC (Condition-N) to yield
5-(6'-(trifluoromethyl)-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
136 (11.8 mg, 0.035 mmol, 7.97% yield). LCMS: m/z=342.1
[M+H].sup.+; ret. time 1.61 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.99 (d, J=7.3 Hz, 1H), 8.86 (dd, J=4.8,
1.6 Hz, 1H), 8.41 (d, J=7.8 Hz, 1H), 8.27-8.12 (m, 3H), 7.80 (d,
J=7.8 Hz, 1H), 7.70 (dd, J=7.8, 4.9 Hz, 1H), 6.85 (d, J=7.3 Hz,
1H), 6.57 (d, J=2.2 Hz, 1H).
Compound 137:
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
##STR00449##
[0893] Compound 137 was synthesized by reacting 25B and
6-bromo-3-fluoro-2-methylpyridine employing experimental procedure
described in Scheme 3 (Method C). The crude compound was purified
by preparative HPLC (Condition-N) to yield
5-(5'-fluoro-6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-c]pyrimidine
137 (10.2 mg, 0.033 mmol, 7.7% yield). LCMS: m/z=306.1 [M+H].sup.+;
ret. time 1.423 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta.=8.94 (d, J=7.1 Hz, 1H), 8.79 (dd, J=4.8, 1.6
Hz, 1H), 8.20 (d, J=2.4 Hz, 1H), 8.11 (dd, J=7.7, 1.6 Hz, 1H), 8.00
(dd, J=8.6, 3.9 Hz, 1H), 7.75 (t, J=9.2 Hz, 1H), 7.62 (dd, J=7.8,
4.6 Hz, 1H), 6.72-6.64 (m, 2H), 1.92 (d, J=2.7 Hz, 3H).
Compound 138:
5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
##STR00450##
[0895] Compound 138 was synthesized by reacting 25B and
2-methyl-6-(tributylstannyl)pyridine employing the experimental
procedure described for compound 81 as shown in Scheme 18. The
crude compound was purified by preparative HPLC (Condition N) to
yield 5-(6'-methyl-[2,2'-bipyridin]-3-yl)pyrazolo[1,5-a]pyrimidine
138 (61 mg, 0.212 mmol, 98% yield). LCMS: m/z=288.1 [M+H].sup.+;
ret. time 1.28 min; condition C. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.91 (dd, J=7.3, 0.7 Hz, 1H), 8.80 (dd,
J=4.6, 1.7 Hz, 1H), 8.19 (d, J=2.4 Hz, 1H), 8.10 (dd, J=7.6, 1.7
Hz, 1H), 7.90 (d, J=7.6 Hz, 1H), 7.84-7.76 (m, 1H), 7.61 (dd,
J=7.8, 4.9 Hz, 1H), 7.17 (d, J=7.3 Hz, 1H), 6.68-6.60 (m, 2H), 1.94
(s, 3H).
Example 4
Biological Assay
[0896] Assays for the compounds reported below were conducted in
1536-well plates and 2 mL reactions are prepared from addition of
HIS-TGF.beta.R1 T204D or HIS-TGF.beta.R2 WT, anti-HIS detection
antibody, a labeled small molecule probe (K.sub.d=<100 nM;
k.sub.off=<0.001 s.sup.-1.) and test compounds in assay buffer
(20 mM HEPES pH 7.4, 10 mM MgCl.sub.2, 0.015% Brij35, 4 mM DTT, and
0.05 mg/ml BSA). The reaction is incubated for 1 hour at room
temperature and the HTRF signal was measured on an Envision plate
reader (Ex: 340 nm; Em: 520 nm/495 nm). Inhibition data were
calculated by comparison to no enzyme control reactions for 100%
inhibition and vehicle-only reactions for 0% inhibition. The final
concentration of reagents in the assay are 1 nM HIS-TGF.beta.R1
T204D or HIS-TGF.beta.R2 WT, 0.2 nM anti-HIS detection antibody,
labeled small molecule probe (at K.sub.d) and 0.5% DMSO. Dose
response curves were generated to determine the concentration
required inhibiting 50% of kinase activity (IC.sub.50). Compounds
were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated
at eleven concentrations. IC.sub.50 values were derived by
non-linear regression analysis.
TABLE-US-00006 TGF TGF BR1T20 BR2WT 4D IC50 IC50 No. (.mu.M)
(.mu.M) 13 0.103 >15 14 0.011 >15 15 0.010 >15 16 0.207
>15 17 0.009 >15 18 0.001 >15 19 0.001 9.617 20 0.103
>15 21 0.005 3.632 22 0.005 12.717 23 0.130 >15 24 -- >15
25 4.477 >15 26 7.651 >15 27 14.348 >15 28 0.009 >15 29
0.001 >15 30 -- >15 31 0.307 >15 32 0.016 >15 33 0.001
14.638 34 0.019 >15 35 0.001 >15 36 0.120 >15 37 0.004
1.600 38 1.925 >15 39 0.006 3.723 40 0.821 >15 41 15.000
>15 42 0.021 >15 43 0.017 >15 44 1.977 >15 45 0.907
>15 46 0.0004 >15 47 0.003 >15 48 0.026 >15 49 0.061
>15 50 0.043 >15 51 0.021 >15 52 0.030 >15 53 0.605
>15 54 0.254 >15 55 5.232 >15 56 5.295 >15 57 0.035
>15 58 0.019 >15 59 0.918 >15 60 0.161 >15 61 0.032
>15 63 1.948 >15 64 0.563 >15 65 0.397 >15 66 0.037
>15 67 0.004 -- 68 0.004 >15 69 0.007 >15 70 0.004 >15
71 -- -- 72 0.002 >15 73 0.026 >15 74 0.108 >15 75 0.025
>15 76 0.001 >15 77 0.004 >15 78 15.000 >15 79 15.000
>15 80 1.019 >15 81 0.016 >15 82 0.001 7.296 83 0.022
>15 84 0.001 >15 85 0.002 14.309 86 0.187 >15 87 0.015
>15 88 0.013 >15 89 3.362 >15 90 0.084 >15 91 0.652
>15 92 0.487 >15 93 15.000 >15 94 15.000 >15 95 0.353
>15 96 0.043 >15 97 0.005 5.215 98 0.002 0.562 99 0.004 2.499
100 11.130 >15 101 0.005 >15 102 0.716 >15 103 0.004
>15 104 0.042 >15 105 0.003 >15 106 0.004 >15 107 0.009
>15 108 0.172 >15 109 0.002 >15 110 0.002 >15 111 0.002
>15 112 0.012 >15 113 0.009 >15 114 0.016 >15 115 0.003
>15 116 0.014 >15 117 0.002 >15 118 0.427 >15 119 0.059
>15 120 0.006 >15 121 0.854 >15 122 0.242 >15 123 0.046
>15 124 0.137 >15 125 0.339 >15 126 0.094 >15 127 0.128
>15 128 0.033 >15 129 0.029 >15 130 0.014 >15 131 0.211
>15 132 0.036 >15 133 0.024 >15 134 0.028 >15 135 0.107
>15 136 0.015 >15 137 0.008 >15 138 0.005 >15
* * * * *